#### (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 25 September 2003 (25.09.2003)

(10) International Publication Number WO 03/078662 A1

- C12Q 1/68, (51) International Patent Classification7: G01N 33/53
- (21) International Application Number: PCT/US03/07713
- (22) International Filing Date: 12 March 2003 (12.03.2003)
- (25) Filing Language:

Ènglish

(26) Publication Language:

English

(30) Priority Data: 13 March 2002 (13.03.2002) 60/364.890 18 September 2002 (18.09.2002) 60/412,049

- (71) Applicant (for all designated States except US): GE-NOMIC HEALTH [US/US]; 301 Penobscot Drive, Redwood City, CA 94063 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BAKER, Joffre, B. [US/US]; P.O. Box 371212, Montara, CA 94937 (US). CRONIN, Maureen, T. [US/US]; 771 Anderson Drive, Los Altos, CA 94024 (US). KIEFER, Michael, C. [US/US]; 401 Wright Court, Clayton, CA 94517 (US) SHAK, Steve [US/US]; 1133 Cambridge Road, Burlingame, CA 94010 (US). WALKER, Michael, G. [US/US]; 1475 Flamingo Way, Sunnyvale, CA 94087 (US).

- Agent: DREGER, Ginger, R.; Heller Ehrman White & McAuliffe, 275 Middlefield Road, Menlo Park, CA 94025-3506 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES

(57) Abstract: The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. Th invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.

BEST AVAILABLE COPY



## GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES

## **Background of the Invention**

## Cross-Reference

5

10

15

20

25

30

This application claims the benefit under 35 U.S.C. 119(h) of provisional applications serial nos. 60/412,049, filed September 18, 2002 and 60/364,890, filed March 13, 2002, the entire disclosures which are herby incorporated by reference.

## Field of the Invention

The present invention relates to gene expression profiling in biopsied tumor tissues. In particular, the present invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. In addition, the invention provides a set of genes the expression of which is important in the diagnosis and treatment of breast cancer.

Oncologists have a number of treatment options available to them, including different combinations of chemotherapeutic drugs that are characterized as "standard of care," and a number of drugs that do not carry a label claim for a particular cancer, but for which there is evidence of efficacy in that cancer. Best likelihood of good treatment outcome requires that patients be assigned to optimal available cancer treatment, and that this assignment be made as quickly as possible following diagnosis.

Currently, diagnostic tests used in clinical practice are single analyte, and therefore do not capture the potential value of knowing relationships between dozens of different markers. Moreover, diagnostic tests are frequently not quantitative, relying on immunohistochemistry. This method often yields different results in different laboratories, in part because the reagents are not standardized, and in part because the interpretations are subjective and cannot be easily quantified. RNA-based tests have not often been used because of the problem of RNA degradation over time and the fact that it is difficult to obtain fresh tissue samples from patients for analysis. Fixed paraffin-embedded tissue is more readily available and methods have been established to detect RNA in fixed tissue. However, these methods typically do not allow for the study of large numbers of genes (DNA or RNA) from small amounts of material. Thus, traditionally fixed tissue has been rarely used other than for immunohistochemistry detection of proteins.

Recently, several groups have published studies concerning the classification of various cancer types by microarray gene expression analysis (see, e.g. Golub et al., Science 286:531-537

**SUBSTITUTE SHEET (RULE 26)** 

(1999); Bhattacharjae et al., Proc. Natl. Acad. Sci. USA 98:13790-13795 (2001); Chen-Hsiang et al., Bioinformatics 17 (Suppl. 1):S316-S322 (2001); Ramaswamy et al., Proc. Natl. Acad. Sci. USA 98:15149-15154 (2001)). Certain classifications of human breast cancers based on gene expression patterns have also been reported (Martin et al., Cancer Res. 60:2232-2238 (2000); West et al., Proc. Natl. Acad. Sci. USA 98:11462-11467 (2001); Sorlie et al., Proc. Natl. Acad. Sci. USA 98:10869-10874 (2001); Yan et al., Cancer Res. 61:8375-8380 (2001)). However, these studies mostly focus on improving and refining the already established classification of various types of cancer, including breast cancer, and generally do not provide new insights into the relationships of the differentially expressed genes, and do not link the findings to treatment strategies in order to improve the clinical outcome of cancer therapy.

Although modern molecular biology and biochemistry have revealed more than 100 genes whose activities influence the behavior of tumor cells, state of their differentiation, and their sensitivity or resistance to certain therapeutic drugs, with a few exceptions, the status of these genes has not been exploited for the purpose of routinely making clinical decisions about drug treatments. One notable exception is the use of estrogen receptor (ER) protein expression in breast carcinomas to select patients to treatment with anti-estrogen drugs, such as tamoxifen. Another exceptional example is the use of ErbB2 (Her2) protein expression in breast carcinomas to select patients with the Her2 antagonist drug Herceptin® (Genentech, Inc., South San Francisco, CA).

Despite recent advances, the challenge of cancer treatment remains to target specific treatment regimens to pathogenically distinct tumor types, and ultimately personalize tumor treatment in order to maximize outcome. Hence, a need exists for tests that simultaneously provide predictive information about patient responses to the variety of treatment options. This is particularly true for breast cancer, the biology of which is poorly understood. It is clear that the classification of breast cancer into a few subgroups, such as ErbB2<sup>+</sup> subgroup, and subgroups characterized by low to absent gene expression of the estrogen receptor (ER) and a few additional transcriptional factors (Perou et al., Nature 406:747-752 (2000)) does not reflect the cellular and molecular heterogeneity of breast cancer, and does not allow the design of treatment strategies maximizing patient response.

30

10

15

20

25

## Summary of the Invention

The present invention provides (1) sensitive methods to measure mRNA levels in biopsied tumor tissue, (2) a set of approximately 190 genes, the expression of which is important in the diagnosis of breast cancer, and (3) the significance of abnormally low or high expression

SUBSTITUTE SHEET (RULE 26)

tor the genes identified and included in the gene set, through activation or disruption of biochemical regulatory pathways that influence patient response to particular drugs used or potentially useful in the treatment of breast cancer. These results permit assessment of genomic evidence of the efficacy of more than a dozen relevant drugs.

The present invention accommodates the use of archived paraffin-embedded biopsy material for assay of all markers in the set, and therefore is compatible with the most widely available type of biopsy material. The invention presents an efficient method for extraction of RNA from wax-embedded, fixed tissues, which reduces cost of mass production process for acquisition of this information without sacrificing quality of the analysis. In addition, the invention describes a novel highly effective method for amplifying mRNA copy number, which permits increased assay sensitivity and the ability to monitor expression of large numbers of different genes given the limited amounts of biopsy material. The invention also captures the predictive significance of relationships between expressions of certain markers in the breast cancer marker set. Finally, for each member of the gene set, the invention specifies the oligonucleotide sequences to be used in the test.

In one aspect, the invention concerns a method for predicting clinical outcome for a patient diagnosed with cancer, comprising

determining the expression level of one or more genes, or their expression products, selected from the group consisting of p53BP2, cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set,

wherein a poor outcome is predicted if:

- (a) the expression level of p53BP2 is in the lower 10<sup>th</sup> percentile; or
- (b) the expression level of either cathepsin B or cathepsin L is in the upper 10<sup>th</sup> percentile; or
  - (c) the expression level of any either Ki67/MiB1 or thymidine kinase is in the upper 10<sup>th</sup> percentile.

Poor clinical outcome can be measured, for example, in terms of shortened survival or increased risk of cancer recurrence, e.g. following surgical removal of the cancer.

In another embodiment, the inventor concerns a method of predicting the likelihood of the recurrence of cancer, following treatment, in a cancer patient, comprising determining the expression level of p27, or its expression product, in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference

10

15

20

cancer tissue set, wherein an expression level in the upper 10th percentile indicates decreased risk of recurrence following treatment.

In another aspect, the invention concerns a method for classifying cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl2, hepatocyte nuclear factor 3, ER, ErbB2, and Grb7, or their expression products, in a cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein (i) tumors expressing at least one of Bcl2, hepatocyte nuclear factor 3, and ER, or their expression products, above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following treatment; and (ii) tumors expressing elevated levels of ErbB2 and Grb7, or their expression products, at levels ten-fold or more above the mean expression level in the reference tissue set are classified as having poor prognosis of disease free and overall patient survival following treatment.

All types of cancer are included, such as, for example, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer. The foregoing methods are particularly suitable for prognosis/classification of breast cancer.

In all previous aspects, in a specific embodiment, the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample. While all techniques of gene expression profiling, as well as proteomics techniques, are suitable for use in performing the foregoing aspects of the invention, the gene expression levels are often determined by reverse transcription polymerase chain reaction (RT-PCR).

If the source of the tissue is a formalin-fixed, paraffin embedded tissue sample, the RNA is often fragmented.

The expression data can be further subjected to multivariate analysis, for example using the Cox Proportional Hazards model.

In a further aspect, the invention concerns a method for the preparation of nucleic acid from a fixed, wax-embedded tissue specimen, comprising:

- (a) incubating a section of the fixed, wax-embedded tissue specimen at a temperature of about 56 °C to 70 °C in a lysis buffer, in the presence of a protease, without prior dewaxing, to form a lysis solution;
  - (b) cooling the lysis solution to a temperature where the wax solidifies; and
  - (c) isolating the nucleic acid from the lysis solution.

SUBSTITUTE SHEET (RULE 26)

10

15

20

25

The lysis buffer may comprise urea, such as 4M urea.

In a particular embodiment, incubation in step (a) of the foregoing method is performed at about 65°C.

In another particular embodiment, the protease used in the foregoing method is proteinase

In another embodiment, the cooling in step (b) is performed at room temperature.

In a further embodiment, the nucleic acid is isolated after protein removal with 2.5 M NH<sub>4</sub>OAc.

The nucleic acid can, for example, be total nucleic acid present in the fixed, waxembedded tissue specimen.

In yet another embodiment, the total nucleic acid is isolated by precipitation from the lysis solution, following protein removal, with 2.5 M NH<sub>4</sub>OAc. The precipitation may, for example, be performed with isopropanol.

The method described above may further comprise the step of removing DNA from the total nucleic acid, for example by DNAse treatment.

The tissue specimen may, for example, be obtained from a tumor, and the RNA may be obtained from a microdissected portion of the tissue specimen enriched for tumor cells.

All types of tumor are included, such as, without limitation, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer, in particular breast cancer..

The method described above may further comprise the step of subjecting the RNA to gene expression profiling. Thus, the gene expression profile may be completed for a set of genes comprising at least two of the genes listed in Table 1.

Although all methods of gene expression profiling are contemplated, in a particular embodiment, gene expression profiling is performed by RT-PCR which may be preceded by an amplification step.

In another aspect, the invention concerns a method for preparing fragmented RNA for gene expression analysis, comprising the steps of:

- (a) mixing the RNA with at least one gene-specific, single-stranded DNA scaffold under conditions such that fragments of the RNA complementary to the DNA scaffold hybridize with the DNA scaffold;
  - (b) extending the hybridized RNA fragments with a DNA polymerase to form a DNA-DNA duplex; and

5

10

15

20

25

(c) removing the DNA scaffold from the duplex.

In a specific embodiment, in step (b) of this method, the RNA may be mixed with a mixture of single-stranded DNA templates specific for each gene of interest.

The method can further comprise the step of heat-denaturing and reannealing the duplexed DNA to the DNA scaffold, with or without additional overlapping scaffolds, and further extending the duplexed sense strand with DNA polymerase prior to removal of the scaffold in step (c).

The DNA templates may be, but do not need to be, fully complementary to the gene of interest.

In a particular embodiment, at least one of the DNA templates is complementary to a specific segment of the gene of interest.

In another embodiment, the DNA templates include sequences complementary to polymorphic variants of the same gene.

The DNA template may include one or more dUTP or rNTP sites. In this case, iin step (c) the DNA template may be removed by fragmenting the DNA template present in the DNA-DNA duplex formed in step (b) at the dUTP or rNTP sites.

In an important embodiment, the RNA is extracted from fixed, wax-embedded tissue specimens, and purified sufficiently to act as a substrate in an enzyme assay. The RNA purification may, but does not need to, include an oligo-dT based step.

In a further aspect, the invention concerns a method for amplifying RNA fragments in a sample comprising fragmented RNA representing at least one gene of interest, comprising the steps of:

- (a) contacting the sample with a pool of single-stranded DNA scaffolds comprising an RNA polymerase promoter at the 5' end under conditions such that the RNA fragments complementary to the DNA scaffolds hybridize with the DNA scaffolds;
- (b) extending the hybridized RNA fragments with a DNA polymerase along the DNA scaffolds to form DNA-DNA duplexes;
  - (c) amplifying the gene or genes of interest by in vitro transcription; and
  - (d) removing the DNA scaffolds from the duplexes.

An exemplary promoter is the T7 RNA polymerase promoter, while an exemplary DNA polymerase is DNA polymerase I.

In step (d) the DNA scaffolds may be removed, for example, by treatment with DNase I.

In a further embodiment, the pool of single-stranded DNA scaffolds comprises partial or complete gene sequences of interest, such as a library of cDNA clones.

SUBSTITUTE SHEET (RULE 26)

15

20

In a specific embodiment, the sample represents a whole genome or a fraction thereof. In a preferred embodiment, the genome is the human genome.

In another aspect, the invention concerns a method of preparing a personalized genomics profile for a patient, comprising the steps of:

- (a) subjecting RNA extracted from a tissue obtained from the patient to gene expression analysis;
- (b) determining the expression level in such tissue of at least two genes selected from the gene set listed in Table 1, wherein the expression level is normalized against a control gene or genes, and is compared to the amount found in a cancer tissue reference set;
- (c) and creating a report summarizing the data obtained by the gene expression analysis.

The tissue obtained from the patient may, but does not have to, comprise cancer cells. Just as before, the cancer can, for example, be breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, or brain cancer, breast cancer being particularly preferred.

In a particular embodiment, the RNA is obtained from a microdissected portion of breast cancer tissue enriched for cancer cells. The control gene set may, for example, comprise S-actin, and ribosomal protein LPO.

The report prepared for the use of the patient or the patient's physician, may include the identification of at least one drug potentially beneficial in the treatment of the patient.

Step (b) of the foregoing method may comprise the step of determining the expression level of a gene specifically influencing cellular sensitivity to a drug, where the gene can, for example, be selected from the group consisting of aldehyde dehydrogenase 1A1, aldehyde dehydrogenase 1A3, amphiregulin, ARG, BRK, BCRP, CD9, CD31, CD82/KAI-1, COX2, c-abl, c-kit, c-kit L, CYP1B1, CYP2C9, DHFR, dihydropyrimidine dehydrogenase, EGF, epiregulin, ER-alpha, ErbB-1, ErbB-2, ErbB-3, ErbB-4, ER-beta, farnesyl pyrophosphate synthetase, gamma-GCS (glutamyl cysteine synthetase), GATA3, geranyl geranyl pyrophosphate synthetase, Grb7, GST-alpha, GST-pi, HB-EGF, hsp 27, human chorionic gonadotropin/CGA, IGF-1, IGF-2, IGF1R, KDR, LIV1, Lung Resistance Protein/MVP, Lot1, MDR-1, microsomal epoxide hydrolase, MMP9, MRP1, MRP2, MRP3, MRP4, PAI1, PDGF-A, PDGF-B, PDGF-C, PDGF-D, PGDFR-alpha, PDGFR-beta, PLAGa (pleiomorphic adenoma 1), PREP prolyl endopeptidase, progesterone receptor, pS2/trefoil factor 1, PTEN, PTB1b, RAR-alpha, RAR-beta2, Reduced

10

15

20

Folate Carrier, SXR, TGF-alpha, thymidine phosphorylase, thymidine synthase, topoisomerase II-alpha, topoisomerase II-beta, VEGF, XIST, and YB-1.

In another embodiment, step (b) of the foregoing process includes determining the expression level of multidrug resistance factors, such as, for example, gamma-glutamyl-cysteine synthetase (GCS), GST-α, GST-π, MDR-1, MRP1-4, breast cancer resistance protein (BCRP), lung cancer resistance protein (MVP), SXR, or YB-1.

In another embodiment, step (b) of the foregoing process comprises determination of the expression level of eukaryotic translation initiation factor 4E (EIF4E).

In yet another embodiment, step (b) of the foregoing process comprises determination of the expression level of a DNA repair enzyme.

In a further embodiment, step (b) of the foregoing process comprises determination of the expression level of a cell cycle regulator, such as, for example, c-MYC, c-Src, Cyclin D1, Ha-Ras, mdm2. p14ARF, p21WAF1/CI, p16INK4a/p14, p23, p27, p53, PI3K, PKC-epsilon, or PKC-delta.

In a still further embodiment, step (b) of the foregoing process comprises determination of the expression level of a tumor suppressor or a related protein, such as, for example, APC or Ecadherin.

In another embodiment, step (b) of the foregoing method comprises determination of the expression level of a gene regulating apoptosis, such as, for example, p53, BC12, Bcl-x1, Bak, Bax, and related factors, NFk-B, CIAP1, CIAP2, survivin, and related factors, p53BP1/ASPP1, or p53BP2/ASPP2.

In yet another embodiment, step (b) of the foregoing process comprises determination of the expression level of a factor that controls cell invasion or angiogenesis, such as, for example, uPA, PAII, cathepsin B, C, and L, scatter factor (HGF), c-met, KDR, VEGF, or CD31.

In a different embodiment, step (b) of the foregoing method comprises determination of the expression level of a marker for immune or inflammatory cells or processes, such as, for example, Ig light chain  $\lambda$ , CD18, CD3, CD68. Fas(CD95), or Fas Ligand.

In a further embodiment, step (b) of the foregoing process comprises determination of the expression level of a cell proliferation marker, such as, for example, Ki67/MiB1, PCNA, Pin1, or thymidine kinase.

In a still further embodiment, step (b) of the foregoing process comprises determination of the expression level of a growth factor or growth factor receptor., such as, for example, IGF1, IGF2, IGFBP3, IGF1R, FGF2, CSF-1, CSF-1R/fms, SCF-1, IL6 or IL8.

8
SUBSTITUTE SHEET (RULE 26)

5

10

15

20

25

In another embodiment, step (b) of the foregoing process comprises determination of the expression level of a gene marker that defines a subclass of breast cancer, where the gene marker can, for example, be GRO1 oncogene alpha, Grb7, cytokeratins 5 and 17, retinol binding protein 4, hepatocyte nuclear factor 3, integrin subunit alpha 7, or lipoprotein lipase.

In a still further aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to 5-fluorouracil (5-FU) or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis;
- (b) determining the expression level in the tissue of thymidylate synthase mRNA, wherein the expression level is normalized against a control gene or genes, and is compared to the amount found in a reference breast cancer tissue set; and
- (c) predicting patient response based on the normalized thymidylate synthase mRNA level.

Step (d) of the foregoing method can further comprise determining the expression level of dihydropyrimidine phosphorylase.

In another embodiment, step (b) of the method can further comprise determining the expression level of thymidine phosphorylase.

In yet another embodiment, a positive response to 5-FU or an analog thereof is predicted if: (i) normalized thymidylate synthase mRNA level determined in step (b) is at or below the 15<sup>th</sup> percentile; or (ii) the sum of normalized expression levels of thymidylate synthase and dihydropyrimidine phosphorylase determined in step (b) is at or below the 25<sup>th</sup> percentile; or (iii) the sum of normalized expression levels of thymidylate synthase, dihydropyrimidine phosphorylase, plus thymidine phosphorylase determined in step (b) is at or below the 20<sup>th</sup> percentile..

In a further embodiment, in step (b) of the foregoing method the expression level of c-myc and wild-type p53 is determined. In this case, a positive response to 5-FU or an analog thereof is predicted, if the normalized expression level of c-myc relative to the normalized expression level of wild-type p53 is in the upper 15<sup>th</sup> percentile.

In a still further embodiment, in step (b) of the foregoing method, expression level of NFkB and cIAP2 is determined. In this particular embodiment, resistance to 5-FU or an analog thereof is typically predicted if the normalized expression level of NFkB and cIAP2 is at or above the 10<sup>th</sup> percentile.

10

15

20

25

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to methotrexate or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting decreased patient sensitivity to methotrexate or analog if (i) DHFR levels are more than tenfold higher than the average expression level of DHFR in the control gene set, or (ii) the normalized expression levels of members of the reduced folate carrier (RFC) family are below the 10<sup>th</sup> percentile.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to an anthracycline or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting patient resistance or decreased sensitivity to the anthracycline or analog if (i) the normalized expression level of topoisomerase IIα is below the 10<sup>th</sup> percentile, or (ii) the normalized expression level of topoisomerase IIβ is below the 10<sup>th</sup> percentile, or (iii) the combined normalized topoisomerase IIα or IIβ expression levels are below the 10<sup>th</sup> percentile.

In a different aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a docetaxol, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to docetaxol if the normalized expression level of CYP1B1 is in the upper 10<sup>th</sup> percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to cyclophosphamide or an analog thereof, comprising

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to the cyclophosphamide or analog if the sum of the expression levels of aldehyde dehydrogenase 1A1 and 1A3 is more than tenfold higher than the average of their combined expression levels in the reference tissue set.

10

10

15

20

In a further aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to anti-estrogen therapy, comprising

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set that contains both specimens negative for and positive for estrogen receptor- $\alpha$  (ER $\alpha$ ) and progesterone receptor- $\alpha$  (PR $\alpha$ ); and
- (b) predicting patient response based upon the normalized expression levels of ERα or PRα, and at least one of microsomal epoxide hydrolase, pS2/trefoil factor 1, GATA3 and human chorionic gonadotropin.

In a specific embodiment, lack of response or decreased responsiveness is predicted if (i) the normalized expression level of microsomal epoxide hydrolase is in the upper 10<sup>th</sup> percentile; or (ii) the normalized expression level of pS2/trefoil factor 1, or GATA3 or human chorionic gonaostropin is at or below the corresponding average expression level in said breast cancer tissue set, regardless of the expression level of ER $\alpha$  or PR $\alpha$  in the breast cancer tissue obtained from the patient.

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a taxane, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to taxane if (i) no or minimal XIST expression is detected; or (ii) the normalized expression level of GST- $\pi$  or propyl endopeptidase (PREP) is in the upper 10<sup>th</sup> percentile; or (iii) the normalized expression level of PLAG1 is in the upper 10<sup>th</sup> percentile.

The invention also concerns a method for predicting the response of a patient diagnosed with breast cancer to cisplatin or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting resistance or reduced sensitivity if the normalized expression level of ERCC1 is in the upper 10<sup>th</sup> percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to an ErbB2 or EGFR antagonist, comprising the steps of:

SUBSTITUTE SHEET (RULE 26)

15

20

25

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and

(b) predicting patient response based on the normalized expression levels of at least one of Grb7, IGF1R, IGF1 and IGF2.

In particular embodiment, a positive response is predicted if the normalized expression level of Grb7 is in the upper 10<sup>th</sup> percentile, and the expression of IGF1R, IGF1 and IGF2 is not elevated above the 90<sup>th</sup> percentile.

In a further particular embodiment, a decreased responsiveness is predicted if the expression level of at least one of IGF1R, IGF1 and IGF2 is elevated.

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a bis-phosphonate drug, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if the breast cancer tissue obtained from the patient expresses mutant Ha-Ras and additionally expresses farnesyl pyrophosphate synthetase or geranyl pyrophosphone synthetase at a normalized expression level at or above the 90<sup>th</sup> percentile.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to treatment with a cyclooxygenase 2 inhibitor, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if the normalized expression level of COX2 in the breast cancer tissue obtained from the patient is at or above the 90<sup>th</sup> percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to an EGF receptor (EGFR) antagonist, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response to an EGFR antagonist, if (i) the normalized expression level of EGFR is at or above the 10<sup>th</sup> percentile, and (ii) the normalized expression

10

15

20

25

level of at least one of epiregulin, TGF- $\alpha$ , amphiregulin, ErbB3, BRK, CD9, MMP9, CD82, and Lot1 is above the 90<sup>th</sup> percentile.

In another aspect, the invention concerns a method for monitoring the response of a patient diagnosed with breast cancer to treatment with an EGFR antagonist, comprising monitoring the expression level of a gene selected from the group consisting of epiregulin, TGF
α, amphiregulin, ErbB3, BRK, CD9, MMP9, CD82, and Lot1 in the patient during treatment, wherein reduction in the expression level is indicative of positive response to such treatment.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a drug targeting a tyrosine kinase selected from the group consisting of abl, c-kit, PDGFR-α, PDGFR-β and ARG, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set;
- (b) determining the normalized expression level of a tyrosine kinase selected from the group consisting of abl, c-kit, PDGFR-α, PDGFR-β and ARG, and the cognate ligand of the tyrosine kinase, and if the normalized expression level of the tyrosine kinase is in the upper 10<sup>th</sup> percentile,
- (c) determining whether the sequence of the tyrosine kinase contains any mutation, wherein a positive response is predicted if (i) the normalized expression level of the tyrosine kinase is in the upper 10<sup>th</sup> percentile, (ii) the sequence of the tyrosine kinase contains an activating mutation, or (iii) the normalized expression level of the tyrosine kinase is normal and the expression level of the ligand is in the upper 10<sup>th</sup> percentile.

Another aspect of the invention is a method for predicting the response of a patient diagnosed with breast cancer to treatment with an anti-angiogenic drug, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if (i) the normalized expression level of VEGF is in the upper 10<sup>th</sup> percentile and (ii) the normalized expression level of KDR or CD31 is in the upper 20<sup>th</sup> percentile.

A further aspect of the invention is a method for predicting the likelihood that a patient diagnosed with breast cancer develops resistance to a drug interacting with the MRP-1 gene coding for the multidrug resistance protein P-glycoprotein, comprising the steps of:

- 10

15

20

25

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis to determine the expression level of PTP1b, wherein the expression level is normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and

(b) concluding that the patient is likely to develop resistance to said drug if the normalized expression level of the MRP-1 gene is above the 90<sup>th</sup> percentile.

The invention further relates to a method for predicting the likelihood that a patient diagnosed with breast cancer develops resistance to a chemotherapeutic drug or toxin used in cancer treatment, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) determining the normalized expression levels of at least one of the following genes: MDR1, SGT $\alpha$ , GST $\pi$ , SXR, BCRP YB-1, and LRP/MVP, wherein the finding of a normalized expression level in the upper 4<sup>th</sup> percentile is an indication that the patient is likely to develop resistance to the drug.

Also included herein is a method for measuring the translational efficiency of VEGF mRNA in a breast cancer tissue sample, comprising determining the expression levels of the VEGF and EIF4E mRNA in the sample, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a higher normalized EIF4E expression level for the same VEGF expression level is indicative of relatively higher translational efficiency for VEGF.

In another aspect, the invention provides a method for predicting the response of a patient diagnosed with breast cancer to a VEGF antagonist, comprising determining the expression level of VEGF and EIF4E mRNA normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a VEGF expression level above the 90<sup>th</sup> percentile and an EIF4E expression level above the 50<sup>th</sup> percentile is a predictor of good patient response.

The invention further provides a method for predicting the likelihood of the recurrence of breast cancer in a patient diagnosed with breast cancer, comprising determining the ratio of p53:p21 mRNA expression or p53:mdm2 mRNA expression in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an above normal ratio is indicative of a higher risk

5

10

15

20

25

of recurrence. Typically, a higher risk of recurrence is indicated if the ratio is in the upper 10<sup>th</sup> percentile.

In yet another aspect, the invention concerns a method for predicting the likelihood of the recurrence of breast cancer in a breast cancer patient following surgery, comprising determining the expression level of cyclin D1 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an expression level in the upper 10<sup>th</sup> percentile indicates increased risk of recurrence following surgery. In a particular embodiment of this method, the patient is subjected to adjuvant chemotherapy, if the expression level is in the upper 10<sup>th</sup> percentile.

Another aspect of the invention is a method for predicting the likelihood of the recurrence of breast cancer in a breast cancer patient following surgery, comprising determining the expression level of APC or E-cadherin in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an expression level in the upper 5<sup>th</sup> percentile indicates high risk of recurrence following surgery, and heightened risk of shortened survival.

A further aspect of the invention is a method for predicting the response of a patient diagnosed with breast cancer to treatment with a proapoptotic drug comprising determining the expression levels of BCl2 and c-MYC in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) a BCl2 expression level in the upper 10<sup>th</sup> percentile in the absence of elevated expression of c-MYC indicates good response, and (ii) a good response is not indicated if the expression level c-MYC is elevated, regardless of the expression level of BCl2.

A still further aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) determining the normalized expression levels of NFkB and at least one gene selected from the group consisting of cIAP1, cIAP2, XIAP, and Survivin,

wherein a poor prognosis is indicated if the expression levels for NFkB and at least one of the genes selected from the group consisting of cIAP1, cIAP2, XIAP, and Survivin is in the upper 5<sup>th</sup> percentile.

10

15

**20**.

25.

30.

The invention further concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of p53BP1 and p53BP2 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor outcome is predicted if the expression level of either p53BP1 or p53BP2 is in the lower 10<sup>th</sup> percentile.

The invention additionally concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of uPA and PAI1 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) a poor outcome is predicted if the expression levels of uPA and PAI1 are in the upper 20<sup>th</sup> percentile, and (ii) a decreased risk of recurrence is predicted if the expression levels of uPA and PAI1 are not elevated above the mean observed in the breast cancer reference set. In a particular embodiment, poor outcome is measured in terms of shortened survival or increased risk of cancer recurrence following surgery. In another particular embodiment, uPA and PAI1 are expressed at normal levels, and the patient is subjected to adjuvant chemotherapy following surgery.

Another aspect of the invention is a method for predicting treatment outcome in a patient diagnosed with breast cancer, comprising determining the expression levels of cathepsin B and cathepsin L in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor outcome is predicted if the expression level of either cathepsin B or cathepsin L is in the upper 10<sup>th</sup> percentile. Just as before, poor treatment outcome may be measured, for example, in terms of shortened survival or increased risk of cancer recurrence.

A further aspect of the invention is a method for devising the treatment of a patient diagnosed with breast cancer, comprising the steps of

- (a) determining the expression levels of scatter factor and c-met in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, and
- (b) suggesting prompt aggressive chemotherapeutic treatment if the expression levels of scatter factor and c-met or the combination of both, are above the 90<sup>th</sup> percentile.

A still further aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of VEGF, CD31, and KDR in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein

10.

15

20

a poor treatment outcome is predicted if the expression level of any of VEGF, CD31, and KDR is in the upper 10<sup>th</sup> percentile.

Yet another aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of Ki67/MiB1, PCNA, Pin1, and thymidine kinase in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor treatment outcome is predicted if the expression level of any of Ki67/MiB1, PCNA, Pin1, and thymidine kinase is in the upper 10<sup>th</sup> percentile.

The invention further concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression level of soluble and full length CD95 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein the presence of soluble CD95 correlates with poor patient survival.

The invention also concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of IGF1, IGF1R and IGFBP3 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor treatment outcome is predicted if the sum of the expression levels of IGF1, IGF1R and IGFBP3 is in the upper 10<sup>th</sup> percentile.

The invention additionally concerns a method for classifying breast cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl12, hepatocyte nuclear factor 3, LIV1, ER, lipoprotein lipase, retinol binding protein 4, integrin  $\alpha$ 7, cytokeratin 5, cytokeratin 17, GRO oncogen, ErbB2 and Grb7, in a breast cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) tumors expressing at least one of Bcl1, hepatocyte nuclear factor 3, LIV1, and ER above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following surgical removal; (ii) tumors characterized by elevated expression of at least one of lipoprotein lipase, retinol binding protein 4, integrin  $\alpha$ 7 compared to the reference tissue set are classified as having intermediate prognosis of disease free and overall patient survival following surgical removal; and (iii) tumors expressing either elevated levels of cytokeratins 5 and 17, and GRO oncogen at levels four-fold or greater above the mean expression level in the reference tissue set, or ErbB2 and Grb7 at levels ten-fold or more above the mean expression level in the reference

10

15

20

25

tissue set are classified as having poor prognosis of disease free and overall patient survival following surgical removal.

Another aspect of the invention is a panel of two or more gene specific primers selected from the group consisting of the forward and reverse primers listed in Table 2.

Yet another aspect of the invention is a method for reverse transcription of a fragmented RNA population in RT-PCR amplification, comprising using a multiplicity of gene specific primers as the reverse primers in the amplification reaction. In a particular embodiment, the method uses between two and about 40,000 gene specific primers in the same amplification reaction. In another embodiment, the gene specific primers are about 18 to 24 bases, such as about 20 bases in length. In another embodiment, the Tm of the primers is about 58-60 °C. The primers can, for example, be selected from the group consisting of the forward and reverse primers listed in Table 2.

The invention also concerns a method of reverse transcriptase driven first strand cDNA synthesis, comprising using a gene specific primer of about 18 to 24 bases in length and having a Tm optimum between about 58 °C and about 60 °C. In a particular embodiment, the first strand cDNA synthesis is followed by PCR DNA amplification, and the primer serves as the reverse primer that drives the PCR amplification. In another embodiment, the method uses a plurality of gene specific primers in the same first strand cDNA synthesis reaction mixture. The number of the gene specific primers can, for example, be between 2 and about 40,000.

In a different aspect, the invention concerns a method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising determining the expression level of one or more prognostic RNA transcripts or their product in a breast cancer tissue sample obtained from said patient, normalized against the expression level of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products, wherein the prognostic transcript is the transcript of one or more genes selected from the group consisting of: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, DIABLO, CDH1, HIF1α, IGFBP3, CTSB, and Her2, wherein overexpression of one or more of FOXM1, PRAME, STK15, Ki-67, CA9, NME1, SURV, TFRC, YB-1, RPS6KB1, Src, Chk1, CCNB1, Chk2, CDC25B, CYP3A4, EpCAM, VEGFC, hENT1, BRCA2, EGFR, TK1, VDR, EPHX1, IF1A, Contig51037, CDH1, HIF1α,

10

15

20

25

IGFBP3, CTSB, Her2, and pENT1 indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the overexpression of one or more of Bcl2, CEGP1, GSTM1, PR, BBC3, GATA3, DPYD, GSTM3, ID1, EstR1, p27, XIAP, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, pS2, WISP1, HNF3A, NFKBp65, and DIABLO indicates an increased likelihood of long-term survival without breast cancer recurrence.

In a particular embodiment of this method, the expression level of at least 2, preferably at least 5, more preferably at least 10, most preferably at least 15 prognostic transcipts or their expression products is determined.

When the breast cancer is invasive breast carcinoma, including both estrogen receptor (ER) overexpressing (ER positive) and ER negative tumors, the analysis includes determination of the expression levels of the transcripts of at least two of the following genes, or their expression products: FOXM1, PRAME, Bel2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, Src, CA9, Contig51037, RPS6K1 and Her2.

When the breast cancer is ER positive invasive breast carcinoma, the analysis includes dtermination of the expression levels of the transcripts of at least two of the following genes, or their expression products: PRAME, Bcl2, FOXM1, DIABLO, EPHX1, HIF1A, VEGFC, Ki-67, IGF1R, VDR, NME1, GSTM3, Contig51037, CDC25B, CTSB, p27, CDH1, and IGFBP3.

Just as before, it is preferred to determine the expression levels of at least 5, more preferably at least 10, most preferably at least 15 genes, or their respective expression products.

In a particular embodiment, the expression level of one or more prognostic RNA transcripts is determined, where RNA may, for example, be obtained from a fixed, wax-embedded breast cancer tissue specimen of the patient. The isolation of RNA can, for example, be carried out following any of the procedures described above or throughout the application, or by any other method known in the art.

In yet another aspect, the invention concerns an array comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2, immobilized on a solid surface.

In a particular embodiment, the array comprosies polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1α, IGFBP3, CTSB, Her2 and DIABLO.

10

15.

**20**-

25

In a further aspect, the invention concerns a method of predicting the likelihood of longterm survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:

- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
  - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
  - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
  - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
- 10 (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
  - (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
  - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- 15 (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
  - (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
  - (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
  - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
  - (l) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
- 25 (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
  - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
- (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1,30 VEGFC; and
  - (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS

20 SUBSTITUTE SHEET (RULE 26)

in a breast cancer tissue sample obtained from said patient, normalized against the expression levels of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products;

- (2) subjecting the data obtained in step (a) to statistical analysis; and
- (3) determining whether the likelihood of said long-term survival has increased or decreased.

In a still further aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:

- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
- (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 15 (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
  - (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
  - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
    - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
    - (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- 25 (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
  - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
  - (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
  - (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- 30 (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
  - (l) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
  - (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

21 SUBSTITUTE SHEET (RULE 26)

10

- (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
- (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
- 5 (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
  - (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
  - (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bc12, CYP3A4, HLAG;
  - (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- 10 (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
  - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
  - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
  - (x). FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 15 (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, EBXO5, CA9, CYP, KRT18; and
  - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF;
    - (2) subjecting the data obtained in step (1) to statistical analysis; and
- 20 (3) determining whether the likelihood of said long-term survival has increased or decreased.

In a different aspect, the invention concerns an array comprising polynucleotides hybridizing to a gene set selected from the group consisting of:

- (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
- 25 (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
  - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
  - (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
- 30 (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
  - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
  - (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;

(h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;

- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
- 5 (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
  - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
  - (I) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
  - (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
    - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
    - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
- 15 (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS,

immobilized on a solid surface.

10

In an additional aspect, the invention concerns an array comprising polynucleotides hybridizing to a gene set selected from the group consisting of:

- 20 (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
  - (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN,CYP3A4, TIMP2, AREG;
  - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
  - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
- 30 (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
  - (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
  - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;

- (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
- (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
- (I) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
- 5 (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
  - (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
  - (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- 10 (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
  - (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
  - (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
  - (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
- 15 (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
  - (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
  - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
  - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
- 20 (x) FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
  - (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP, KRT18; and
  - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF,
- 25 immobilized on a solid surface.

In all aspects, the polynucleotides can be cDNAs ("cDNA arrays") that are typically about 500 to 5000 bases long, although shorter or longer cDNAs can also be used and are within the scope of this invention. Alternatively, the polynucleotids can be oligonucleotides (DNA microarrays), which are typically about 20 to 80 bases long, although shorter and longer oligonucleotides are also suitable and are within the scope of the invention. The solid surface can, for example, be glass or nylon, or any other solid surface typically used in preparing arrays, such as microarrays, and is typically glass.

#### Brief Description of the Drawings

Figure 1 is a chart illustrating the overall workflow of the process of the invention for measurement of gene expression. In the Figure, FPET stands for "fixed paraffin-embedded tissue," and "RT-PCR" stands for "reverse transcriptase PCR." RNA concentration is determined by using the commercial RiboGreen™ RNA Quantitation Reagent and Protocol.

Figure 2 is a flow chart showing the steps of an RNA extraction method according to the invention alongside a flow chart of a representative commercial method.

Figure 3 is a scheme illustrating the steps of an improved method for preparing fragmented mRNA for expression profiling analysis.

Figure 4 illustrates methods for amplification of RNA prior to RT-PCR.

Figure 5 illustrates an alternative scheme for repair and amplification of fragmented mRNA.

Figure 6 shows the measurement of estrogen receptor mRNA levels in 40 FPE breast cancer specimens via RT-PCR. Three 10 micron sections were used for each measurement. Each data point represents the average of triplicate measurements.

Figure 7 shows the results of the measurement of progesterone receptor mRNA levels in 40 FPE breast cancer specimens via RT-PCR performed as described in the legend of Figure 6 above.

Figure 8 shows results from an IVT/RT-PCR experiment.

Figure 9 is a representation of the expression of 92 genes across 70 FPE breast cancer specimens. The y-axis shows expression as cycle threshold times. These genes are a subset of the genes listed in Table 1.

Table 1 shows a breast cancer gene list.

Table 2 sets forth amplicon and primer sequences used for amplification of fragmented 25 mRNA.

Table 3 shows the Accession Nos. and SEQ ID NOS of the breast cance genes examined.

## Detailed Description of the Preferred Embodiment

#### A. Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms

10

15

20

and Structure 4th ed., John Wiley & Sons (New York, NY 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

The term "microarray" refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes, on a substrate.

The term "polynucleotide," when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "polynucleotide" specifically includes DNAs and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "polynucleotides" as defined herein. In general, the term "polynucleotide" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.

The term "oligonucleotide" refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available. However, oligonucleotides can be made by a variety of other methods, including *in vitro* recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.

5

10

15

20

25

The terms "differentially expressed gene," "differential gene expression" and their synonyms, which are used interchangeably, refer to a gene whose expression is activated to a higher or lower level in a subject suffering from a disease, specifically cancer, such as breast cancer, relative to its expression in a normal or control subject. The terms also include genes whose expression is activated to a higher or lower level at different stages of the same disease. It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a change in mRNA levels, surface expression, secretion or other partitioning of a polypeptide, for example. Differential gene expression may include a comparison of expression between two or more genes, or a comparison of the ratios of the expression between two or more genes, or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease, specifically cancer, or between various stages of the same disease. Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages. For the purpose of this invention, "differential gene expression" is considered to be present when there is at least an about two-fold, preferably at least about fourfold, more preferably at least about six-fold, most preferably at least about ten-fold difference between the expression of a given gene in normal and diseased subjects, or in various stages of disease development in a diseased subject.

The phrase "gene amplification" refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as "amplicon." Usually, the amount of the messenger RNA (mRNA) produced, *i.e.*, the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.

The term "prognosis" is used herein to refer to the prediction of the likelihood of cancerattributable death or progression, including recurrence, metastatic spread, and drug resistance, of
a neoplastic disease, such as breast cancer. The term "prediction" is used herein to refer to the
likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs,
and also the extent of those responses. The predictive methods of the present invention can be
used clinically to make treatment decisions by choosing the most appropriate treatment
modalities for any particular patient. The predictive methods of the present invention are
valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such

5

15

20

25

as surgical intervention, chemotherapy with a given drug or drug combination, and/or radiation therapy.

The term "increased resistance" to a particular drug or treatment option, when used in accordance with the present invention, means decreased response to a standard dose of the drug or to a standard treatment protocol.

The term "decreased sensitivity" to a particular drug or treatment option, when used in accordance with the present invention, means decreased response to a standard dose of the drug or to a standard treatment protocol, where decreased response can be compensated for (at least partially) by increasing the dose of drug, or the intensity of treatment.

"Patient response" can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, to some extent, of tumor growth, including slowing down and complete growth arrest; (2) reduction in the number of tumor cells; (3) reduction in tumor size; (4) inhibition (i.e., reduction, slowing down or complete stopping) of tumor cell infiltration into adjacent peripheral organs and/or tissues; (5) inhibition (i.e. reduction, slowing down or complete stopping) of metastasis; (6) enhancement of anti-tumor immune response, which may, but does not have to, result in the regression or rejection of the tumor; (7) relief, to some extent, of one or more symptoms associated with the tumor; (8) increase in the length of survival following treatment; and/or (9) decreased mortality at a given point of time following treatment.

The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. In tumor (e.g., cancer) treatment, a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.

The term "tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.

10

15

20

25

The "pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium cirrate), 50 mM sodium phosphate (pH 7.6), 5 x

5

15

20

25

Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

In the context of the present invention, reference to "at least one," "at least two," "at least five," etc. of the genes listed in any particular gene set means any one or any and all combinations of the genes listed.

The terms "splicing" and "RNA splicing" are used interchangeably and refer to RNA processing that removes introns and joins exons to produce mature mRNA with continuous coding sequence that moves into the cytoplasm of an eukaryotic cell.

In theory, the term "exon" refers to any segment of an interrupted gene that is represented in the mature RNA product (B. Lewin. <u>Genes IV</u> Cell Press, Cambridge Mass. 1990). In theory the term "intron" refers to any segment of DNA that is transcribed but removed from within the transcript by splicing together the exons on either side of it. Operationally, exon sequences occur in the mRNA sequence of a gene as defined by Ref. Seq ID numbers. Operationally, intron sequences are the intervening sequences within the genomic DNA of a gene, bracketed by exon sequences and having GT and AG splice consensus sequences at their 5' and 3' boundaries.

## B. <u>Detailed Description</u>

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", 2<sup>nd</sup> edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology", 4<sup>th</sup> edition (D.M. Weir & C.C. Blackwell, eds., Blackwell Science Inc., 1987); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987); and "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994).

## 1. Gene Expression Profiling

In general, methods of gene expression profiling can be divided into two large groups: methods based on hybridization analysis of polynucleotides, and methods based on sequencing of polynucleotides. The most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and *in situ* hybridization (Parker & Barnes, *Methods in Molecular Biology* 106:247-283 (1999)); RNAse protection assays (Hod,

10.

15

20

25

Biotechniques 13:852-854 (1992)); and reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)). Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPSS).

## 2. Reverse Transcriptase PCR (RT-PCR)

Of the techniques listed above, the most sensitive and most flexible quantitative method is RT-PCR, which can be used to compare mRNA levels in different sample populations, in normal and tumor tissues, with or without drug treatment, to characterize patterns of gene expression, to discriminate between closely related mRNAs, and to analyze RNA structure.

The first step is the isolation of mRNA from a target sample. The starting material is typically total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a variety of primary tumors, including breast, lung, colon, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines, with pooled DNA from healthy donors. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.

General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest. 56:A67 (1987), and De Andrés et al., BioTechniques 18:42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPure™ Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, WI), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation.

As RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus

15

20

25

reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.

Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5'-3' nuclease activity but lacks a 3'-5' proofreading endonuclease activity. Thus, TaqMan® PCR typically utilizes the 5'-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' nuclease activity can be used. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

TaqMan® RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700<sup>TM</sup> Sequence Detection System<sup>TM</sup> (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700<sup>TM</sup> Sequence Detection System<sup>TM</sup>. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product

5.

10

15

20

25

amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (C<sub>i</sub>).

To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β-actin.

A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan® probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g. Held et al., Genome Research 6:986-994 (1996).

## 3. Microarrays

15

20

25

30

Differential gene expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of breast cancer-associated genes can be measured in either fresh or paraffin-embedded tumor tissue, using microarray technology. In this method, polynucleotide sequences of interest are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. Just as in the RT-PCR method, the source of mRNA typically is total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.

In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate in a dense array. Preferably at least 10,000 nucleotide sequences are applied to the substrate. The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions. Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed

element allows for assessment of corresponding mRNA abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)). Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's microarray technology.

The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.

## 4. <u>Serial Analysis of Gene Expression (SAGE)</u>

10

15

20

25

30

BNSDOCID: <WO

\_\_03078662A1\_l\_>

Serial analysis of gene expression (SAGE) is a method that allows the simultaneous and quantitative analysis of a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript. First, a short sequence tag (about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript, provided that the tag is obtained from a unique position within each transcript. Then, many transcripts are linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. For more details see, e.g. Velculescu et al., Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51 (1997).

## 5. Gene Expression Analysis by Massively Parallel Signature Sequencing (MPSS)

This method, described by Brenner et al., Nature Biotechnology 18:630-634 (2000), is a sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate 5 µm diameter microbeads. First, a microbead library of DNA templates is constructed by in vitro cloning. This is followed by the assembly of a planar array of the template-containing microbeads in a flow cell at a high density (typically greater than 3 x 10<sup>6</sup> microbeads/cm<sup>2</sup>). The free ends of the cloned templates on each microbead are analyzed simultaneously, using a fluorescence-based signature sequencing method that does not require DNA fragment separation. This method has been shown to simultaneously and accurately

provide, in a single operation, hundreds of thousands of gene signature sequences from a yeast cDNA library.

# 6. General Description of the mRNA Isolation, Purification and Amplification Methods of the Invention

The steps of a representative protocol of the invention, including mRNA isolation, purification, primer extension and amplification are illustrated in Figure 1. As shown in Figure 1, this representative process starts with cutting about 10 µm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed, following the method of the invention described below. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumor sample examined. The individual steps of this protocol will be discussed in greater detail below.

## 7. Improved Method for Isolation of Nucleic Acid from Archived Tissue Specimens

As discussed above, in the first step of the method of the invention, total RNA is extracted from the source material of interest, including fixed, paraffin-embedded tissue specimens, and purified sufficiently to act as a substrate in an enzyme assay. Despite the availability of commercial products, and the extensive knowledge available concerning the isolation of nucleic acid, such as RNA, from tissues, isolation of nucleic acid (RNA) from fixed, paraffin-embedded tissue specimens (FPET) is not without difficulty.

In one aspect, the present invention concerns an improved method for the isolation of nucleic acid from archived, e.g. FPET tissue specimens. Measured levels of mRNA species are useful for defining the physiological or pathological status of cells and tissues. RT-PCR (which is discussed above) is one of the most sensitive, reproducible and quantitative methods for this "gene expression profiling". Paraffin-embedded, formalin-fixed tissue is the most widely available material for such studies. Several laboratories have demonstrated that it is possible to successfully use fixed-paraffin-embedded tissue (FPET) as a source of RNA for RT-PCR (Stanta et al., Biotechniques 11:304-308 (1991); Stanta et al., Methods Mol. Biol. 86:23-26 (1998); Jackson et al., Lancet 1:1391 (1989); Jackson et al., J. Clin. Pathol. 43:499-504 (1999); Finke et al., Biotechniques 14:448-453 (1993); Goldsworthy et al., Mol. Carcinog. 25:86-91 (1999); Stanta and Bonin, Biotechniques 24:271-276 (1998); Godfrey et al., J. Mol. Diagnostics 2:84 (2000); Specht et al., J. Mol. Med. 78:B27 (2000); Specht et al., Am. J. Pathol. 158:419-429 (2001)). This allows gene expression profiling to be carried out on the most commonly available

15

20

25.

source of human biopsy specimens, and therefore potentially to create new valuable diagnostic and therapeutic information.

The most widely used protocols utilize hazardous organic solvents, such as xylene, or octane (Finke et al., supra) to dewax the tissue in the paraffin blocks before nucleic acid (RNA and/or DNA) extraction. Obligatory organic solvent removal (e.g. with ethanol) and rehydration steps follow, which necessitate multiple manipulations, and addition of substantial total time to the protocol, which can take up to several days. Commercial kits and protocols for RNA extraction from FPET [MasterPure<sup>TM</sup> Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, WI); Paraffin Block RNA Isolation Kit (Ambion, Inc.) and RNeasy<sup>TM</sup> Mini kit (Qiagen, Chatsworth, CA)] use xylene for deparaffinization, in procedures which typically require multiple centrifugations and ethanol buffer changes, and incubations following incubation with xylene.

The present invention provides an improved nucleic acid extraction protocol that produces nucleic acid, in particular RNA, sufficiently intact for gene expression measurements. The key step in the nucleic acid extraction protocol herein is the performance of dewaxing without the use of any organic solvent, thereby eliminating the need for multiple manipulations associated with the removal of the organic solvent, and substantially reducing the total time to the protocol. According to the invention, wax, e.g. paraffin is removed from wax-embedded tissue samples by incubation at 65-75 °C in a lysis buffer that solubilizes the tissue and hydrolyzes the protein, following by cooling to solidify the wax.

Figure 2 shows a flow chart of an RNA extraction protocol of the present invention in comparison with a representative commercial method, using xylene to remove wax. The times required for individual steps in the processes and for the overall processes are shown in the chart. As shown, the commercial process requires approximately 50% more time than the process of the invention.

The lysis buffer can be any buffer known for cell lysis. It is, however, preferred that oligo-dT-based methods of selectively purifying polyadenylated mRNA not be used to isolate RNA for the present invention, since the bulk of the mRNA molecules are expected to be fragmented and therefore will not have an intact polyadenylated tail, and will not be recovered or available for subsequent analytical assays. Otherwise, any number of standard nucleic acid purification schemes can be used. These include chaotrope and organic solvent extractions, extraction using glass beads or filters, salting out and precipitation based methods, or any of the purification methods known in the art to recover total RNA or total nucleic acids from a biological source.

10

15

20

25

Lysis buffers are commercially available, such as, for example, from Qiagen, Epicentre, or Ambion. A preferred group of lysis buffers typically contains urea, and Proteinase K or other protease. Proteinase K is very useful in the isolation of high quality, undamaged DNA or RNA, since most mammalian DNases and RNases are rapidly inactivated by this enzyme, especially in the presence of 0.5 - 1% sodium dodecyl sulfate (SDS). This is particularly important in the case of RNA, which is more susceptible to degradation than DNA. While DNases require metal ions for activity, and can therefore be easily inactivated by chelating agents, such as EDTA, there is no similar co-factor requirement for RNases.

Cooling and resultant solidification of the wax permits easy separation of the wax from the total nucleic acid, which can be conveniently precipitated, e.g. by isopropanol. Further processing depends on the intended purpose. If the proposed method of RNA analysis is subject to bias by contaminating DNA in an extract, the RNA extract can be further treated, e.g. by DNase, post purification to specifically remove DNA while preserving RNA. For example, if the goal is to isolate high quality RNA for subsequent RT-PCR amplification, nucleic acid precipitation is followed by the removal of DNA, usually by DNase treatment. However, DNA can be removed at various stages of nucleic acid isolation, by DNase or other techniques well known in the art.

While the advantages of the nucleic acid extraction protocol of the invention are most apparent for the isolation of RNA from archived, paraffin embedded tissue samples, the wax removal step of the present invention, which does not involve the use of an organic solvent, can also be included in any conventional protocol for the extraction of total nucleic acid (RNA and DNA) or DNA only. All of these aspects are specifically within the scope of the invention.

By using heat followed by cooling to remove paraffin, the process of the present invention saves valuable processing time, and eliminates a series of manipulations, thereby potentially increasing the yield of nucleic acid. Indeed, experimental evidence presented in the examples below, demonstrates that the method of the present invention does not compromise RNA yield.

## 8. <u>5'-multiplexed Gene Specific Priming of Reverse Transcription</u>

RT-PCR requires reverse transcription of the test RNA population as a first step. The most commonly used primer for reverse transcription is oligo-dT, which works well when RNA is intact. However, this primer will not be effective when RNA is highly fragmented as is the case in FPE tissues.

The present invention includes the use of gene specific primers, which are roughly 20 bases in length with a Tm optimum between about 58 °C and 60 °C. These primers will also serve as the reverse primers that drive PCR DNA amplification.

10...

15

20

25

Another aspect of the invention is the inclusion of multiple gene-specific primers in the same reaction mixture. The number of such different primers can vary greatly and can be as low as two and as high as 40,000 or more. Table 2 displays examples of reverse primers that can be successfully used in carrying out the methods of the invention. Figure 9 shows expression data obtained using this multiplexed gene-specific priming strategy. Specifically, Figure 9 is a representation of the expression of 92 genes (a subset of genes listed in Table 1) across 70 FPE breast cancer specimens. The y-axis shows expression as cycle threshold times.

An alternative approach is based on the use of random hexamers as primers for cDNA synthesis. However, we have experimentally demonstrated that the method of using a multiplicity of gene-specific primers is superior over the known approach using random hexamers.

## 9. Preparation of Fragmented mRNA for Expression Profiling Assays

It is of interest to analyze the abundance of specific mRNA species in biological samples, since this expression profile provides an index of the physiological state of that sample. mRNA is notoriously difficult to extract and maintain in its native state, consequently, mRNA recovered from biological sources is often fragmented or somewhat degraded. This is especially true of human tissue specimen which have been chemically fixed and stored for extended periods of time.

In one aspect, the present invention provides a means of preparing the mRNA extracted from various sources, including archived tissue specimens, for expression profiling in a way that its relative abundance is preserved and the mRNA's of interest can be successfully measured. This method is useful as a means of preparing mRNA for analysis by any of the known expression profiling methods, including RT-PCR coupled with 5' exonuclease of reporter probes (TaqMan® type assays), as discussed above, flap endonuclease assays (Cleavase® and Invader® type assays), oligonucleotide hybridization arrays, cDNA hybridization arrays, oligonucleotide ligation assays, 3' single nucleotide extension assays and other assays designed to assess the abundance of specific mRNA sequences in a biological sample.

According to the method of the invention, total RNA is extracted from the source material and sufficiently purified to act as a substrate in an enzyme assay. The extraction procedure, including a new and improved way of removing the wax (e.g. paraffin) used for embedding the tissue samples, has been discussed above. It has also been noted that it is preferred that oligo-dT based methods of selectively purifying polyadenylated mRNA not be used to isolate RNA for this invention since the bulk of the mRNA is expected to be fragmented, will not be polyadenylated

10

15

20

25

and, therefore, will not be recovered and available for subsequent analytical assays if an oligo-dT based method is used.

A diagram of an improved method for repairing fragmented RNA is shown in Figure 3. The fragmented RNA purified from the tissue sample is mixed with universal or gene-specific, single-stranded, DNA templates for each mRNA species of interest. These templates may be full length DNA copies of the mRNA derived from cloned gene sources, they may be fragments of the gene representing only the segment of the gene to be assayed, they may be a series of long oligonucleotides representing either the full length gene or the specific segment(s) of interest. The template can represent either a single consensus sequence or be a mixture of polymorphic variants of the gene. This DNA template, or scaffold, will preferably include one or more dUTP or rNTP sites in its length. This will provide a means of removing the template prior to carrying out subsequent analytical steps to avoid its acting as a substrate or target in later analysis assays. This removal is accomplished by treating the sample with uracil-DNA glycosylase (UDG) and heating it to cause strand breaks where UDG has generated abasic sites. In the case of rNTP's, the sample can be heated in the presence of a basic buffer (pH ~10) to induce strand breaks where rNTP's are located in the template.

The single stranded DNA template is mixed with the purified RNA, the mixture is denatured and annealed so that the RNA fragments complementary to the DNA template effectively become primers that can be extended along the single stranded DNA templates. DNA polymerase I requires a primer for extension but will efficiently use either a DNA or an RNA primer. Therefore in the presence of DNA polymerase I and dNTP's, the fragmented RNA can be extended along the complementary DNA templates. In order to increase the efficiency of the extension, this reaction can be thermally cycled, allowing overlapping templates and extension products to hybridize and extend until the overall population of fragmented RNA becomes represented as double stranded DNA extended from RNA fragment primers.

Following the generation of this "repaired" RNA, the sample should be treated with UDG or heat-treated in a mildly based solution to fragment the DNA template (scaffold) and prevent it from participating in subsequent analytical reactions.

The product resulting from this enzyme extension can then be used as a template in a standard enzyme profiling assay that includes amplification and detectable signal generation such as fluorescent, chemiluminescent, colorimetric or other common read outs from enzyme based assays. For example, for TaqMan® type assays, this double stranded DNA product is added as the template in a standard assay; and, for array hybridization, this product acts as the cDNA

20

25

template for the cRNA labeling reaction typically used to generate single-stranded, labeled RNA for array hybridization.

This method of preparing template has the advantage of recovering information from mRNA fragments too short to effectively act as templates in standard cDNA generation schemes. In addition, this method acts to preserve the specific locations in mRNA sequences targeted by specific analysis assays. For example, TaqMan® assays rely on a single contiguous sequence in a cDNA copy of mRNA to act as a PCR amplification template targeted by a labeled reporter probe. If mRNA strand breaks occur in this sequence, the assay will not detect that template and will underestimate the quantity of that mRNA in the original sample. This target preparation method minimizes that effect from RNA fragmentation.

The extension product formed in the RNA primer extension assay can be controlled by controlling the input quantity of the single stranded DNA template and by doing limited cycling of the extension reaction. This is important in preserving the relative abundance of the mRNA sequences targeted for analysis.

This method has the added advantage of not requiring parallel preparation for each target sequence since it is easily multiplexed. It is also possible to use large pools of random sequence long oligonucleotides or full libraries of cloned sequences to extend the entire population of mRNA sequences in the sample extract for whole expressed genome analysis rather than targeted gene specific analysis.

10. Amplification of mRNA Species Prior to RT-PCR

Due to the limited amount and poor quality of mRNA that can be isolated from FPET, a new procedure that could accurately amplify mRNAs of interest would be very useful, particularly for real time quantitation of gene expression (TaqMan®) and especially for quantitatively large number (>50) of genes >50 to 10,000.

Current protocols (e.g. Eberwine, *Biotechniques* 20:584-91 (1996)) are optimized for mRNA amplification from small amount of total or poly A<sup>+</sup> RNA mainly for microarray analysis. The present invention provides a protocol optimized for amplification of small amounts of fragmented total RNA (average size about 60-150 bps), utilizing gene-specific sequences as primers, as illustrated in Figure 4.

The amplification procedure of the invention uses a very large number, typically as many as 100 - 190,000 gene specific primers (GSP's) in one reverse transcription run. Each GSP contains an RNA polymerase promoter, e.g. a T7 DNA-dependent RNA polymerase promoter, at the 5' end for subsequent RNA amplification. GSP's are preferred as primers because of the small size of the RNA. Current protocols utilize dT primers, which would not adequately

SUBSTITUTE SHEET (RULE 26)

10

15

20

25

represent all reverse transcripts of mRNAs due to the small size of the FPET RNA. GSP's can be designed by optimizing usual parameters, such as length, Tm, etc. For example, GSP's can be designed using the Primer Express® (Applied Biosystems), or Primer 3 (MIT) software program. Typically at least 3 sets per gene are designed, and the ones giving the lowest Ct on FPET RNA (best performers) are selected.

Second strand cDNA synthesis is performed by standard procedures (see Figure 4, Method 1), or by GSP<sub>f</sub> primers and Taq pol under PCR conditions (e.g., 95 °C, 10 min (Taq activation) then 60 °C, 45 sec). The advantages of the latter method are that the second gene specific primer, SGF<sub>f</sub> adds additional specificity (and potentially more efficient second strand synthesis) and the option of performing several cycles of PCR, if more starting DNA is necessary for RNA amplification by T7 RNA polymerase. RNA amplification is then performed under standard conditions to generate multiple copies of cRNA, which is then used in a standard TaqMan® reaction.

Although this process is illustrated by using T7-based RNA amplification, a person skilled in the art will understand that other RNA polymerase promoters that do not require a primer, such as T3 or Sp6 can also be used, and are within the scope of the invention.

## 11. A method of Elongation of Fragmented RNA and Subsequent Amplification

This method, which combines and modifies the inventions described in sections 9 and 10 above, is illustrated in Figure 5. The procedure begins with elongation of fragmented mRNA. This occurs as described above except that the scaffold DNAs are tagged with the T7 RNA polymerase promoter sequence at their 5' ends, leading to double-stranded DNA extended from RNA fragments. The template sequences need to be removed after *in vitro* transcription. These templates can include dUTP or rNTP nucleotides, enabling enzymatic removal of the templates as described in section 9, or the templates can be removed by DNaseI treatment.

The template DNA can be a population representing different mRNAs of any number. A high sequence complexity source of DNA templates (scaffolds) can be generated by pooling RNA from a variety of cells or tissues. In one embodiment, these RNAs are converted into double stranded DNA and cloned into phagemids. Single stranded DNA can then be rescued by phagemid growth and single stranded DNA isolation from purified phagemids.

This invention is useful because it increases gene expression profile signals two different ways: both by increasing test mRNA polynucleotide sequence length and by *in vitro* transcription amplification. An additional advantage is that it eliminates the need to carry out reverse transcription optimization with gene specific primers tagged with the T7 RNA polymerase promoter sequence, and thus, is comparatively fast and economical.

15

20

25

This invention can be used with a variety of different methods to profile gene expression, e.g., RT-PCR or a variety of DNA array methods. Just as in the previous protocol, this approach is illustrated by using a T7 promoter but the invention is not so limited. A person skilled in the art will appreciate, however, that other RNA polymerase promoters, such as T3 or Sp6 can also be used.

# 12. <u>Breast Cancer Gene Set, Assayed Gene Subsequences, and Clinical Application of</u> Gene Expression Data

An important aspect of the present invention is to use the measured expression of certain genes by breast cancer tissue to match patients to best drugs or drug combinations, and to provide prognostic information. For this purpose it is necessary to correct for (normalize away) both differences in the amount of RNA assayed and variability in the quality of the RNA used. Therefore, the assay measures and incorporates the expression of certain normalizing genes, including well known housekeeping genes, such as GAPDH and Cypl. Alternatively, normalization can be based on the mean or median signal (Ct) of all of the assayed genes or a large subset thereof (global normalization approach). On a gene-by-gene basis, measured normalized amount of a patient tumor mRNA is compared to the amount found in a breast cancer tissue reference set. The number (N) of breast cancer tissues in this reference set should be sufficiently high to ensure that different reference sets (as a whole) behave essentially the same way. If this condition is met, the identity of the individual breast cancer tissues present in a particular set will have no significant impact on the relative amounts of the genes assayed. Usually, the breast cancer tissue reference set consists of at least about 30, preferably at least about 40 different FPE breast cancer tissue specimens. Unless noted otherwise, normalized expression levels for each mRNA/tested tumor/patient will be expressed as a percentage of the expression level measured in the reference set. More specifically, the reference set of a sufficiently high number (e.g. 40) tumors yields a distribution of normalized levels of each mRNA species. The level measured in a particular tumor sample to be analyzed falls at some percentile within this range, which can be determined by methods well known in the art. Below, unless noted otherwise, reference to expression levels of a gene assume normalized expression relative to the reference set although this is not always explicitly stated.

The breast cancer gene set is shown in Table 1. The gene Accession Numbers, and the SEQ ID NOs for the forward primer, reverse primer and amplicon sequences that can be used for gene amplification, are listed in Table 2. The basis for inclusion of markers, as well as the clinical significance of mRNA level variations with respect to the reference set, is indicated below. Genes are grouped into subsets based on the type of clinical significance indicated by

15

20

25

their expression levels: A. Prediction of patient response to drugs used in breast cancer treatment, or to drugs that are approved for other indications and could be used off-label in the treatment of breast cancer. B. Prognostic for survival or recurrence of cancer.

## C. Prediction of Patient Response to Therapeutic Drugs

## 1. Molecules that specifically influence cellular sensitivity to drugs

Table 1 lists 74 genes (shown in italics) that specifically influence cellular sensitivity to potent drugs, which are also listed. Most of the drugs shown are approved and already used to treat breast cancer (e.g., anthracyclines; cyclophosphamide; methotrexate; 5-FU and analogues). Several of the drugs are used to treat breast cancer off-label or are in clinical development phase (e.g., bisphosphonates and anti-VEGF mAb). Several of the drugs have not been widely used to treat breast cancer but are used in other cancers in which the indicated target is expressed (e.g., Celebrex is used to treat familial colon cancer; cisplatin is used to treat ovarian and other cancers.)

Patient response to 5FU is indicated if normalized thymidylate synthase mRNA amount is at or below the 15<sup>th</sup> percentile, or the sum of expression of thymidylate synthase plus dihydropyrimidine phosphorylase is at or below the 25<sup>th</sup> percentile, or the sum of expression of these mRNAs plus thymidine phosphorylase is at or below the 20<sup>th</sup> percentile. Patients with dihydropyrimidine dehydrogenase below 5<sup>th</sup> percentile are at risk of adverse response to 5FU, or analogs such as Xeloda.

When levels of thymidylate synthase, and dihydropyrimidine dehydrogenase, are within the acceptable range as defined in the preceding paragraph, amplification of c-myc mRNA in the upper 15%, against a background of wild-type p53 [as defined below] predicts a beneficial response to 5FU (see D. Arango et al., Cancer Res. 61:4910-4915 (2001)). In the presence of normal levels of thymidylate synthase and dihydropyrimidine dehydrogenase, levels of NFkB and cIAP2 in the upper 10% indicate resistance of breast tumors to the chemotherapeutic drug 5FU.

Patient resistance to anthracyclines is indicated if the normalized mRNA level of topoisomerase II $\alpha$  is below the  $10^{th}$  percentile, or if the topoisomerase II $\beta$  normalized mRNA level is below the  $10^{th}$  percentile or if the combined normalized topoisomerase II $\alpha$  and  $\beta$  signals are below the  $10^{th}$  percentile.

Patient sensitivity to methotrexate is compromised if DHFR levels are more than tenfold higher than the average reference set level for this mRNA species, or if reduced folate carrier levels are below 10<sup>th</sup> percentile.

20

25

Patients whose tumors express CYP1B1 in the upper 10%, have reduced likelihood of responding to docetaxol.

The sum of signals for aldehyde dehydrogenase 1A1 and 1A3, when more than tenfold higher than the reference set average, indicates reduced likelihood of response to cyclophosphamide.

Currently, estrogen and progesterone receptor expression as measured by immunohistochemistry is used to select patients for anti-estrogen therapy. We have demonstrated RT-PCR assays for estrogen and progesterone receptor mRNA levels that predict levels of these proteins as determined by a standard clinical diagnostic tests, with high degree of concordance (Figures 6 and 7).

Patients whose tumors express ER $\alpha$  or PR mRNA in the upper 70%, are likely to respond to tamoxifen or other anti-estrogens (thus, operationally, lower levels of ER $\alpha$  than this are to defined ER $\alpha$ -negative). However, when the signal for microsomal epoxide hydrolase is in the upper 10% or when mRNAs for pS2/trefoil factor, GATA3 or human chorionic gonadotropin are at or below average levels found in ER $\alpha$ -negative tumors, anti-estrogen therapy will not be beneficial.

Absence of XIST signal compromises the likelihood of response to taxanes, as does elevation of the GST- $\pi$  or prolyl endopeptidase [PREP] signal in the upper 10%. Elevation of PLAG1 in the upper 10% decreases sensitivity to taxanes.

Expression of ERCC1 mRNA in the upper 10% indicate significant risk of resistance to cisplatin or analogs.

An RT-PCR assay of Her2 mRNA expression predicts Her2 overexpression as measured by a standard diagnostic test, with high degree of concordance (data not shown). Patients whose tumors express Her2 (normalized to cyp.1) in the upper 10% have increased likelihood of beneficial response to treatment with Herceptin or other ErbB2 antagonists. Measurement of expression of Grb7 mRNA serves as a test for HER2 gene amplification, because the Grb7 gene is closely linked to Her2. When Her2 is expression is high as defined above in this paragraph, similarly elevated Grb7 indicates Her2 gene amplification. Overexpression of IGF1R and or IGF1 or IGF2 decreases likelihood of beneficial response to Herceptin and also to EGFR antagonists.

Patients whose tumors express mutant Ha-Ras, and also express farnesyl pyrophosphate synthetase or geranyl pyrophosphonate synthetase mRNAs at levels above the tenth percentile comprise a group that is especially likely to exhibit a beneficial response to bis-phosphonate drugs.

44

10

15

20

25

Cox2 is a key control enzyme in the synthesis of prostaglandins. It is frequently expressed at elevated levels in subsets of various types of carcinomas including carcinoma of the breast. Expression of this gene is controlled at the transcriptional level, so RT-PCR serves a valid indicator of the cellular enzyme activity. Nonclinical research has shown that cox2 promotes tumor angiogenesis, suggesting that this enzyme is a promising drug target in solid tumors. Several Cox2 antagonists are marketed products for use in anti-inflammatory conditions. Treatment of familial adenomatous polyposis patients with the cox2 inhibitor Celebrex significantly decreased the number and size of neoplastic polyps. No cox2 inhibitor has yet been approved for treatment of breast cancer, but generally this class of drugs is safe and could be prescribed off-label in breast cancers in which cox2 is over-expressed. Tumors expressing COX2 at levels in the upper ten percentile have increased chance of beneficial response to Celebrex or other cyclooxygenase 2 inhibitors.

The tyrosine kinases ErbB1 [EGFR], ErbB3 [Her3] and ErbB4 [Her4]; also the ligands TGFalpha, amphiregulin, heparin-binding EGF-like growth factor, and epiregulin; also BRK, a non-receptor kinase. Several drugs in clinical development block the EGF receptor. ErbB2-4, the indicated ligands, and BRK also increase the activity of the EGFR pathway. Breast cancer patients whose tumors express high levels of EGFR or EGFR and abnormally high levels of the other indicated activators of the EGFR pathway are potential candidates for treatment with an EGFR antagonist.

Patients whose tumors express less than 10% of the average level of EGFR mRNA observed in the reference panel are relatively less likely to respond to EGFR antagonists [such as Iressa, or ImClone 225]. In cases in which the EGFR is above this low range, the additional presence of epiregulin, TGFα, amphiregulin, or ErbB3, or BRK, CD9, MMP9, or Lot1 at levels above the 90<sup>th</sup> percentile predisposes to response to EGFR antagonists. Epiregulin gene expression, in particular, is a good surrogate marker for EGFR activation, and can be used to not only to predict response to EGFR antagonists, but also to monitor response to EGFR antagonists [taking fine needle biopsies to provide tumor tissue during treatment]. Levels of CD82 above the 90<sup>th</sup> percentile suggest poorer efficacy from EGFR antagonists.

The tyrosine kinases abl, c-kit, PDGFRalpha, PDGFbeta, and ARG; also, the signal transmitting ligands c-kit ligand, PDGFA, B, C and D. The listed tyrosine kinases are all targets of the drug Gleevec<sup>TM</sup> (imatinib mesylate, Novartis), and the listed ligands stimulate one or more of the listed tyrosine kinases. In the two indications for which Gleevec<sup>TM</sup> is approved, tyrosine kinase targets (bcr-abl and ckit) are overexpressed and also contain activating mutations. A finding that one of the Gleevec<sup>TM</sup> target tyrosine kinase targets is expressed in breast cancer tissue

15

20

25.

will prompt a second stage of analysis wherein the gene will be sequenced to determine whether it is mutated. That a mutation found is an activating mutation can be proved by methods known in the art, such as, for example, by measuring kinase enzyme activity or by measuring phosphorylation status of the particular kinase, relative to the corresponding wild-type kinase. Breast cancer patients whose tumors express high levels of mRNAs encoding Gleevec<sup>TM</sup> target tyrosine kinases, specifically, in the upper ten percentile, or mRNAs for Gleevec<sup>TM</sup> target tyrosine kinases in the average range and mRNAs for their cognate growth stimulating ligands in the upper ten percentile, are particularly good candidates for treatment with Gleevec<sup>TM</sup>.

VEGF is a potent and pathologically important angiogenic factor. (See below under Prognostic Indicators.) When VEGF mRNA levels are in the upper ten percentile, aggressive treatment is warranted. Such levels particularly suggest the value of treatment with anti-angiogenic drugs, including VEGF antagonists, such as anti-VEGF antibodies. Additionally, KDR or CD31 mRNA level in the upper 20 percentile further increases likelihood of benefit from VEGF antagonists.

Farnesyl pyrophosphatase synthetase and geranyl geranyl pyrophosphatase synthetase. These enzymes are targets of commercialized bisphosphonate drugs, which were developed originally for treatment of osteoporosis but recently have begun to prescribe them off-label in breast cancer. Elevated levels of mRNAs encoding these enzymes in breast cancer tissue, above the 90<sup>th</sup> percentile, suggest use of bisphosphonates as a treatment option.

## 2. Multidrug Resistance Factors

These factors include 10 Genes: gamma glutamyl cysteine synthetase [GCS]; GST-α; GST-π; MDR-1; MRP1-4; breast cancer resistance protein [BCRP]; lung resistance protein [MVP]; SXR; YB-1.

GCS and both GST- $\alpha$  and GST- $\pi$  regulate glutathione levels, which decrease cellular sensitivity to chemotherapeutic drugs and other toxins by reductive derivatization. Glutathione is a necessary cofactor for multi-drug resistant pumps, MDR-1 and the MRPs. MDR1 and MRPs function to actively transport out of cells several important chemotherapeutic drugs used in breast cancer.

GSTs, MDR-1, and MRP-1 have all been studied extensively to determine possible have prognostic or predictive significance in human cancer. However, a great deal of disagreement exists in the literature with respect to these questions. Recently, new members of the MRP family have been identified: MRP-2, MRP-3, MRP-4, BCRP, and lung resistance protein [major vault protein]. These have substrate specificities that overlap with those of MDR-1 and MRP-1. The incorporation of all of these relevant ABC family members as well as glutathione synthetic

10.

15

20

25

enzymes into the present invention captures the contribution of this family to drug resistance, in a way that single or double analyte assays cannot.

MRP-1, the gene coding for the multidrug resistance protein.

P-glycoprotein, is not regulated primarily at the transcriptional level. However, p-glycoprotein stimulates the transcription of PTP1b. An embodiment of the present invention is the use of the level of the mRNA for the phosphatase PTP1b as a surrogate measure of MRP-1/p-glycoprotein activity.

The gene SXR is also an activator of multidrug resistance, as it stimulates transcription of certain multidrug resistance factors.

The impact of multidrug resistance factors with respect to chemotherapeutic agents used in breast cancer is as follows. Beneficial response to doxorubicin is compromised when the mRNA levels of either MDR1, GST $\alpha$ , GST $\pi$ , SXR, BCRP YB-1, or LRP/MVP are in the upper four percentile. Beneficial response to methotrexate is inhibited if mRNA levels of any of MRP1, MRP2, MRP3, or MRP4 or gamma-glutamyl cysteine synthetase are in the upper four percentile.

## 3. Eukaryotic Translation Initiation Factor 4E [EIF4E]

EIF4E mRNA levels provides evidence of protein expression and so expands the capability of RT-PCR to indicate variation in gene expression. Thus, one claim of the present invention is the use of EIF4E as an added indicator of gene expression of certain genes [e.g., cyclinD1, mdm2, VEGF, and others]. For example, in two tissue specimens containing the same amount of normalized VEGF mRNA, it is likely that the tissue containing the higher normalized level of EIF4E exhibits the greater level of VEGF gene expression.

The background is as follows. A key point in the regulation of mRNA translation is selection of mRNAs by the EIF4G complex to bind to the 43S ribosomal subunit. The protein EIF4E [the m7G CAP-binding protein] is often limiting because more mRNAs than EIF4E copies exist in cells. Highly structured 5'UTRs or highly GC-rich ones are inefficiently translated, and these often code for genes that carry out functions relevant to cancer [e.g., cyclinD1, mdm2, and VEGF]. EIF4E is itself regulated at the transcriptional/ mRNA level. Thus, expression of EIF4E provides added indication of increased activity of a number of proteins.

It is also noteworthy that overexpression of EIF4E transforms cultured cells, and hence is an oncogene. Overexpression of EIF4E occurs in several different types of carcinomas but is particularly significant in breast cancer. EIF4E is typically expressed at very low levels in normal breast tissue.

10

15

20

25

10

15

20

25

30

## D. Prognostic Indicators

## 1. DNA Repair Enzymes

Loss of BRCA1 or BRCA2 activity via mutation represents the critical oncogenic step in the most common type[s] of familial breast cancer. The levels of mRNAs of these important enzymes are abnormal in subsets of sporadic breast cancer as well. Loss of signals from either [to within the lower ten percentile] heightens risk of short survival.

## 2. Cell Cycle Regulators

Cell cycle regulators include 14 genes: c-MYC; c-Src; Cyclin D1; Ha-Ras; mdm2; p14ARF; p21WAF1/CIP; p16INK4a/p14; p23; p27; p53; PI3K; PKC-epsilon; PKC-delta.

The gene for p53 [TP53] is mutated in a large fraction of breast cancers. Frequently p53 levels are elevated when loss of function mutation occurs. When the mutation is dominant-negative, it creates survival value for the cancer cell because growth is promoted and apoptosis is inhibited. Thousands of different p53 mutations have been found in human cancer, and the functional consequences of many of them are not clear. A large body of academic literature addresses the prognostic and predictive significance of mutated p53 and the results are highly conflicting. The present invention provides a functional genomic measure of p53 activity, as follows. The activated wild type p53 molecule triggers transcription of the cell cycle inhibitor p21. Thus, the ratio of p53 to p21 should be low when p53 is wild-type and activated. When p53 is detectable and the ratio of p53 to p21 is elevated in tumors relative to normal breast, it signifies nonfunctional or dominant negative p53. The cancer literature provides evidence for this as born out by poor prognosis.

Mdm2 is an important p53 regulator. Activated wildtype p53 stimulates transcription of mdm2. The mdm2 protein binds p53 and promotes its proteolytic destruction. Thus, abnormally low levels of mdm2 in the presence of normal or higher levels of p53 indicate that p53 is mutated and inactivated.

One aspect of the present invention is the use of ratios of mRNAs levels p53:p21 and p53:mdm2 to provide a picture of p53 status. Evidence for dominant negative mutation of p53 (as indicated by high p53:p21 and/or high p53:mdm2 mRNA ratios—specifically in the upper ten percentile) presages higher risk of recurrence in breast cancer and therefore weights toward a decision to use chemotherapy in node negative post surgery breast cancer.

Another important cell cycle regulator is p27, which in the activated form blocks cell cycle progression at the level of cdk4. The protein is regulated primarily via phosphorylation/dephosphorylation, rather than at the transcriptional level. However, levels of

p27 mRNAs do vary. Therefore a level of p27 mRNA in the upper ten percentile indicates reduced risk of recurrence of breast cancer post surgery.

Cyclin D1 is a principle positive regulator of entry into S phase of the cell cycle. The gene for cyclin D1 is amplified in about 20% of breast cancer patients, and therefore promotes tumor promotes tumor growth in those cases. One aspect of the present invention is use of cyclin D1 mRNA levels for diagnostic purposes in breast cancer. A level of cyclin D1 mRNA in the upper ten percentile suggests high risk of recurrence in breast cancer following surgery and suggests particular benefit of adjuvant chemotherapy.

## 3. Other tumor suppressors and related proteins

These include APC and E-cadherin. It has long been known that the tumor suppressor APC is lost in about 50% of colon cancers, with concomitant transcriptional upregulation of E-cadherin, an important cell adhesion molecule and growth suppressor. Recently, it has been found that the APC gene silenced in 15-40 % of breast cancers. Likewise, the E-cadherin gene is silenced [via CpG island methylation] in about 30% of breast cancers. An abnormally low level of APC and/or E-cadherin mRNA in the lower 5 percentile suggests high risk of recurrence in breast cancer following surgery and heightened risk of shortened survival.

#### 4. Regulators of Apoptosis

These include BCl/BAX family members BCl2, Bcl-xl, Bak, Bax and related factors, NFk-B and related factors, and also p53BP1/ASPP1 and p53BP2/ASPP2.

Bax and Bak are pro-apoptotic and BCl2 and Bcl-xl are anti-apoptotic. Therefore, the ratios of these factors influence the resistance or sensitivity of a cell to toxic (pro-apoptotic) drugs. In breast cancer, unlike other cancers, elevated level of BCl2 (in the upper ten percentile) correlates with good outcome. This reflects the fact that BCl2 has growth inhibitory activity as well as anti-apoptotic activity, and in breast cancer the significance of the former activity outweighs the significance of the latter. The impact of BCl2 is in turn dependent on the status of the growth stimulating transcription factor c-MYC. The gene for c-MYC is amplified in about 20% of breast cancers. When c-MYC message levels are abnormally elevated relative to BCl2 (such that this ratio is in the upper ten percentile), then elevated level of BCl2 mRNA is no longer a positive indicator.

NFκ-B is another important anti-apoptotic factor. Originally, recognized as a proinflammatory transcription factor, it is now clear that it prevents programmed cell death in response to several extracellular toxic factors [such as tumor necrosis factor]. The activity of this transcription factor is regulated principally via phosphorylation/dephosphorylation events. However, levels of NFκ-B nevertheless do vary from cell to cell, and elevated levels should

10

15

20:

25

correlate with increased resistance to apoptosis. Importantly for present purposes, NFk-B, exerts its anti-apoptotic activity largely through its stimulation of transcription of mRNAs encoding certain members of the IAP [inhibitor of apoptosis] family of proteins, specifically cIAP1, cIAP2, XIAP, and Survivin. Thus, abnormally elevated levels of mRNAs for these IAPs and for NFk-B any in the upper 5 percentile] signify activation of the NFk-B anti-apoptotic pathway. This suggests high risk of recurrence in breast cancer following chemotherapy and therefore poor prognosis. One embodiment of the present invention is the inclusion in the gene set of the above apoptotic regulators, and the above-outlined use of combinations and ratios of the levels of their mRNAs for prognosis in breast cancer.

The proteins p53BP1 and 2 bind to p53 and promote transcriptional activation of proapoptotic genes. The levels of p53BP1 and 2 are suppressed in a significant fraction of breast cancers, correlating with poor prognosis. When either is expressed in the lower tenth percentile poor prognosis is indicated.

## 5. Factors that control cell invasion and angiogenesis

These include uPA, PAI1, cathepsinsB, G and L, scatter factor [HGF], c-met, KDR, VEGF, and CD31. The plasminogen activator uPA and its serpin regulator PAI1 promote breakdown of extracellular matrices and tumor cell invasion. Abnormally elevated levels of both mRNAs in malignant breast tumors (in the upper twenty percentile) signify an increased risk of shortened survival, increased recurrence in breast cancer patients post surgery, and increased importance of receiving adjuvant chemotherapy. On the other hand, node negative patients whose tumors do not express elevated levels of these mRNA species are less likely to have recurrence of this cancer and could more seriously consider whether the benefits of standard chemotherapy justifies the associated toxicity.

Cathepsins B or L, when expressed in the upper ten percentile, predict poor disease-free and overall survival. In particular, cathepsin L predicts short survival in node positive patients.

Scatter factor and its cognate receptor c-met promote cell motility and invasion, cell growth, and angiogenesis. In breast cancer elevated levels of mRNAs encoding these factors should prompt aggressive treatment with chemotherapeutic drugs, when expression of either, or the combination, is above the 90<sup>th</sup> percentile.

VEGF is a central positive regulator of angiogenesis, and elevated levels in solid tumors predict short survival [note many references showing that elevated level of VEGF predicts short survival]. Inhibitors of VEGF therefore slow the growth of solid tumors in animals and humans. VEGF activity is controlled at the level of transcription. VEGF mRNA levels in the upper ten percentile indicate significantly worse than average prognosis. Other markers of vascularization,

10

15

20

25

CD31 [PECAM], and KDR indicate high vessel density in tumors and that the tumor will be particularly malignant and aggressive, and hence that an aggressive therapeutic strategy is warranted.

## 6. Markers for Immune and Inflammatory Cells and Processes

These markers include the genes for Immunoglobulin light chain  $\lambda$ , CD18, CD3, CD68, Fas [CD95], and Fas Ligand.

Several lines of evidence suggest that the mechanisms of action of certain drugs used in breast cancer entail activation of the host immune/inflammatory response (For example, Herceptin®). One aspect of the present invention is the inclusion in the gene set of markers for inflammatory and immune cells, and markers that predict tumor resistance to immune surveillance. Immunoglobulin light chain lambda is a marker for immunoglobulin producing cells. CD18 is a marker for all white cells. CD3 is a marker for T-cells. CD68 is a marker for macrophages.

CD95 and Fas ligand are a receptor: ligand pair that mediate one of two major pathways by which cytotoxic T cells and NK cells kill targeted cells. Decreased expression of CD95 and increased expression of Fas Ligand indicates poor prognosis in breast cancer. Both CD95 and Fas Ligand are transmembrane proteins, and need to be membrane anchored to trigger cell death. Certain tumor cells produce a truncated soluble variant of CD95, created as a result of alternative splicing of the CD95 mRNA. This blocks NK cell and cytotoxic T cell Fas Ligand-mediated killing of the tumors cells. Presence of soluble CD95 correlates with poor survival in breast cancer. The gene set includes both soluble and full-length variants of CD95.

#### 7. Cell proliferation markers

The gene set includes the cell proliferation markers Ki67/MiB1, PCNA, Pin1, and thymidine kinase. High levels of expression of proliferation markers associate with high histologic grade, and short survival. High levels of thymidine kinase in the upper ten percentile suggest in creased risk of short survival. Pin1 is a prolyl isomerase that stimulates cell growth, in part through the transcriptional activation of the cyclin D1 gene, and levels in the upper ten percentile contribute to a negative prognostic profile.

#### 8. Other growth factors and receptors

This gene set includes IGF1, IGF2, IGFBP3, IGF1R, FGF2, FGFR1, CSF-1R/fms, CSF-1, IL6 and IL8. All of these proteins are expressed in breast cancer. Most stimulate tumor growth. However, expression of the growth factor FGF2 correlates with good outcome. Some have antiapoptotic activity, prominently IGF1. Activation of the IGF1 axis via elevated IGF1, IGF1R, or

20

25

IGFBP3 (as indicated by the sum of these signals in the upper ten percentile) inhibits tumor cell death and strongly contributes to a poor prognostic profile.

## 9. Gene expression markers that define subclasses of breast cancer

These include: GRO1 oncogene alpha, Grb7, cytokeratins 5 and 17, retinal binding protein 4, hepatocyte nuclear factor 3, integrin alpha 7, and lipoprotein lipase. These markers subset breast cancer into different cell types that are phenotypically different at the level of gene expression. Tumors expressing signals for Bcl2, hepatocyte nuclear factor 3, LIV1 and ER above the mean have the best prognosis for disease free and overall survival following surgical removal of the cancer. Another category of breast cancer tumor type, characterized by elevated expression of lipoprotein lipase, retinol binding protein 4, and integrin α7, carry intermediate prognosis. Tumors expressing either elevated levels of cytokeratins 5, and 17, GRO oncogene at levels four-fold or greater above the mean, or ErbB2 and Grb7 at levels ten-fold or more above the mean, have worst prognosis.

Although throughout the present description, including the Examples below, various aspects of the invention are explained with reference to gene expression studies, the invention can be performed in a similar manner, and similar results can be reached by applying proteomics techniques that are well known in the art. The proteome is the totality of the proteins present in a sample (e.g. tissue, organism, or cell culture) at a certain point of time. Proteomics includes, among other things, study of the global changes of protein expression in a sample (also referred to as "expression proteomics"). Proteomics typically includes the following steps: (1) separation of individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual proteins recovered from the gel, e.g. my mass spectrometry and/or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods of the present invention, to detect the products of the gene markers of the present invention.

Further details of the invention will be described in the following non-limiting Examples.

#### Example 1

Isolation of RNA from formalin-fixed, paraffin-embedded (FPET) tissue specimens

A. <u>Protocols</u>

I. EPICENTRE® Xylene Protocol

#### **RNA** Isolation

(1) Cut 1-6 sections (each 10  $\mu$ m thick) of paraffin-embedded tissue per sample using a clean microtome blade and place into a 1.5 ml eppendorf tube.

**52** 

15

20

25

(2) To extract paraffin, add 1 ml of xylene and invert the tubes for 10 minutes by rocking on a nutator.

- (3) Pellet the sections by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
  - (4) Remove the xylene, leaving some in the bottom to avoid dislodging the pellet.
  - (5) Repeat steps 2-4.
  - (6) Add 1 ml of 100% ethanol and invert for 3 minutes by rocking on the nutator.
- (7) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
  - (8) Remove the ethanol, leaving some at the bottom to avoid the pellet.
  - (9) Repeat steps 6-8 twice.
  - (10) Remove all of the remaining ethanol.
- (11) For each sample, add 2 μl of 50 μg/μl Proteinase K to 300 μl of Tissue and Cell Lysis Solution.
- (12) Add 300 μl of Tissue and Cell Lysis Solution containing the Proteinase K to each sample and mix thoroughly.
  - (13) Incubate at 65 °C for 90 minutes (vortex mixing every 5 minutes). Visually monitor the remaining tissue fragment. If still visible after 30 minutes, add an additional 2 μl of 50 μg/μl Proteinase K and continue incubating at 65 °C until fragment dissolves.
- (14) Place the samples on ice for 3-5 minutes and proceed with protein removal and total nucleic acid precipitation.

## Protein Removal and Precipitation of Total Nucleic Acid

- (1) Add 150 µl of MPC Protein Precipitation Reagent to each lysed sample and vortex vigorously for 10 seconds.
- 25 (2) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
  - (3) Transfer the supernatant into clean eppendorf tubes and discard the pellet.
  - (4) Add 500 µl of isopropanol to the recovered supernatant and thoroughly mix by rocking on the nutator for 3 minutes.
- 30 (5) Pellet the RNA/DNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
  - (6) Remove all of the isopropanol with a pipet, being careful not to dislodge the pellet.

10

15

## Removal of Contaminating DNA from RNA Preparations

- (1) Prepare 200 μl of DNase I solution for each sample by adding 5 μl of RNase-Free DNase I (1 U/μl) to 195 μl of 1X DNase Buffer.
- (2) Completely resuspend the pelleted RNA in 200 µl of DNase I solution by vortexing.
  - (3) Incubate the samples at 37 °C for 60 minutes.
  - (4) Add 200 µl of 2X T and C Lysis Solution to each sample and vortex for 5 seconds.
- (5) Add 200 µl of MPC Protein Precipitation Reagent, mix by vortexing for 10 seconds and place on ice for 3-5 minutes.
  - (6) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
  - (7) Transfer the supernatant containing the RNA to clean eppendorf tubes and discard the pellet. (Be careful to avoid transferring the pellet.)
- 15 (8) Add 500 μl of isopropanol to each supernatant and rock samples on the nutator for 3 minutes.
  - (9) Pellet the RNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
- (10) Remove the isopropanol, leaving some at the bottom to avoid dislodging the 20 pellet.
  - (11) Rinse twice with 1 ml of 75% ethanol. Centrifuge briefly if the RNA pellet is dislodged.
    - (12) Remove ethanol carefully.
    - (13) Set under fume hood for about 3 minutes to remove residual ethanol.
- 25 (14) Resuspend the RNA in 30 μl of TE Buffer and store at -30 °C.

## II. Hot Wax/Urea Protocol of the Invention

## **RNA Isolation**

- (1) Cut 3 sections (each 10  $\mu m$  thick) of paraffin-embedded tissue using a clean microtome blade and place into a 1.5 ml eppendorf tube.
- 30 (2) Add 300 μl of lysis buffer (10 mM Tris 7.5, 0.5% sodium lauroyl sarcosine, 0.1 mM EDTA pH 7.5, 4M Urea) containing 330 μg/ml Proteinase K (added freshly from a 50 μg/μl stock solution) and vortex briefly.

54 SUBSTITUTE SHEET (RULE 26)

(3) Incubate at 65 °C for 90 minutes (vortex mixing every 5 minutes). Visually monitor the tissue fragment. If still visible after 30 minutes, add an additional 2 μl of 50 μg/μl Proteinase K and continue incubating at 65 °C until fragment dissolves.

- (4) Centrifuge for 5 minutes at 14,000 x g and transfer upper aqueous phase to new tube, being careful not to disrupt the paraffin seal.
- (5) Place the samples on ice for 3-5 minutes and proceed with protein removal and total nucleic acid precipitation.

## Protein Removal and Precipitation of Total Nucleic Acid

- (1) Add 150  $\mu$ l of 7.5M NH<sub>4</sub>OAc to each lysed sample and vortex vigorously for 10 seconds.
  - (2) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
    - (3) Transfer the supernatant into clean eppendorf tubes and discard the pellet.
  - (4) Add 500 µl of isopropanol to the recovered supernatant and thoroughly mix by rocking on the nutator for 3 minutes.
    - (5) Pellet the RNA/DNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
    - (6) Remove all of the isopropanol with a pipet, being careful not to dislodge the pellet.

#### Removal of Contaminating DNA from RNA Preparations

- (1) Add 45 μl of 1X DNase I buffer (10 mM Tris-Cl, pH 7,5, 2.5 mM MgCl<sub>2</sub>, 0.1 mM CaCl<sub>2</sub>) and 5 μl of RNase-Free DNase I (2U/μl, Ambion) to each sample.
  - (2) Incubate the samples at 37 °C for 60 minutes. Inactivate the DNaseI by heating at 70 °C for 5 minutes.

#### 25 B. Results

15

20

30

Experimental evidence demonstrates that the hot RNA extraction protocol of the invention does not compromise RNA yield. Using 19 FPE breast cancer specimens, extracting RNA from three adjacent sections in the same specimens, RNA yields were measured via capillary electrophoresis with fluorescence detection (Agilent Bioanalyzer). Average RNA yields in nanograms and standard deviations with the invented and commercial methods, respectively, were: 139+/-21 versus 141+/-34.

Also, it was found that the urea-containing lysis buffer of the present invention can be substituted for the EPICENTRE® T&C lysis buffer, and the 7.5 M NH<sub>4</sub>OAc reagent used for protein precipitation in accordance with the present invention can be substituted for the

EPICENTRE® MPC protein precipitation solution with neither significant compromise of RNA yield nor TaqMan® efficiency.

## Example 2

10

15

20

25

## Amplification of mRNA Species Prior to RT-PCR

The method described in section 10 above was used with RNA isolated from fixed, paraffin-embedded breast cancer tissue. TaqMan® analyses were performed with first strand cDNA generated with the T7-GSP primer (unamplified (T7-GSPr)), T7 amplified RNA (amplified (T7-GSPr)). RNA was amplified according to step 2 of Figure 4. As a control, TaqMan® was also performed with cDNA generated with an unmodified GSPr (amplified (GSPr)). An equivalent amount of initial template (1 ng/well) was used in each TaqMan® reaction.

The results are shown in Figure 8. In vitro transcription increased RT-PCR signal intensity by more than 10 fold, and for certain genes by more than 100 fold relative to controls in which the RT-PCR primers were the same primers used in method 2 for the generation of double-stranded DNA for in vitro transcription (GSP-T7, and GSP,). Also shown in Figure 8 are RT-PCR data generated when standard optimized RT-PCR primers (i.e., lacking T7 tails) were used. As shown, compared to this control, the new method yielded substantial increases in RT-PCR signal (from 4 to 64 fold in this experiment).

The new method requires that each T7-GSP sequence be optimized so that the increase in the RT-PCR signal is the same for each gene, relative to the standard optimized RT-PCR (with non-T7 tailed primers).

#### Example 3

## A Study of Gene Expression in Premalignant and Malignant Breast Tumors

A gene expression study was designed and conducted with the primary goal to molecularly characterize gene expression in paraffin-embedded, fixed tissue samples of invasive breast ductal carcinoma, and to explore the correlation between such molecular profiles and disease-free survival. A further objective of the study was to compare the molecular profiles in tissue samples of invasive breast cancer with the molecular profiles obtained in ductal carcinoma in situ. The study was further designed to obtain data on the molecular profiles in lobular carcinoma in situ and in paraffin-embedded, fixed tissue samples of invasive lobular carcinoma.

Molecular assays were performed on paraffin-embedded, formalin-fixed primary breast tumor tissues obtained from 202 individual patients diagnosed with breast cancer. All patients underwent surgery with diagnosis of invasive ductal carcinoma of the breast, pure ductal carcinoma in situ (DCIS), lobular carcinoma of the breast, or pure lobular carcinoma in situ

(LCIS). Patients were included in the study only if histopathologic assessment, performed as described in the Materials and Methods section, indicated adequate amounts of tumor tissue and homogeneous pathology.

The individuals participating in the study were divided into the following groups:

Group 1: Pure ductal carcinoma in situ (DCIS); n=18

Group 2: Invasive ductal carcinoma n=130

Group 3: Pure lobular carcinoma in situ (LCIS); n=7

Group 4: Invasive lobular carcinoma n=16

#### Materials and Methods

10

15

20

25

30

Each representative tumor block was characterized by standard histopathology for diagnosis, semi-quantitative assessment of amount of tumor, and tumor grade. A total of 6 sections (10 microns in thickness each) were prepared and placed in two Costar Brand Microcentrifuge Tubes (Polypropylene, 1.7 mL tubes, clear; 3 sections in each tube). If the tumor constituted less than 30% of the total specimen area, the sample may have been crudely dissected by the pathologist, using gross microdissection, putting the tumor tissue directly into the Costar tube.

If more than one tumor block was obtained as part of the surgical procedure, all tumor blocks were subjected to the same characterization, as described above, and the block most representative of the pathology was used for analysis.

#### Gene Expression Analysis

mRNA was extracted and purified from fixed, paraffin-embedded tissue samples, and prepared for gene expression analysis as described in chapters 7-11 above.

Molecular assays of quantitative gene expression were performed by RT-PCR, using the ABI PRISM 7900<sup>TM</sup> Sequence Detection System<sup>TM</sup> (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA). ABI PRISM 7900<sup>TM</sup> consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 384-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 384 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

## **Analysis and Results**

Tumor tissue was analyzed for 185 cancer-related genes and 7 reference genes. The threshold cycle (CT) values for each patient were normalized based on the median of all genes

for that particular patient. Clinical outcome data were available for all patients from a review of registry data and selected patient charts.

Outcomes were classified as:

- died due to breast cancer or to unknown cause or alive with breast cancer recurrence;
- alive without breast cancer recurrence or died due to a cause other than breast cancer

Analysis was performed by:

- 1. Analysis of the relationship between normalized gene expression and the binary outcomes of 0 or 1.
  - 2. Analysis of the relationship between normalized gene expression and the time to outcome (0 or 1 as defined above) where patients who were alive without breast cancer recurrence or who died due to a cause other than breast cancer were censored. This approach was used to evaluate the prognostic impact of individual genes and also sets of multiple genes.

Analysis of 147 patients with invasive breast carcinoma by binary approach

In the first (binary) approach, analysis was performed on all 146 patients with invasive breast carcinoma. At test was performed on the group of patients classified as 0 or 1 and the p-values for the differences between the groups for each gene were calculated.

The following Table 4 lists the 45 genes for which the p-value for the differences between the groups was <0.05.

Table 4

Gene/	Mean CT	Mean CT	t-value	Degrees of freedom	p
SEQ ID NO:	Alive 33.66	Deceased 32.52	3.92	144	0.0001
FOXM1					
PRAME	35.45	33.84	3.71	144	0.0003
Bcl2	28.52	29.32	-3.53	144	0.0006
STK15	30.82	30.10	3.49	144	0.0006
CEGP1	29.12	30.86	-3.39	144	0.0009
Ki-67	30.57	29.62	3.34	144	0.0011
GSTM1	30.62	31.63	-3.27	144	0.0014
CA9	34.96	33.54	3.18	144	0.0018
PR	29.56	31.22	-3.16	144	0.0019
BBC3	31.54	32.10	-3.10	144	0.0023
NME1	27.31	26.68	3.04	144	0.0028
SURV	31.64	30.68	2.92	144	0.0041
GATA3	26.06	26.99	-2.91	144	0.0042
TFRC	28.96	28.48	2.87	144	0.0047
YB-1	26.72	26.41	2.79	144	0.0060
DPYD	28.51	28.84	-2.67	144	0.0084
GSTM3	28.21	29.03	-2.63	144	0.0095
RPS6KB1	31.18	30.61	2.61	144	0.0099
Src	27.97	27.69	2.59	144	0.0105
Chkl	32.63	31.99	2.57	144	0.0113
ID1	28.73	29.13	-2.48	144	0.0141
EstR1	24.22	25.40	-2.44	144	0.0160
p27	27.15	27.51	-2.41	144	0.0174
CCNB1	31.63	30.87	2.40	144	0.0176
XIAP	30.27	30.51	-2.40	144	0.0178
Chk2	31.48	31.11	2.39	144	0.0179
CDC25B	29.75	29.39	2.37	144	0.0193
IGF1R	28.85	29.44	-2.34	144	0.0209

SUBSTITUTE SHEET (RULE 26)

• • • • • • • • • • • • • • • • • • • •			50		•
AK055699	33.23	34.11	-2.28	144	0.0242
PI3KC2A	31.07	31.42	-2.25	144	0.0257
TGFB3	28.42	28.85	-2.25	144	0.0258
BAGI1	28.40	28.75	-2.24	144	0.0269
CYP3A4	35.70	35.32	2.17	144	0.0317
EpCAM	28.73	28.34	2.16	144	0.0321
VEGFC	32.28	31.82	2.16	144	0.0326
pS2	28.96	30.60	-2.14	144	0.0341
hENT1	27.19	26.91	2.12	144	0.0357
WISP1	31.20	31.64	-2.10	144	0.0377
HNF3A	27.89	28.64	-2.09	144	0.0384
NFKBp65	33.22	33.80	-2.08	144	0.0396
BRCA2	33.06	32.62	2.08	144	0.0397
EGFR	30.68	30.13	2.06	144	0.0414
TK1	32.27	31.72	2.02	144	0.0453
VDR	30.08	29.73	1.99	144	0.0488
1	1 >	<u> </u>	1	. <del> </del>	

In the foregoing Table 4, lower (negative) t-values indicate higher expression (or lower CTs), associated with better outcomes, and, inversely, higher (positive) t-values indicate higher expression (lower CTs) associated with worse outcomes. Thus, for example, elevated expression of the FOXM1 gene (t-value = 3.92, CT mean alive> CT mean deceased) indicates a reduced likelihood of disease free survival. Similarly, elevated expression of the CEGP1 gene (t-value = -3.39; CT mean alive< CT mean deceased) indicates an increased likelihood of disease free survival.

Based on the data set forth in Table 4, the overexpression of any of the following genes in breast cancer indicates a reduced likelihood of survival without cancer recurrence following surgery: FOXM1; PRAME; SKT15, Ki-67; CA9; NME1; SURV; TFRC; YB-1; RPS6KB1; Src; Chk1; CCNB1; Chk2; CDC25B; CYP3A4; EpCAM; VEGFC; hENT1; BRCA2; EGFR; TK1; VDR.

Based on the data set forth in Table 4, the overexpression of any of the following genes in breast cancer indicates a better prognosis for survival without cancer recurrence following surgery: Blc12; CEGP1; GSTM1; PR; BBC3; GATA3; DPYD; GSTM3; ID1; EstR1; p27; XIAP; IGF1R; AK055699; P13KC2A; TGFB3; BAGI1; pS2; WISP1; HNF3A; NFKBp65.

10

## Analysis of 108 ER positive patient by binary approach

108 patients with normalized CT for estrogen receptor (ER) < 25.2 (i.e., ER positive patients) were subjected to separate analysis. A t test was performed on the groups of patients classified as 0 or 1 and the p-values for the differences between the groups for each gene were calculated. The following Table 5 lists the 12 genes where the p-value for the differences between the groups was <0.05.

Table 5

				and the second second	
Gene/	Mean CT	Mean CT	t-value	Degrees of	p
SEQ ID NO:	Alive	Deceased		freedom	
PRAME	35.54	33.88	3.03	106	0.0031
Bcl2	28.24	28.87	-2.70	106	0.0082
FOXM1	33.82	32.85	2.66	106	0.089
DIABLO	30.33	30.71	-2.47	106	0.0153
EPHX1	28.62	28.03	2.44	106	0.0163
HIF1A	29.37	28.88	2.40	106	0.0180
VEGFC	32.39	31.69	2.39	106	0.0187
Ki-67	30.73	29.82	2.38	106	0.0191
IGF1R	28.60	29.18	-2.37	106	0.0194
VDR	30.14	29.60	2.17	106	0.0322
NME1	27.34	26.80	2.03	106	0.0452
GSTM3	28.08	28.92	-2.00	106	0.0485

10

15

20

For each gene, a classification algorithm was utilized to identify the best threshold value (CT) for using each gene alone in predicting clinical outcome.

Based on the data set forth in Table 5, overexpression of the following genes in ER-positive cancer is indicative of a reduced likelihood of survival without cancer recurrence following surgery: PRAME; FOXM1; EPHX1; HIF1A; VEGFC; Ki-67; VDR; NME1. Some of these genes (PRAME; FOXM1; VEGFC; Ki-67; VDR; and NME1) were also identified as indicators of poor prognosis in the previous analysis, not limited to ER-positive breast cancer. The overexpression of the remaining genes (EPHX1 and HIF1A) appears to be negative indicator of disease free survival in ER-positive breast cancer only. Based on the data set forth in Table 5, overexpression of the following genes in ER-positive cancer is indicative of a better

**SUBSTITUTE SHEET (RULE 26)** 

prognosis for survival without cancer recurrence following surgery: Bcl-2; DIABLO; IGF1R; GSTM3. Of the latter genes, Bcl-2; IGFR1; and GSTM3 have also been identified as indicators of good prognosis in the previous analysis, not limited to ER-positive breast cancer. The overexpression of DIABLO appears to be positive indicator of disease free survival in ER-positive breast cancer only.

## Analysis of multiple genes and indicators of outcome

Two approaches were taken in order to determine whether using multiple genes would provide better discrimination between outcomes.

First, a discrimination analysis was performed using a forward stepwise approach. Models were generated that classified outcome with greater discrimination than was obtained with any single gene alone.

According to a second approach (time-to-event approach), for each gene a Cox Proportional Hazards model (see, e.g. Cox, D. R., and Oakes, D. (1984), Analysis of Survival Data, Chapman and Hall, London, New York) was defined with time to recurrence or death as the dependent variable, and the expression level of the gene as the independent variable. The genes that have a p-value < 0.05 in the Cox model were identified. For each gene, the Cox model provides the relative risk (RR) of recurrence or death for a unit change in the expression of the gene. One can choose to partition the patients into subgroups at any threshold value of the measured expression (on the CT scale), where all patients with expression values above the threshold have higher risk, and all patients with expression values below the threshold have lower risk, or vice versa, depending on whether the gene is an indicator of good (RR>1.01) or poor (RR<1.01) prognosis. Thus, any threshold value will define subgroups of patients with respectively increased or decreased risk. The results are summarized in the following Tables 6 and 7.

25

20

10

<u>Table 6</u>

<u>Cox Model Results for 146 Patients with Invasive Breast Cancer</u>

Gene	Relative Risk (RR)	SE Relative Risk	p value
FOXMI	0.58	0.15	0.0002
STK15	0.51	0.20	0.0006
PRAME	0.78	0.07	0.0007
Bcl2	1.66	0.15	0.0009
CEGP1	1.25	0.07	0.0014
GSTM1	1.40	0.11	0.0014
Ki67	0.62	0.15	0.0016
PR	1.23	0.07	0.0017
Contig51037	0.81	0.07	0.0022
NME1	0.64	0.15	0.0023
YB-1	0.39	0.32	0.0033
TFRC	0.53	0.21	0.0035
BBC3	1.72	0.19	0.0036
GATA3	1.32	0.10	0.0039
CA9	0.81	0.07	0.0049
SURV	0.69	0.13	0.0049
DPYD	2.58	0.34	0.0052
RPS6KB1	0.60	0.18	0.0055
GSTM3	1.36	0.12	0.0078
Src.2	0.39	0.36	0.0094
TGFB3	1.61	0.19	0.0109
CDC25B	0.54	0.25	0.0122
XIAP	3.20	0.47	0.0126
CCNB1	0.68	0.16	0.0151
IGF1R	1.42	0.15	0.0153
Chk1	0.68	0.16	0.0155
ID1	1.80	0.25	0.0164
p27	1.69	0.22	0.0168
Chk2	0.52	0.27	0.0175

 $$^{63}$$  SUBSTITUTE SHEET (RULE 26)

EstR1	1.17	0.07	0.0196
HNF3A	1.21	0.08	0.206
pS2	1.12	0.05	0.0230
BAGI1	1.88	0.29	0.0266
AK055699	1.24	0.10	0.0276
pENT1	0.51	0.31	0.0293
EpCAM	0.62	0.22	0.0310
WISP1	1.39	0.16	0.0338
VEGFC	0.62	0.23	0.0364
TK1	0.73	0.15	0.0382
NFKBp65	1.32	0.14	0.0384
BRCA2	0.66	0.20	0.0404
CYP3A4	0.60	0.25	0.0417
EGFR	0.72	0.16	0.0436

Table 7

Cox Model Results for 108 Patients wih ER+ Invasive Breast Cancer

Gene	Relative Risk (RR)	SE Relative Risk	p-value
PRAME	0.75	0.10	0.0045
Contig51037	0.75	0.11	0.0060
Blc2	2.11	0.28	0.0075
HIF1A	0.42	0.34	0.0117
IGF1R	1.92	0.26	0.0117
FOXM1	0.54	0.24	0.0119
EPHX1	0.43	0.33	0.0120
Ki67	0.60	0.21	0.0160
CDC25B	0.41	0.38	0.0200
VEGFC	0.45	0.37	0.0288
CTSB	0.32	0.53	0.0328
DIABLO	2.91	0.50	0.0328
p27	1.83	0.28	0.0341
CDH1	0.57	0.27	0.0352
IGFBP3	0.45	0.40	. 0.0499

SUBSTITUTE SHEET (RULE 26)

The binary and time-to-event analyses, with few exceptions, identified the same genes as prognostic markers. For example, comparison of Tables 4 and 6 shows that, with the exception of a single gene, the two analyses generated the same list of top 15 markers (as defined by the smallest p values). Furthermore, when both analyses identified the same gene, they were concordant with respect to the direction (positive or negative sign) of the correlation with survival/recurrence. Overall, these results strengthen the conclusion that the identified markers have significant prognostic value.

For Cox models comprising more than two genes (multivariate models), stepwise entry of each individual gene into the model is performed, where the first gene entered is pre-selected from among those genes having significant univariate p-values, and the gene selected for entry into the model at each subsequent step is the gene that best improves the fit of the model to the data. This analysis can be performed with any total number of genes. In the analysis the results of which are shown below, stepwise entry was performed for up to 10 genes.

Multivariate analysis is performed using the following equation:

In this equation, coefficiencts for genes that are predictors of beneficial outcome are positive numbers and coefficients for genes that are predictors of unfavorable outcome are negative numbers. The "Ct" values in the equation are  $\Delta$ Cts, i.e. reflect the difference between the average normalized Ct value for a population and the normalized Ct measured for the patient in question. The convention used in the present analysis has been that  $\Delta$ Cts below and above the population average have positive signs and negative signs, respectively (reflecting greater or lesser mRNA abundance). The relative risk (RR) calculated by solving this equation will indicate if the patient has an enhanced or reduced chance of long-term survival without cancer recurrence.

## Multivariate gene analysis of 147 patients with invasive breast carcinoma

(a) A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 147 patients with invasive breast carcinoma. Genes CEGP1, FOXM1, STK15 and PRAME were excluded from this analysis. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.

10

15

20

25

1. Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;

- 2. Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
- 3. GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65,

5 ErbB3;

- 4. PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
- 5. CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
- 6. TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65.
- (b) A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 147 patients with invasive breast carcinoma, using an interrogation set including a reduced number of genes. The following tengene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.
  - 1. Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
  - 2. FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- 20 3. PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
  - 4. Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
  - 5. STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
  - 6. GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1,
- 25 PLAUR;
  - 7. PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
  - 8. CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
- 9. TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC;
  - 10. CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS.

## Multivariate analysis of patients with ER positive invasive breast carcinoma

A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for patients with ER positive invasive breast carcinoma. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.

- 1. PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 2. Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 3. Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
- 4. HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 5. IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
  - 6. FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- 7. EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 8. Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- 9. CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
- 10. VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- 11. CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
- 12. DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
- 13. p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 14. CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
- IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
  - 16. GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
  - 17. hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
  - 18. STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;

5

15

20

25.

19. NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;

- 20. VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- 21. EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1,

HER2;

- 22. CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
- 23. ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
- 24. FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 25. GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP,

KRT18;

10 26. Belx, Bel2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF.

It is noteworthy that many of the foregoing gene sets include genes that alone did not have sufficient predictive value to qualify as prognostic markers under the standards discussed above, but in combination with other genes, their presence provides valuable information about the likelihood of long-term patient survival without cancer recurrence

All references cited throughout the disclosure are hereby expressly incorporated by reference.

While the present invention has been described with reference to what are considered to be the specific embodiments, it is to be understood that the invention is not limited to such embodiments. To the contrary, the invention is intended to cover various modifications and equivalents included within the spirit and scope of the appended claims. For example, while the disclosure focuses on the identification of various breast cancer associated genes and gene sets, and on the diagnosis and treatment of breast cancer, similar genes, gene sets and methods concerning other types of cancer are specifically within the scope herein.

25

20

#### WHAT IS CLAIMED IS:

1. A method for predicting clinical outcome for a patient diagnosed with cancer, comprising

determining the expression level of one or more genes, or their expression products, selected from the group consisting of p53BP2, cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set,

wherein a poor outcome is predicted if:

- (a) the expression level of p53BP2 is in the lower 10<sup>th</sup> percentile; or
- 10 (b) the expression level of either cathepsin B or cathepsin L is in the upper 10<sup>th</sup> percentile; or
  - (c) the expression level of any either Ki67/MiB1 or thymidine kinase is in the upper 10<sup>th</sup> percentile.
- 15 2. The method of claim 1 wherein poor clinical outcome is measured in terms of shortened survival or increased risk of cancer recurrence.
  - 3. The method of claim 2 wherein poor clinical outcome is measured in terms of shortened survival or increased risk of cancer recurrence following surgical removal of the cancer.
  - 4. The method of claim 1 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
    - 5. The method of claim 4 wherein the cancer is breast cancer.
    - 6. The method of claim 5 wherein the expression level of p53BP2 is determined.
  - 7. The method of claim 5 wherein the expression levels of cathepsin B and cathepsin L are determined.
    - 8. The method of claim 5 wherein the expression level of cathepsin L is determined.

SUBSTITUTE SHEET (RULE 26)

20

25

- 9. The method of claim 5 wherein the expression levels of Ki67/MiB1 and thymidine kinase are determined.
  - 10. The method of claim 5 wherein the expression level of Ki67/MiB1 is determined.
- 11. The method of claim 5 wherein the expression level of thymidine kinase is determined.
- 10 12. The method of claim 1 wherein the expression level of more than one gene, or gene product, is determined.
  - 13. The method of claim 1 wherein the expression level of more than two genes is determined.
  - 14. The method of claim 13 further comprising the step of subjecting the expression data to multivariate analysis using the Cox Proportional Hazards model.
- 15. The method of claim 1 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
  - 16. The method of claim 1 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
- The method of claim 16 wherein said RNA is fragmented.
  - 18. A method of predicting the likelihood of the recurrence of cancer following treatment in a cancer patient, comprising determining the expression level of p27, or its expression product, in a cancer tissue obtained from said patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein an expression level in the upper 10th percentile indicates decreased risk of recurrence following treatment.
- 19. The method of claim 18 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, 70

30

pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.

20. The method of claim 19 wherein the cancer is breast cancer.

5.

20

25

- 21. The method of claim 20 wherein the expression level is determined following surgical removal of cancer.
- 22. The method of claim 20 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
  - 23. The method of claim 22 wherein said RNA is fragmented.
- 24. The method of claim 22 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
  - 25. A method for classifying cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl2, hepatocyte nuclear factor 3, ER, ErbB2 and Grb7, or their expression products, in a cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein (i) tumors expressing at least one of Bcl2, hepatocyte nuclear factor 3, and ER, or their expression products, above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following treatment; and (ii) tumors expressing elevated levels of ErbB2 and Grb7, or their expression products, at levels ten-fold or more above the mean expression level in the reference tissue set are classified as having poor prognosis of disease free and overall patient survival following treatment.
  - 26. The method of claim 26 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
    - 27. The method of claim 26 wherein the cancer is breast cancer.

WO 03/078662 PCT/US03/07713

28. The method of claim 26 wherein the expression level is determined following surgical removal of cancer.

- 29. The method of claim 26 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
  - 30. The method of claim 29 wherein said RNA is fragmented.
- 31. The method of claim 29 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
  - A method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising determining the expression level of one or more prognostic RNA transcripts or their product in a breast cancer tissue sample obtained from said patient, normalized against the expression level of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products, wherein the prognostic transcript is the transcript of one or more genes selected from the group consisting of: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, DIABLO, CDH1, HIF1a, IGFBP3, CTSB, and Her2, wherein overexpression of one or more of FOXM1, PRAME, STK15, Ki-67, CA9, NME1, SURV, TFRC, YB-1, RPS6KB1, Src, Chk1, CCNB1, Chk2, CDC25B, CYP3A4, EpCAM, VEGFC, hENT1, BRCA2, EGFR, TK1, VDR, EPHX1, IF1A, Contig51037, CDH1, HIF1α, IGFBP3, CTSB, Her2, and pENT1 indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the overexpression of one or more of Bcl2, CEGP1, GSTM1, PR, BBC3, GATA3, DPYD, GSTM3, ID1, EstR1, p27, XIAP, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, pS2, WISP1, HNF3A, NFKBp65, and DIABLO indicates an increased likelihood of long-term survival without breast cancer recurrence.
    - 33. The method of claim 32 comprising determining the expression level of at least two of said prognostic transcipts or their expression products.

15.

20

25

WO 03/078662 PCT/US03/07713

The method of claim 32 wherein the breast cancer is invasive breast carcinoma, comprising determination of the expression levels of the transcripts of the following genes, or their expression products: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2.

- 35. The method of claim 32 wherein said breast cancer is characterized by overexpression of the estrogen receptor (ER).
- 10 36. The method of claim 35 comprising determination of the expression levels of the transcripts of at least two of the following genes, or their expression products: PRAME, Bcl2, FOXM1, DIABLO, EPHX1, HIF1A, VEGFC, Ki-67, IGF1R, VDR, NME1, GSTM3, Contig51037, CDC25B, CTSB, p27, CDH1, and IGFBP3.
- The method of claim 32 wherein the expression level of one or more prognostic RNA transcripts is determined.
  - 38. The method of claim 37 wherein said RNA is isolated from a fixed, waxembedded breast cancer tissue specimen of said patient.
  - 39. An array comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2, immobilized on a solid surface.
- 40. The array of claim 39 comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1α, IGFBP3, CTSB, Her2 and DIABLO, immobilized on a solid surface.

- 41. A method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:
- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
  - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
  - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
  - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
- 10 (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
  - (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
  - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- 15 (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
  - (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
  - (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
  - (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
  - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
  - (l) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
- 25 (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
  - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
  - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
  - (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS

20

WO 03/078662 PCT/US03/07713

in a breast cancer tissue sample obtained from said patient, normalized against the expression levels of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products;

- (2) subjecting the data obtained in step (a) to statistical analysis; and
- (3) determining whether the likelihood of said long-term survival has increased or decreased.
- 42. A method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:
- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
  - (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 15 (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
  - (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
  - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
  - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
  - (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- 25 (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
  - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
  - (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
  - (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
  - (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
    - (l) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
    - (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

20

- (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
- (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
- (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
- (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
- (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
- (t) VDR, Bc12, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
  - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
  - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
  - (x). FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 15 (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, EBXO5, CA9, CYP, KRT18; and
  - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF;
    - (2) subjecting the data obtained in step (1) to statistical analysis; and
  - (3) determining whether the likelihood of said long-term survival has increased or decreased.
  - 43. The method of claim 41 or claim 42 wherein said statistical analysis is performed by using the Cox Proportional Hazards model.
  - 44. An array comprising polynucleotides hybridizing to a gene set selected from the group consisting of
    - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
    - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
- 30 (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
  - (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;

76 SUBSTITUTE SHEET (RULE 26)

20

WO 03/078662 PCT/US03/07713

(e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;

- (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
- (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
- 10 (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
  - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
  - (1) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
  - (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
  - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
  - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
- 20 (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS,

immobilized on a solid surface.

- 45. An array comprising polynucleotides hybridizing to a gene set selected from the group consisting of
  - (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
  - (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 30 (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
  - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

77
SUBSTITUTE SHEET (RULE 26)

5

IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, (e) TIMP2; FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, **(f)** cyclinG1, BAG1; EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, (g) CYP2C8; Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1; (h) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP; (i) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1; **(j)** CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP; (k) 10 DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB; **(l)** p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, (m) DIABLO: CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, (n) p27; 15 IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF; (o) · GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC; **(p)** hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, (q) CYP3A4, TIMP2, AREG; STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1; 20 **(r)**. NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG; (s) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1; - (t) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, (u) HER2; CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa; (v) 25 ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP; (w) FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN; (x) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP, **(y)** KRT18; and

immobilized on a solid surface.

HBEGF,

Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1,

(z)

# Overall FPET/RT-PCR Flow Chart






FIGURE 1

2/9 SUBSTITUTE SHEET (RULE 26)




3/9

RT-PCR (one-step or two-step)




4/9
SUBSTITUTE SHEET (RULE 26)



WO 03/078662 PCT/US03/07713

Estrogen Receptor Comparison




- Impath Prognostic Grouping: Unfavorable Impath Prognostic Grouping: Favorable
- •

FIGURE 6

WO 03/078662 PCT/US03/07713

#### Progesterone Receptor Comparison



- Impath Prognostic Grouping: Unfavorable Impath Prognostic Grouping: Favorable

#### FIGURE 7

Gene Specific Amplication of RNA for Taqman Expression Profiling Test of Concept





Figure 8

8/9

SUBSTITUTE SHEET (RULE 26)

Ct Distribution by Gene



9/9

## SEQUENCE LISTING

<110> GENOMIC HEALTH Baker, Joffre B. Cronin, Maureen T Kiefer, Michael C Shak, Steve Walker, Michael G	raham	
<120> GENE EXPRESSION F	ROFILING IN BIOPSIED TUMO	R TISSUES
<130> 39740-0001PCT		
<140> to be assigned <141> 2003-03-12		
<150> US 60/412,049 <151> 2002-09-18		
<150> US 60/364,890 <151> 2002-03-13		
<160> 384		
<170> FastSEQ for Wind	ows Version 4.0	
<210> 1 <211> 18 <212> DNA <213> Homo sapiens		
<400> 1 gtcccaggag cccatcct		18
<210> 2 <211> 19 <212> DNA <213> Homo sapiens		
<400> 2 cccggctgtt gtctccata		19
<210> 3 <211> 68 <212> DNA <213> Homo sapiens		
<400> 3 gtcccaggag cccatcctgt cagccggg	ttgactgcag cattgctgag aac	attgcct atggagacaa 60 68
<210> 4 <211> 18 <212> DNA <213> Homo sapiens		
<400> 4 tcatggtgcc cgtcaatg		18
<210> 5 <211> 23 <212> DNA <213> Homo sapiens		
<400> 5 cgattgtctt tgctcttcat	gtg Page 1	23

<210> 6 <211> 79 <212> DNA <213> Homo	sapiens				
<400> 6 tcatggtgcc tgaagagcaa		gtgatggcga tgaaga	ccaa gacgtatcag	gtggcccaca	60 79
<210> 7 <211> 20 <212> DNA <213> Homo	sapiens				•
<400> 7 aggggatgac	ttggacacat				20
<210> 8 <211> 20 <212> DNA <213> Homo	sapiens				
<400> 8 aaaactgcat	ggctttgtca				20
<210> 9 <211> 65 <212> DNA <213> Homo	sapiens			~	
<400> 9 aggggatgac gtttt	ttggacacat	ctgccattcg acatga	tgc aattttgaca	aagccatgca	60 65
<210> 10 <211> 22 <212> DNA <213> Homo	sapiens		<i>y</i>		
<400> 10 tcatcctggc	gatctacttc	ct			22
<210> 11 <211> 20 <212> DNA <213> Homo	sapiens				
<400> 11 ccgttgagtg	gaatcagcaa				20
<210> 12 <211> 91 <212> DNA <213> Homo	sapiens				
<400> 12 tcatcctggc ctttcatggt	gatctacttc cttgctgatt	ctctggcaga acctago ccactcaacg g	jtcc ctctgtcctg	gctggagtcg	60 91
<210> 13 <211> 20 <212> DNA <213> Homo	sapiens				
<400> 13 agcgcctgga	atctacaact	· · · · · · · · · · · · · · · · · · ·			20

Page 2

<2:	10> 11>	20		· ·								
<2. <2.	12> 13>	HOMO	sapiens				· ·					
	00> agcc		gagagaagat		• • •			· · ·				20
<2	10> 11>	66										
<2 <2	12> 13>	DNA Homo	sapiens	.•			٠				•	
ag	00> cgc( ctct	tgga	atctacaact	cggag	gtccag	tgttt	tccca (	cttgtc	atct t	ctctc	agg (	60 66
<2 <2	10> 11> 12> 13>	24 DNA	sapiens	· · · · · · · · · · · · · · · · · · ·						•		
<4	00>	16	ggtctatga	a ctca						•	-	24
<2 <2		22 DNA	sapiens									•
<4 gt	100>	17 aaagg	cttggtgga	t tt.					•			22
<2 <2		94 DNA	sapiens									•
a	400> ccca ctcc	gagaa	ggtctatga tgaaatcca	a ctca c caag	tgcgag cctttg	catgt aaac	tggca	gtggaa	itccc	tctgac	cggc	60 94
< <		21 DNA	sapiens	,							· .	
	400>	19	ctgagtato	t g			•			•		21
< <	212>	21 DNA	sapiens					•				
		20 cagggo	tactctca	et t					:			21
· <	211:	> 21 > 80 > DNA > Home	o sapiens						•			
C	gca	> 21 gtgca agagt	g ctgagtato a gccctggg	ct gct ca	cagcag1	t ctaa	tcaatg	gcagc	ttcct	ggtgc	gagaa	60 80
<	210	> ·22					Dage 3	•				

#### 39740-0001PCT.txt <211> 21 <212> DNA <213> Homo sapiens <400> 22 21 cagcagatgt ggatcagcaa g <210> 23 <211> 18 <212> DNA <213> Homo sapiens <400> 23 18 gcatttgcgg tggacgat <210> 24 <211> 66 <212> DNA <213> Homo sapiens <400> 24 cagcagatgt ggatcagcaa gcaggagtat gacgagtccg gcccctccat cgtccaccgc 60 aaatgc <210> 25 <211> 20 <212> DNA <213> Homo sapiens <400> 25 20 cgcttctatg gcgctgagat <210> 26 <211> 20 <212> DNA <213> Homo sapiens <400> 26 20 tcccggtaca ccacgttctt <210> 27 <211> 71 <212> DNA <213> Homo sapiens <400> 27 cgcttctatg gcgctgagat tgtgtcagcc ctggactacc tgcactcgga gaagaacgtg 60 gtgtaccggg a <210> 28 <211> 25 <212> DNA <213> Homo sapiens <400> 28 25 ttgtctctgc cttggactat ctaca <210> 29 <211> 24 <212> DNA <213> Homo sapiens <400> 29 24 ccagcattag attctccaac ttga <210> 30 <211> 75 <212> DNA

Page 4

<213> Homo	sapiens	• • • • • • • • • • • • • • • • • • • •				
<400> 30 ttgtctctgc agaatctaat	cttggactat gctgg	ctacattccg	gaaagattgt	gtaccgtgat	ctcaagttgg	60 75
<210> 31 <211> 25 <212> DNA <213> Homo	sapiens					
<400> 31 gaaggagata	aggaggatgt	tgaca				25
<210> 32 <211> 18 <212> DNA <213> Homo	sapiens					
<400> 32 cgccacggag	atccaatc					18
<210> 33 <211> 74 <212> DNA <213> Homo	sapiens					
<400> 33 gaaggagata ggatctccgt	aggaggatgt ggcg	tgacaaggca	gtgaaggccg	, caagacaggo	: ttttcagatt	60 74
<210> 34 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 34 tggtgaacat	tgtgccagga	t .				21
<210> 35 <211> 22 <212> DNA <213> Homo	sapiens					
<400> 35 gaaggcgato	ttgttgatc	t ga				22
<210> 36 <211> 80 <212> DNA <213> Homo	sapiens					· .
<400> 36 tggtgaacat agatcaacaa	tgtgccagg agatcgcctt	a ttcgggccc c	a cagtgggag	c agcaatttc	t tctcaccct	c 60 80
<210> 37 <211> 20 <212> DNA <213> Home	o sapiens					
<400> 37 ggacagcag	g aatgtgttt	c	. ·			20
<210> 38 <211> 20 <212> DNA <213> Hom	o sapiens		Page	. 5		

acccactcga	tttgtttctg					20
<210> 39 <211> 69 <212> DNA <213> Homo	sapiens					. · · · .
<400> 39 ggacagcagg cgagtgggt	aatgtgtttc	tccatacagg	tcacggggag	ccaatggttc	agaaacaaat	60 69
<210> 40 <211> 27 <212> DNA <213> Homo	sapiens					
<400> 40 tgtgagtgaa	atgccttcta	gtagtga				27
<210> 41 <211> 27 <212> DNA <213> Homo	sapiens					3
<400> 41 ttgtggttcg	ttatcatact	cttctga				27
<210> 42 <211> 82 <212> DNA <213> Homo	sapiens					
<400> 42 tgtgagtgaa agagtatgat	atgccttcta aacgaaccac	gtagtgaacc aa	gtcctcggga	gccgactatg	actactcaga	60 82
			• * * * * * * * * * * * * * * * * * * *	•		
<210> 43 <211> 19 <212> DNA <213> Homo	sapiens			· .		
<211> 19 <212> DNA						19
<211> 19 <212> DNA <213> Homo <400> 43	gtggcctta					19
<211> 19 <212> DNA <213> Homo <400> 43 gtctcgctcc <210> 44 <211> 24 <212> DNA <213> Homo <400> 44	gtggcctta	tgga				19
<211> 19 <212> DNA <213> Homo <400> 43 gtctcgctcc <210> 44 <211> 24 <212> DNA <213> Homo <400> 44	gtggcctta sapiens cctgaatctt	tgga				
<211> 19 <212> DNA <213> Homo <400> 43 gtctcgctcc <210> 44 <211> 24 <212> DNA <213> Homo <400> 44 cgtgagtaaa <210> 45 <211> 93 <212> DNA <213> Homo <400> 45 cgtgagtaaa	gtggcctta sapiens cctgaatctt sapiens	ctatactcgo	gctactctct acg	ctttctggcc	tggaggcta	24

Page 6

#### 39740-0001PCT.txt <400> 46 20 ccattcccac cattctacct <210> 47 <211> 20 <212> DNA <213> Homo sapiens <400> 47 20 gggaacatag acccaccaat <210> 48 <211> 66 <212> DNA <213> Homo sapiens <400> 48 ccattcccac cattctacct gaggccagga cgtctggggt gtggggattg gtgggtctat 60 gttccc <210> 49 <211> 18 <212> DNA <213> Homo sapiens <400> 49 18 ccgccgtgga cacagact <210> 50 <211> 21 <212> DNA <213> Homo sapiens <400> 50 21 ttgccgtcag aaaacatgtc a <210> 51 <211> 70 <212> DNA <213> Homo sapiens <400> 51 ccgccgtgga cacagactcc ccccgagagg tcttttccg agtggcagct gacatgtttt 60 ctgacggcaa <210> 52 <211> 25 <212> DNA <213> Homo sapiens <400> 52 25 cagatggacc tagtacccac tgaga <210> 53 <211> 24 <212> DNA <213> Homo sapiens <400> 53 24 cctatgattt aagggcattt ttcc <210> 54 <211> 73 <212> DNA <213> Homo sapiens <400> 54 cagatggacc tagtacccac tgagatttcc acgccgaagg acagcgatgg gaaaaatgcc 60 Page 7

		39740-0001PCT.txt	
cttaaatcat	agg		73
<210> 55 <211> 24 <212> DNA <213> Homo	sapiens		· · · ·
<400> 55 cttttgtgga	actctatggg	aaca	24
<210> 56 <211> 19 <212> DNA <213> Homo	sapiens		
<400> 56 cagcggttga	agcgttcct		19
<210> 57 <211> 70 <212> DNA <213> Homo	capione		·
<400> 57	actctatggg	aacaatgcag cagccgagag ccgaaagggc caggaacgct	60 70
<210> 58 <211> 24 <212> DNA <213> Homo			
<400> 58 ggatatttcc	gtggctctta	ttca	24
<210> 59 <211> 25 <212> DNA <213> Homo	sapiens		
<400> 59 cttctcatca	aggcagaaaa	atctt	.25
<210> 60 <211> 86 <212> DNA <213> Homo	sapiens		· .
<400> 60 ggatatttcc caagattttt	gtggctctta ctgccttgat	ttcaaactct ccatcaaatc ctgtaaactc cagagcaaat gagaag	60 86
<210> 61 <211> 23 <212> DNA <213> Homo	sapiens		
<400> 61 gcagttggaa	gacacaggaa	agt	23
<210> 62 <211> 21 <212> DNA <213> Homo	sapiens		
<400> 62 tgcgtggcac	tattttcaag	a	21

Page 8

<210> <211> <212> <213>	77 DNA	sapiens					
	tggaa.	gacacaggaa ccacgca	agtatcccca	aattgcagat	ttatcaacgg	cttttatctt	60 77
<210> <211> <212> <213>	20 DNA	sapiens					
<400> tgttt		cccgggctta					20
<210> <211> <212> <213>	24 DNA	sapiens					
<400> caaag		agctctagca	aaag				24
<210> <211> <212> <213>	80 DNA	sapiens					
	tgatt	cccgggctta gacagctttg		agtgagggag	gaagaaggca	gtgtcccttt	60 80
<210> <211> <212> <213>	20 DNA	sapiens					
<400> tcagg		agaaatctgt					20
<210><211><211><212><213>	20 DNA	sapiens					
<400> ccatt		tgatctgtgg				er e	20
<210><211><212><213>	65 DNA	sapiens					
<400> tcagg aatgg	gggct	agaaatctgt	tgctatgggc	ccttcaccaa	catgcccaca	gatcaactgg	60 65
<210> <211> <212> <213>	· 20 · DNA	o sapiens					
<400> agtto		: ttgcaagatg	. <u>.</u> I				20
<210>		2 -	•	•			

Page 9

<211> 20 <212> DNA <213> Homo	sapiens					
<400> 71 aaggtaagct	gggtctgctg					20 .
<210> 72 <211> 70 <212> DNA <213> Homo	sapiens					•
.400- 72	ttgcaagatg	gtgcagagct	ttatgaagca (	gtgaagaatg	cagcagaccc	60 70
<210> 73 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 73	ggcctctaag	a				21
<210> 74 <211> 22 <212> DNA <213> Homo	sapiens					
<400> 74 cggtgtagat	gcacagcttc	tc				22
<210> 75 <211> 69 <212> DNA <213> Homo	sapiens					•
<400> 75 gcatgttcgt tctacaccg	ggcctctaag	atgaaggaga	ccatccccct	gacggccgag	aagctgtgca	60 69
<210> 76 <211> 20 <212> DNA <213> Homo	sapiens					
<400> 76 agatgaagtg	gaaggcgctt					20
<210> 77 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 77 tgcctctgta	atcggcaact	g				21
<210> 78 <211> 65 <212> DNA <213> Home	sapiens					
<400> 78 agatgaagt aggca	gaaggcgctt	ttcaccgcgg	ccatcctgca	ggcacagttg	ccgattacaç	60 65
<210> 79 <211> 18			Page 1	0		

<212> DNA <213> Homo S	sapiens					.: -
<400> 79 tggttcccag (	ccctgtgt					18
<210> 80 <211> 19 <212> DNA <213> Homo	sapiens					
<400> 80 ctcctccacc	ctgggttgt					19
<210> 81 <211> 74 <212> DNA <213> Homo	sapiens					
<400> 81 tggttcccag ccagggtgga	ccctgtgtcc ggag	acctccaagc	ccagattcag	attcgagtca	tgtacacaac	60 74
<210> 82 <211> 20 <212> DNA <213> Homo	sapiens					
<400> 82 tcttgctggc	tacgcctctt					20
<210> 83 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 83 ctgcattgtg	gcacagttct	g				21
<210> 84 <211> 71 <212> DNA <213> Homo	sapiens					
<400> 84 tcttgctggc ccacaatgca	tacgcctctt g	ctgtccctgt	tagacgtcct	ccgtccatat	cagaactgt	9 60 71
<210> 85 <211> 21 <212> DNA <213> HOMO	sapiens					
<400> 85 tgagtgtccc	ccggtatctt	: <b>C</b>	· .	<u>.</u> ·		21
<210> 86 <211> 21 <212> DNA <213> Homo	o sapiens		· · · · · · · · · · · · · · · · · · ·			
<400> 86 cagccgctt1	cagattttca	at ·				23
<210> 87 <211> 81 <212> DNA <213> Home	o sapiens		Page	11		

<400> 8 tgagtgt atgaaaa	ccc (	ccggtatctt gaaagcggct	ccccgccctg ccaatcccga tgaaattgga aattttattg	60 81
<210> 8 <211> 2 <212> D <213> H	l NA	sapiens		•
<400> 8		cagggtcgaa	a	21
<210> 8 <211> 2 <212> 0 <213> F	22 DNA Homo	sapiens		
		gtggtagaaa	tc	22
<210> 9 <211> 6 <212> 1 <213> 1	55 DNA	sapiens		; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
<400> ! tggaga acgcc	90 ctct	cagggtcgaa	aacggcggca gaccagcatg acagatttct accactcca	a 60 65
<210> (211> (211> (212> (213>	21 DNA	sapiens		
<400> cggtgg		cgaagagtta	<b>a</b>	21
<210> <211> <212> <213>	19 DNA	sapiens		
<400> ggctcg		ttccatgtc		19
<210> <211> <212> <213>	66 DNA	sapiens		
<400> cggtgg cgagco	acca	cgaagagtta	a acccgggact tggagaagca ctgcagagac atggaagag	g 60 66
<210> <211> <212> <213>	19 DNA	sapiens		
<400> gcggaa		cctcagaca		19
<210> <211> <212> <213>	23 DNA	sapiens		

Page 12

<400> 95 tctaagtttc ccgaggtttc tca	23
<210> 96 <211> 70 <212> DNA <213> Homo sapiens	
<400> 96 gcggaaggtc cctcagacat ccccgattga aagaaccaga gaggctctga gaaacttaga	gaaacctcgg 60 70
<210> 97 <211> 22 <212> DNA <213> Homo sapiens	
<400> 97 ccagctttgt gcctgtcact at	22
<210> 98 <211> 20 <212> DNA <213> Homo sapiens	
<400> 98 gggaatgtgg tagcccaaga	20
<210> 99 <211> 71 <212> DNA <213> Homo sapiens	
<400> 99 ccagctttgt gcctgtcact attcctcatg ccaccactgc caacacctct accacattcc c	gtcttgggct 60 71
<210> 100 <211> 27 <212> DNA <213> Homo sapiens	
<400> 100 ttgctataac taagtgcttc tccaaga	27
<210> 101 <211> 22 <212> DNA <213> Homo sapiens	
<400> 101 gtggaatggc agctcactgt ag	22
<210> 102 <211> 73 <212> DNA <213> Homo sapiens	
<400> 102 ttgctataac taagtgcttc tccaagaccc caactgagtc cccagcacc	t gctacagtga 60 73
<210> 103 <211> 19 <212> DNA <213> Homo sapiens	

		3	9740-0001PC	T.txt		
aggacgcaag	gagggtttg		•		• • •	19
<210> 104 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 104 gatgtccgcc	gagtccttac	<b>t</b>				21
<210> 105 <211> 87 <212> DNA <213> Homo	sapiens					
<400> 105 aggacgcaag gtgctcagta	gagggtttgt aggactcggc	cactggcaga ggacatc	ctcgagactg	taggcactgc	catggcccct	60 87
<210> 106 <211> 24 <212> DNA <213> Homo	sapiens					· · · · · · · · · · · · · · · · · · ·
<400> 106 ctatatgcag	ccagagatgt	gaca	:			24
<210> 107 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 107 ccacgagttt	cttactgaga	atgg				24
<210> 108 <211> 82 <212> DNA <213> Homo	o sapiens					-:
	g ccagagatgt agaaactcgt		gtggacagcc	tgccactcat	cacagcctcc	60 82
<210> 109 <211> 20 <212> DNA <213> Homo	o sapiens					
<400> 109 tgtcgatgga	a cttccagaac					20
<210> 110 <211> 19 <212> DNA <213> Home		,				
<400> 110 attgggaca	g cttggatca					19
<210> 111 <211> 62 <212> DNA <213> Home	o sapiens		•			
<400> 111 tgtcgatgga at	a cttccagaac	cacctgggca	gctgccaaaa		agctgtccca	60 62

<: <:	210> 1 211> 2 212> D 213> H	3 NA	apiens					
g.	400> 1 atctaa	l12 igat g	gcgactgtc	gaa				23
<	210> 1 211> 2 212> E 213> F	25 DNA	sapiens					
` <	:400> 1 tagatt	l13 tccg 1	tttctcctc	ttctg				25
` <	210> 1 211> 8 212> 1 213> F	B2 DNA	sapiens					
С	<400> gatcta aagagg	agat 🧃	ggcgactgtc aacggaatct	gaaccggaaa aa	ccacccctac	tcctaatccc	ccgactacag	60 82
< <	<210> <211> <212> (<213>	20 DNA:	sapiens					
(	<400> cggtgt	115 gaga	agtgcagcaa					20
. •	<210> <211> <212> <213>	19 DNA	sapiens					
	<400> cctctc	116 gcaa	gtgctccat					19
	<210> <211> <212> <213>	70 DNA	sapiens					
	<400> cggtgt ttgcga	tgaga	agtgcagcaa	gccctgtgcc	cgagtgtgct	atggtctggg	, catggagca	c 60 70
	<210> <211> <212> <213>	23 DNA	sapiens	•				
	<400> cggtta	118 atgtc	atgccagata	cac				23
	<210> <211> <212> <213>	24 DNA	sapiens			•	,	· · · .
	<400> gaact	119 gagac	ccactgaaga	aagg				24
	<210>	120			Page 1	L5		

				39/40-0001P0	T.txt		•
<211> <212> <213>	DNA	sapiens					
<400> cggtt ttctt	atgtc	atgccagata ggtctcagtt	cacacctcaa c	aggtactccc	tcctcccggg	aaggcaccct	60 81
 <210> <211> <212> <213>	19 DNA	sapiens					
<400> cgtgg		ctctatgac					19
<210><211><211><212><213>	19 DNA	sapiens					
<400> ggcta		cgcatgtag					19
<210><211><211><212><213>	68 DNA	sapiens					
<400> cgtgg cacta	tgccc	ctctatgacc	tgctgctgga	gatgctggac	gcccaccgcc	tacatgcgcc	60 68
 <210><211><211><212><213>	20 DNA	sapiens					
<400> tggt(		ccagttatca					. 20
<211: <212:	> DNA	sapiens					
	> 125 ctagcg	atcttgcttc	aca				23
<211: <212:	> DNA	sapiens			5		
tggt		ccagttatca agaaca	a catctgtate	, cggaacctca	aaagagtcco	tggtgtgaag	60 76
<211 <212	> DNA	o sapiens					
	> 127 catgao	aactttggta	a tcgt				24
<210 <211	> 128 > 21			Page 1	16		
			•				

<212> DNA <213> Homo sapiens		
<400> 128 cagtcttctg ggtggcagtg	a	21
<210> 129 <211> 74 <212> DNA <213> Homo sapiens		
<400> 129 catccatgac aactttggta cacccagaag actg	tcgtggaagg actcatgacc acagtccatg ccatcactgc	60 74
<210> 130 <211> 23 <212> DNA <213> Homo sapiens		
<400> 130 caaaggagct cactgtggtg	tct	23
<210> 131 <211> 26 <212> DNA <213> Homo sapiens		
<400> 131 gagtcagaat ggcttattca	cagatg	26
<210> 132 <211> 75 <212> DNA <213> Homo sapiens		
<400> 132 caaaggagct cactgtggtg aagccattct gactc	tctgtgttcc aaccactgaa tctggacccc atctgtgaat	60 75
<210> 133 <211> 20 <212> DNA <213> Homo sapiens		
<400> 133 ccatctgcat ccatcttgtt		20
<210> 134 <211> 20 <212> DNA <213> Homo sapiens		
<400> 134 ggccaccagg gtattatct	9	20
<210> 135 <211> 67 <212> DNA <213> Homo sapiens		•
<400> 135 ccatctgcat ccatcttgt ggtggcc	t tgggctcccc acccttgaga agtgcctcag ataataccc	t 60 67
<210> 136 <211> 23 <212> DNA	Page 17	

		39740-0001PCT.txt	
<213> F	lomo	sapiens	
<400> 3 cgaaaa	l36 gatg	ctgaacagtg aca	23
<210> 1 <211> 2 <212> 0 <213> 1	20 DNA	sapiens	
<400> tcagga		ccaccagtga	20
<210> <211> <212> ! <213> !	73 DNA:	sapiens	
<400> cgaaaa tggctg	gatg	ctgaacagtg acaaatccaa ctgaccagaa gggaggagga agctcactgg	60 73
<210> <211> <212> <213>	20 DNA	sapiens	
<400> gagacc		tgtcccagaa	20
<210> <211> <212> <213>	23 Dna	sapiens	
<400> ggttgt		agcgaaggag atc	23
<210> <211> <212> <213>	76 DNA	sapiens	
	ctgc	tgtcccagaa ccagggaggc aagaccttca ttgtgggaga ccagatctcc acaacc	60 76
<210> <211> <212> <213>	20 DNA	sapiens	
<400> cccact		agccaagtca	20
<210> <211> <212> <213>	20 DNA	sapiens	
<400> cacgca		gtatcagtct	20
<210><211><211><212><213>	73 DNA	n saniens	

Page 18

			33740-000TE	CI. CAC	•	
<400> 144 cccactcagt taccacctgc		caatgtttgg	aaaacagccc	gtttacttga	gcaagactga	60 73
<210> 145 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 145 catcaaatgt	cagccctgga	gttc				24
<210> 146 <211> 26 <212> DNA <213> Homo	sapiens		•	•		
<400> 146 ttcctgtagg	tctttacccc	gatagc		•		26
<210> 147 <211> 85 <212> DNA <213> Homo	sapiens					
<400> 147 catcaaatgt ctatcggggt	cagccctgga aaagacctac	gttccatgat aggaa	accacacgaa	cacagctttt	tgccttcgag	60 85
<210> 148 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 148 tccaggatgt	taggaactgt	gaag		٠.	•	24
<210> 149 <211> 22 <212> DNA <213> Homo	sapiens					•
<400> 149 gcgtgtctgo	gtagtagctg	, tt				22
<210> 150 <211> 73 <212> DNA <213> Homo	o sapiens					
<400> 150 tccaggatgi tacgcagaca	t taggaactgt a cgc	gaagatggaa	a gggcatgaaa	a ccagcgacte	g gaacagctad	60 73
<210> 151 <211> 23 <212> DNA <213> Home	o sapiens				· ·	
<400> 151 aacgactgc	t actccaagc	t caa		•		23
<210> 152 <211> 22 <212> DNA <213> Home						
<400> 152			Page	19	·	

				39740-0001 p/	~T +v+		
ggattt	ccat	cttgctcacc		39740-0001P0	·	•	22
<210> <211> <212> <213>	76 DNA	sapiens					
	tgct	actccaagct aaatcc	caaggagctg	gtgcccagca	tecccagaa	caagaaggtg	60 76
<210> <211> <212> <213>	21 DNA	sapiens					
<400> tccgga		tgatctaagg	a		•		21
<210> <211> <212> <213>	20 DNA	sapiens					
<400> cggaca		gagctgactt					20
<210> <211> <212> <213>	76 DNA	sapiens					
<400> tccgga cagcto	gctg	tgatctaagg tgtccg	aggctggaga	tgtattgcgc	acccctcaag	cctgccaagt	60 76
<210> <211> <212> <213>	17 DNA	sapiens					
<400> acgcad		tgtctga				•	17
<210> <211> <212> <213>	24 DNA	sapiens					
<400> tgccct		tgatgatgat	tatc	•			24
<210> <211> <212> <213>	68 Dna	sapiens			•		
<400> acgcac aaaggg	cggg	tgtctgatcc	caagttccac	cccctccatt	caaagataat	catcatcaag	60 68
<210> <211> <212> <213>	22 DNA	sapiens					
<400> ccatto		tgtgtaacag	ga	Page 20	)		22

210 161				•		
<210> 161 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 161	aggttaaggc	a				21
<210> 162 <211> 68 <212> DNA						
<213> Homo	sapiens					•
<400> 162 ccattcaccc agggtcgg	tgtgtaacag	gaccccaagg a	cctgcctcc	ccggaagtgc	cttaacctag	60 68
<210> 163 <211> 20 <212> DNA	canions					
<213> Homo	Saprens					
<400> 163 cgtcaggacc	caccatgtct					20
<210> 164 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 164 ggttaattgg	tgacatcctc	aaga				24
<210> 165 <211> 81 <212> DNA	caniens					
<213> Homo	Saprens	:	*.	•		
<400> 165 cgtcaggacc tgaggatgtc	caccatgtct accaattaac	gccccatcac c	cggccgaga	catggcttgg	ccacagctct	60 81
<210> 166 <211> 23 <212> DNA		•				
<213> Homo	sapiens					•
<400> 166 caaacgctga	catgtacggt	cta		•		23
<210> 167 <211> 18 <212> DNA			:	·		
<213> Homo	sapiens					
<400> 167 gctcgttggc	gcactctt	· ,				18
<210> 168 <211> 88 <212> DNA <213> Homo						
<400> 168 caaacgctga cagttggagg	catgtacggt aagagtgcgc	ctatgccatt ( caacgagc	cctccccgc	atcacatcca	ctggtattgg	60 88

Page 21

<210> <211> <212> <213>	25 DNA	sapiens					
<400> gaggca	169 actg	cttatggctt	aatta				25
<210> <211> <212> <213>	18 DNA	sapiens					
<400> ggcact	170 .cgg.c	ttgagcat					18
<210> <211> <212> <213>	75 DNA	sapiens					
<400> gaggca ctcaag	actg	cttatggctt gtgcc	aattaagtca	gatgcggcca	tgactgtcgc	tgtaaagatg	60 75
<210> <211> <212> <213>	18 DNA	sapiens					·.
<400> gtccc		tggatgtt					18
<210> <211> <212> <213>	25 DNA	sapiens					
<400> gatca		gctgtctgac	aattg		•		25
<210> <211> <212> <213>	79 DNA	sapiens					•
<400> gtccc tcaga	cggga	tggatgtttt tgactgatc	gccaagtcat	tgttggataa	gcgagatggt	agtacaattg	60 79
<210> <211> <212> <213>	21 DNA	sapiens					
<400> cgagg		ttcttcagca	a				21
<210> <211> <212> <213>	22 DNA	sapiens		· · · ·			-
<400> actct		agctcactgt	tg ·				22
<210> <211>	177 73				_		

٠.,		•	• • •	39/40-0001PC1	.txt	•	
<21 <21	L2> DNA L3> Homo	sapiens					. :
cga	00> 177 aggattgg tggtgcag	ttcttcagca agt	agacagagga	actgaaccgc g	aggtggcca	ccaacagtga	60 73
<2: <2:	10> 178 11> 20 12> DNA 13> Homo	sapiens					
<40 tc	00> 178 agtggaga	aggagttgga					20
<2 <2	10> 179 11> 20 12> DNA 13> Homo	sapiens					
<4 tg	00> 179 ccatatcc	agaggaaaca					20
<2 <2	10> 180 11> 69 12> DNA 13> Homo	sapiens					
to	100> 180 cagtggaga atatggca	aggagttgga	ccagtcaaca	tctctgttgt (	cacaagcagt	gtttcctctg	60 69
<; <;	210> 181 211> 26 212> DNA 213> Homo	sapiens					
<	400> 181 tacaagaga	gaaccagac	t ccaatg				26
< <	210> 182 211> 18 212> DNA 213> Homo	o sapiens					
<b>9</b>	400> 182 tgtagccc	g cggacact		•			18
<	210> 183 211> 87 212> DNA 213> Home	o sapiens	•				1.
	(400> 183 gtacaagag gcattaccc	a gaaccagac a gtgtccgcg	t ccaatgtca g gctacac	t tgtggtggac	tggctgtca	c gggctcagg	a 60 87
· •	<210> 184 <211> 22 <212> DNA <213> Hom				•	•	
•	<400> 184 gacatttcc	a gtcctgca	gt ca				22
	<210> 185 <211> 20 <212> DNA	•		Page 2	3		

<213>	Homo	sapiens	•	•	•		
<400> ctccga		acacatttgt					20
<210> <211> <212> <213>	86 DŅA	sapiens					
<400> gacatt gccacg	tcca	gtcctgcagt atgtgtgcga	caatgcctct tcggag	ctgccccacc	ctttgttcag	tgtggctggt	60 86
<210> <211> <212> <213>	24 DNA	sapiens					
<400> gttttg		aaatgtgttc	ttca				24
<210> <211> <212> <213>	26 DNA	sapiens					,
<400> ttctc1		cactgccgtc	ttaagg				26
<210> <211> <212> <213>	101 DNA	sapiens					
<400> gttttg gctctg	gagg	aaatgtgttc ccctccctta	ttcagtgcac agacggcagt	agaatgcagc gtattagaga	aaaacagcca a	tctgataaat	60 101
<210> <211> <212> <213>	22 DNA	sapiens	·				
<400> acgaga		gggcatctat	gt	•		. ·	22
<210> <211> <212> <213>	22 DNA	sapiens		•			. 7
<400> gcatg		gcttccaatc	ac				22
<210> <211> <212> <213>	75 DNA	sapiens				·	. • •
	aacga	gggcatctat catgc	gtgcaggatg	tcaagaccgg	g aaaggtgcgc	gctgtgattg	60 75
<210><211><212><213>	21 DNA	sapiens					

<400> 193 tccctccact cggaagga	act a			21
<210> 194 <211> 22 <212> DNA <213> Homo sapiens				
<400> 194 cggttgttgc tgatctg	tct ca			22
<210> 195 <211> 84 <212> DNA <213> Homo sapiens				· · · · · · · · · · · · · · · · · · ·
<400> 195 tccctccact cggaagg cctgagacag atcagca	act atcctgctgc aca accg	caagagggtc aa	igttggaca gtgtcaga	gt 60 84
<210> 196 <211> 19 <212> DNA <213> Homo sapiens	: :			
<400> 196 ttgttggtgt gccctgg	gtg			19
<210> 197 <211> 21 <212> DNA <213> Homo sapien	5			
<400> 197 tgggttctgt ccaaac	actg g			21
<210> 198 <211> 67 <212> DNA <213> Homo sapien	S			•
<400> 198 ttgttggtgt gccctg gaaccca	gtgc cgtggtggc	g gtcactccct o	tgctgccag tgtttgg	aca 60 67
<210> 199 <211> 20 <212> DNA <213> Homo sapier	าร			
<400> 199 actgaaggag accct	tggag			20
<210> 200 <211> 20 <212> DNA <213> Homo sapie	ns	· .		
<400> 200 taaataaccc tgccc	acaca			20
<210> 201 <211> 62 <212> DNA <213> Homo sapie	ns	·	•	
<400> 201		Page 2	5	

			39740-0001PC			
actgaaggag ta	acccttggag	cctaggggca	tcggcaggag	agtgtgtggg	cagggttatt	60 62
<210> 202 <211> 28 <212> DNA <213> Homo	sapiens					
<400> 202 agttactaaa	aaataccacg	aggtcctt				28
<210> 203 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 203 gtcggtgagt	gatttgtgca	a				21
<210> 204 <211> 79 <212> DNA <213> Homo	sapiens					
<400> 204 agttactaaa gcacaaatca	aaataccacg ctcaccgac	aggtccttca	gttgagacca	aagaccggtg	tcaggggatt	60 79
<210> 205 <211> 20 <212> DNA <213> Homo	sapiens					· ·
<400> 205 gggagtttcc	aagagatgga					20
<210> 206 <211> 20 <212> DNA <213> Homo	sapiens	• • • • • • • • • • • • • • • • • • • •			. 1	٠
<400> 206 cttcaaccac	cttcccaaac		•		· ·	20
<210> 207 <211> 72 <212> DNA <213> Homo	sapiens					
<400> 207 gggagtttco aggtggttga	aagagatgga ag	ctagtgcttg	gtcgggtctt	ggggtctgga	gcgtttggga	a 60 72
<210> 208 <211> 23 <212> DNA <213> Homo	sapiens	· · · · · · · · · · · · · · · · · · ·				
<400> 208 aggtgtcate	catcaacgto	: tct				23
<210> 209 <211> 20 <212> DNA <213> Homo	o sapiens					
<400> 209 tcccgatcae	c aatgcacato	3	Page 2	6		20

<210> 210 <211> 90 <212> DNA <213> Homo sapiens					
<400> 210 aggtgtcatc catcaacgtc acatcaccct catgtgcatt	tctgtgaacg gtgatcggga	cagtgcagac	tgtggtccgc	cagggtgaga	60 90
<210> 211 <211> 24 <212> DNA <213> Homo sapiens					
<400> 211 agagccagtt gctgtagaac	tcaa				24
<210> 212 <211> 21 <212> DNA <213> Homo sapiens					
<400> 212 ctgggcctac acagtccttc	<b>a</b>				21
<210> 213 <211> 74 <212> DNA <213> Homo sapiens					
<400> 213 agagccagtt gctgtagaac ctgtgtaggc ccag	tcaaatctct	gctgggcaag	g gatgttctgt	tcttgaagg	a 60 74
<210> 214 <211> 26 <212> DNA <213> Homo sapiens					
<400> 214 gaaatgactg catcgttga	t aaaatc				26
<210> 215 <211> 19 <212> DNA <213> Homo sapiens					
<400> 215 tgccagcctg acagcactt					<b>19</b>
<210> 216 <211> 78 <212> DNA <213> Homo sapiens					
<400> 216 gaaatgactg catcgttga agtgctgtca ggctggca	t aaaatccgc	a gaaaaaact	cg cccagcatg	t cgccttag	aa 60 78
<210> 217 <211> 20 <212> DNA <213> Homo sapiens					
<400> 217 gatcaacggc tacatccag	ga				20

### 39740-0001PCT.txt <210> 218 <211> 20 <212> DNA <213> Homo sapiens <400> 218 20 tgaactgtga ggccagagac <210> 219 <211> 68 <212> DNA <213> Homo sapiens <400> 219 gatcaacggc tacatccaga agatcaagtc gggagaggag gactttgagt ctctggcctc 60 acagttca <210> 220 <211> 19 <212> DNA <213> Homo sapiens <400> 220 19 gtggatgtgc cctgaagga <210> 221 <211> 20 <212> DNA <213> Homo sapiens <400> 221 20 ctgcggatcc agggtaagaa <210> 222 <211> 70 <212> DNA <213> Homo sapiens <400> 222 gtggatgtgc cctgaaggac aagccaggcg tctacacgag agtctcacac ttcttaccct 60 ggatccgcag <210> 223 <211> 27 <212> DNA <213> Homo sapiens <400> 223 27 tggacttcta gtgatgagaa agattga <210> 224 <211> 22 <212> DNA <213> Homo sapiens <400> 224 22 cactgcgaga tcaccacagg ta <210> 225 <211> 84 <212> DNA <213> Homo sapiens <400> 225 tggacttcta gtgatgagaa agattgagaa tgttcccaca ggccccaaca ataagcccaa 60 gctacctgtg gtgatctcgc agtg <210> 226 Page 28

<211> 2 <212> 0 <213> F	NA .	sapiens						
<400> 2 tggctaa	226 agtg a	agatgacaa	tcatg					25
<210> 2 <211> 2 <212> 0 <213> 1	25 Ona	sapiens						
<400> a	227 tatc	attacaccag	ttcgt		· . ·			25
<210> / <211> / <212> / <213> /	81 DNA	sapiens						
<400> tggcta actggt	agtg	aagatgacaa tgatatgtgc	tcatgttg a	ca gcaat	tcact	gtaaagctgg	aaagggacga	60 81
<210> <211> <212> <213>	23 DNA	sapiens						
<400> tctgca	229 gagt	tggaagcact	cta					23
<210> <211> <212> <213>	21 DNA	sapiens						
<400> gccgag	230 gctt	ttctaccaga	ı a	:				21
<210> <211> <212> <213>	79 DNA	sapiens			•			
<400> tctgca ctggta	agagt	tggaagcact agcctcggc	ctatggt	gac atcg	atgctg	tggagctgta	tcctgccct	t 60 79
<210> <211> <212> <213>	24 DNA	sapiens			·	•		•
<400> acgaca	232 acgta	tgccgtacag	g tact					24
<210> <211> <212> <213>	18 DNA	sapiens						٠.
<400> ccggg		acgaagga						18
<210> <211> <212>	86				Dago	a		

<213> Homo	sapiens					•
<400> 234 acgacacgta acagctactc	tgccgtacag cttcgtgttt	tactcctgcc tcccgg	gcctcctgaa	cctcgatggc	acctgtgctg	60 86
<210> 235 <211> 19 <212> DNA <213> Homo	sapiens					
<400> 235 ctgccgggat	ggcttctat					19
<210> 236 <211> 22 <212> DNA <213> Homo	sapiens					
<400> 236 ccaggttctg	gaaactgtgg	at				22
<210> 237 <211> 68 <212> DNA <213> Homo	sapiens					· 4,
<400> 237 ctgccgggat gaacctgg	ggcttctatg	aggctgagct	ctgcccggac	cgctgcatcc	acagtttcca	60 68
<210> 238 <211> 20 <212> DNA <213> Homo	sapiens					
<400> 238 ccacaagctg	aaggcagaca	• .	with the state of			20
<210> 239 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 239 gcgtgcttcc	ttggtcttag	a				21
<210> 240 <211> 85 <212> DNA <213> Homo	sapiens			•		
<400> 240 ccacaagctg caggtctaag	aaggcagaca accaaggaag	aggcccgcaa cacgc	gaagctcctg	gctgaccagg	g ctgaggcccg	) 60 85
<210> 241 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 241 ccattctatc	; atcaacgggt	acaa				-24
<210> 242 <211> 23 <212> DNA <213> Homo	sapiens		Page :			

	·					
<400> 242 tcagcaagtg gg	jaaggtgta at	:c				23
<210> 243 <211> 75 <212> DNA <213> Homo Sa	apiens					
<400> 243 ccattctatc at cttcccactt go	tcaacgggt ac tga	caaacgagt	cctggccttg	tctgtggag	a cggattaca	ac 60 75
<210> 244 <211> 20 <212> DNA <213> Homo Sa	apiens					
<400> 244 tatcgaggca g	gtcatacca					20
<210> 245 <211> 20 <212> DNA <213> Homo s	apiens					
<400> 245 taacgcttgg C	atcatcatt					20
<210> 246 <211> 74 <212> DNA <213> Homo S	apiens					
<400> 246 tatcgaggca g gatgccaagc	gtcatacca t gtta	gaccggaag	tcaaaagtt	g acctggata	ig gctcaatg	at 60 74
<210> 247 <211> 19 <212> DNA <213> Homo 9	sapiens					
<400> 247 ccgcaacgtg	gttttctca					19
<210> 248 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 248 tgctgggttt	ctcctcctgt	t		•••••		21
<210> 249 <211> 81 <212> DNA <213> Homo	sapiens		·•			.:
<400> 249 ccgcaacgtg aacaggagga	gttttctcac gaaacccagc	cctatgggg a	t ggcctcgg1	tg ttggccat	gc tccagct	gac 60 81
<210> 250 <211> 25 <212> DNA <213> Homo	sapiens					••

Page 31

<400> tcaaga	ccat (	catcactttc	attgt	25
<210> <211> <212> <213>	27 DNA	sapiens		
<400> ggatca	251 iggaa	gtacacggag	tataact	27
<210> <211> <212> <213>	96 DNA	sapiens		
<400> tcaaga agcagt	accat ·	catcactttc gttatactcc	attgtctcgg acgtgcgggg cctgggcctc ccggtgtgtacttcc tgatcc	ccgca 60 96
<210><211><211><212><213>	19 DNA	sapiens		
<400>	253	ccgaatata		19
<210> <211> <212> <213>	23 DNA	sapiens		
<400> cgtgg		ttatcctcat	gat	23
<210><211><211><212><213>	65 DNA	sapiens		
<400> gcccg ccacg	aaacg	ccgaatataa	tcccaagcgg tttgctgcgg taatcatgag gata	agagag 60 65
<210> <211> <212> <213>	19 DNA	sapiens		
<400> gccct		tgtgcaaat		19
<210><211><211><212><213>	25 DNA	sapiens		
<400> cgtcg		attaggatag	g aagca	25
<210><211><211><212><213>	86 DNA	sapiens		
<400> gccc1	258 cccag	tgtgcaaata	a agggctgctg tttcgacgac accgttcgtg gggt Page 32	cccctg 60

39740-0001PCT.txt	9.0
gtgcttctat cctaatacca tcgacg	86
<210> 259 <211> 27 <212> DNA <213> Homo sapiens	
<400> 259 caagctagat cagcattctc taacttg	27
<210> 260 <211> 25 <212> DNA <213> Homo sapiens	
<400> 260 cacatgactg tratcgccat ctact	25
<210> 261 <211> 99 <212> DNA <213> Homo sapiens	
<400> 261 caagctagat cagcattctc taacttgttt ggtggagaac cattgtcata tacagcctggctc ggcaagtaga tggcgataac agtcatgtg	ccggttc 60 99
<210> 262 <211> 22 <212> DNA <213> Homo sapiens	
<400> 262 cacaggaaca acagcatctt tc	22
<210> 263 <211> 20 <212> DNA <213> Homo sapiens	
<400> 263 agataagccc ctgggatcca	20
<210> 264 <211> 75 <212> DNA <213> Homo sapiens	
<400> 264 cacaggaaca acagcatctt tcaccaagat gggtggcacc aaccttgctg ggcccaggggct tatct	acttggat 60 75
<210> 265 <211> 21 <212> DNA <213> Homo sapiens	
<400> 265 ggattgctca acaaccatgc t	21
<210> 266 <211> 24 <212> DNA <213> Homo sapiens	
<400> 266 ggcattaaca cttttggacg ataa	· 24

Page 33

```
<210> 267
<211> 91
<212> DNA
<213> Homo sapiens
<400> 267
ggattgctca acaaccatgc tgggcatctg gaccctccta cctctggttc ttacgtctgt 60
tgctagatta tcgtccaaaa gtgttaatgc c
<210> 268
<211> 24
<212> DNA
<213> Homo sapiens
<400> 268
                                                                          24
gcactttggg attctttcca ttat
<210> 269
<211> 24
<212> DNA
<213> Homo sapiens
<400> 269
gcatgtaaga agaccctcac tgaa
 <210> 270
 <211> 80
 <212> DNA
 <213> Homo sapiens
 gcacttiggg attctttcca ttatgattct ttgttacagg caccgagaat gttgtattca 60
 gtgagggtct tcttacatgc
 <210> 271
<211> 20
<212> DNA
 <213> Homo sapiens
 <400> 271
                                                                           20
 aatccaaggg ggagagtgat
 <210> 272
<211> 20
<212> DNA
 <213> Homo sapiens
 <400> 272
                                                                           20
 gtacagattt tgcccgagga
 <210> 273
<211> 72
 <212> DNA
  <213> Homo sapiens
  <400> 273
 aatccaaggg ggagagtgat gacttccata tggactttga ctcagctgtg gctcctcggg 60
  caaaatctgt ac
  <210> 274
  <211> 21
  <212> DNA
  <213> Homo sapiens
  <400> 274
                                                                            21
  tgtggacatc ttcccctcag a
  <210> 275
                                           Page 34
```

- .

	337 40° 00011 CT. CXC	
<211> 18 <212> DNA <213> Homo sapiens		· · · · · · · · · · · · · · · · · · ·
<400> 275 ctagcccgac cggttcgt	1	8
<210> 276 <211> 66 <212> DNA <213> Homo sapiens		•
<400> 276 tgtggacatc ttcccctcag a ggctag	acttccctac tgagccacct tctctgccac gaaccggtcg (	50 56
<210> 277 <211> 20 <212> DNA <213> Homo sapiens		
<400> 277 ctttgaaccc ttgcttgcaa		20
<210> 278 <211> 18 <212> DNA <213> Homo sapiens		
<400> 278 cccgggacaa agcaaatg		18
<210> 279 <211> 68 <212> DNA <213> Homo sapiens		
<400> 279 ctttgaaccc ttgcttgcaa gtcccggg	taggtgtgcg tcagaagcac ccaggacttc catttgcttt	60 68
<210> 280 <211> 18 <212> DNA <213> Homo sapiens		
<400> 280 gcctcggtgt gcctttca		18
<210> 281 <211> 19 <212> DNA <213> Homo sapiens		
<400> 281 cgtgatgtgc gcaatcatg		19
<210> 282 <211> 65 <212> DNA <213> Homo sapiens		
<400> 282 gcctcggtgt gcctttcaac tcacg	atcgccagct acgccctgct cacgtacatg attgcgcaca	a 60 65
<210> 283 <211> 20	Page 35	

```
<212> DNA
<213> Homo sapiens
<400> 283
ctgctgtctt gggtgcattg
<210> 284
<211> 18
 <212> DNA
 <213> Homo sapiens
<400> 284
                                                                                                                                                                                                 18
 gcagcctggg accacttg
 <210> 285
<211> 71
<212> DNA
 <213> Homo sapiens
 <400> 285
 ctgctgtctt gggtgcattg gagccttgcc ttgctgctct acctccacca tgccaagtgg 60
 tcccaggctg C
 <210> 286
<211> 1947
  <212> DNA
  <213> Homo sapiens
  <400> 286
  ttttccccag atatggggtt ctattcagcc atagataatc tagacagagg atttcagaat 60
 gaaaggaaaa atgtgtggag attagtccta gttcattctg agggccgact aagtggctca 120 gccagcttct tactccatct gcagttcata ctgccaaaga gctcccactt ccaaatcccc 180
gccagcttct tactccatct gcagttcata aggagacttta tggagaagat tctgcattaa attgtcttc gaatgatggg gaagcaaggc 240 attatattggg aagttttct ttcttttaga attatatccca agttacatt tggaaggaagt tctgtaattt tgtacccca agttacatt tttcttctc aggagaagat tctgtaattt tgtaccca agttacatt tttcttctc cttgtaattt tgtaaggcat tattattct gaacaaagtg atcaaattag ttattgaaa gttatcataa atacttgcac cagtggtgaa attgcaagac tattcaatag tttattgaaa gttatcataa atacttgcac cagtgttgaa aaaaggttaac 600 attggaacat tattcaggtg gtgaccatca aggattttcc tggaaacttg gtgaaaccat ggctaataaa ggctaataaa ggctaataaa ggctaataaa ggctaataaa ggctaataaa aatgctctg gtgaaactt ggctaaaaa aatgcctc agagaccat aaaattgaact gacagcagta actctgatac aaaattgaact aaaattgaact aaaattgaact aaaattgaact aaaattgaact aaaattgaact aaaattgaact aaaattgaact aaaattgaact aaaatggcctt 900
  aatatgaact gacagcagta actctgatac agaataatct aaattgcatc aaatggcctt
  aattcagagt ttgttaggct tatcagtatg ttgcttttaa ttggggtggg aaagtagagg
gagagaaagc aagacattta ttaagcacct cgtatgtgcc aggcactatg ctaagcactt
tacataagtt aggattaatc cctgcaagaa tcctataaag aatgttacta gcatttacac
                                                                                                                                                                                                   960
                                                                                                                                                                                                   1080
  cctgctgttg caggatgcta tttgcatgtg tccccaggtg atgtttttc tttggggagt 1320 aggggtttgg cttcctcatt catcctctt gctaaaagag gagatagttg atgttgcatc 1380 taaagatgct ataaagacaat gaaagtttga tgttgtacat acctacaagt accatttttg 1440 tgcatgatta cactccactg acatcttcca agtactgcat gtgattgaat aagaaacaag 1500 aaagtgacca caccaaagcc tccctggctg gtgtacaggg atcaggtca cagtggtaca 1560 gattcaacca ccacccaggg agtgcttgca gactctgcat agatgtgct gcatgcgtcc 1620 catgtgcctg tcagaatggc agtgttaat tctcttgaaa gaaagttatt tgctcactat 1680 ccccagcct aaggagcca gagaggcca ttcacatgga aggtccgggt cagtgtaaatgccatggtaaaagg ccatgatgtg tatattaagc cattactct cactacttggt aatggcttaa 1800 gtgtaaaagag catgatgtg tatattaagc cctaaacttt gtaaatttt ttagactctc 1860 cacagcattc atgccaatat gggattaatg cctaaacttt gtaaatttg tacagtttgt 1920 aaatcaatga ataaaaggttt tgagtgt
   <210> 287
    <211> 1311
    <212> DNA
    <213> Homo sapiens
```

Page 36

```
tagtcgggcg gggttgtgag acgccgcgct cagcttccat cgctgggcgg tcaacaagtg 60
<400> 287
tagtcgggcg gggttgtgag acgccgcgct cagcttccat cgctgggcgg tcaacaagtg 60 cgggcctggc tcagcgggg ggggcgcgga gaccgcgagg cgaccgggag cggctgggt 120 cgcgctgcc ccaggccggg cgccctcacctg cccaggggag cgccgggac cccggcccagc 180 ccccacagggg cgcccgccc cccggcgcc cccggagtac cccacagggg cgcccgccc cccggcgcc ggcgctcgac ggcgcggat tgacccgga ggcgcggat gaccctgagt gaggaagcga 360 ggcgagggt gacccgggac cagagtgag aggggagcca agggagtcga cccggagca ggaggtgac cccggagca agggagcac agggagcac cccacagcaa tgagaagcac gaccttcatg 540 cgcggcagc tgggcagc cccacagcaa tgagaagcac gaccttcatg 540 cgcggcagc tgggcagc cagaggcga cccacagcaa tgagaagcac agtgataccag ttgtccaaca cctqqcccaa gtcatcaac 600 cgccgcgag cgccgggat cggcgggag cggcggagag cggggagaa aggggagaa aggggagaa cccaggagag cccaggagga cccaaggagaa cccaaggaa cccaagaa cctqqcccaa gtcatcaac 600 cgccgggag cggcggagagag cggcggagagaa aggggagaa aggggagaa cccaaggaa cccaaggaa cccaaggaa cccaaggaa cccaagaa agggagaaa agggagagaa aggagagaa agggagaaa agggagaaa agggagaaa aggagagaa aggagagaa aggagagaa aggagagaa aggagagaa aggagagaa aggagagaa aggagaaa aggagagaa aggagaaa aggagaaaa aggagaaaa aggagaaaa aggagaaaa aggagaaaa aggagaaa aggagaaaa aggagaaaa aggagaa
 <210> 288
<211> 582
    <212> DNA
     <213> Homo sapiens
    <210> 289
        <211> 6030
        <212> DNA
        <213> Homo sapiens
      cacacacaca caacaattaa cagtcttcag gcaaaacgtc gaatcagcta tttactgcca 960 aagggaaata tcatttattt tttacattat taagaaaaaa agatttattt atttaagaca 1020
          gtcccatcaa aactcctgtc tttggaaatc cgaccactaa ttgccaagca ccgcttcgtg 1080
          tggctccacc tggatgttct gtgcctgtaa acatagattc gctttccatg ttgttggccg 1140 gatcaccatc tgaagagcag acggatggaa aaaggacctg atcattgggg aagctggctt 1200 tctggctgct ggaggctggg gagaaggtgt tcattcactt gcatttcttt gccctggggg 1260
                                                                                                                                                 Page 37
```

```
39740-0001PCT.txt
  ctgtgatatt aacagaggga gggttcctgt ggggggaagt ccatgcctcc ctggcctgaa 1320 gaagagactc tttgcatatg actcacatga tgcatacctg gtgggaggaa aagagttggg 1380
aacttcagat ggacctagta cccactgaga tttccacgcc gaaggacagc gatgggaaaa 1440
 aaaaagttcc aggtgtggaa tatgggggtt atctgtacat cctggggcat taaaaaaaaa 2340 aggaaattt tttttctcc agtttagaat cagccttgaa acattgatgg aataactctg 2460 tggcattatt gcattatat ccatttatct gtattaactt tggaatgtac tctgttcaat 2520 gtgttaatgt tttaattgtat ttagttatgg cctatacact atttgtgagc acagggggt 2580 ttttttgtt taattgtat ttagttatgg cctatacact atttgtgagc aaaggtgatc 2640 gtttcaacca gtcatgtga tttccacgt tctgaaaga cattctgaga aggtgagata 2700 agccctgagt ctcagctacc taagaaaaaa ctggatgtca ctggccactg aggagctttg 2520 tgtgtcct ttgaccttgt ttcttgaagg tttccacgtc taagaaaaac ctggatgtca ctggccactg aggagctttg 2580 tttcaaccaa gtcatgtgca tttccacgtc aacagaattg tttattgga cagtgagata 2700 aacagaattg ttcaaggat ttccacgtc ttcttgaagg tttcctcgtc cctgggcaat tccggcattt 2820 tgtgtcct ttcagggat cagcagatt tggttaaacc catgagattc attcaggat aaatccaga ggcaaatgac cagcagattc aggaaaccc cagcagatc catcagggc cttctggcc tttagagag 3000 tggtttaacc ggcctgtc cttcagggtc cctcagag cccccagagc cctcctgccc tccttccgcg 3060 ggaggctttct catggctgtc cttcagggtc ttcctgaaa ggaaacctg tggtatgaag acatcttcag gctgctatcc tgccaaaatc 3300 attttaatgg agtcagttg cagtatgac caacaagacc gcagtggtaa gatcctcaa gctgctttag 3360 attttaatgg agtcagtttg cagtatgct cacgtggtaa gatcctccaa gctgctttag 3360 attttaatgg agtcagtttg cagtatgct cacgtggtaa gatcctccaa gctgctttag 3360
  actgtacttt taaggcagtg gctgttttta gactttctta tcacttatag ttagtaatgt 4500 acacctactc tatcagagaa aaacaggaaa ggctcgaaat acaagccatt ctaaggaaat 4560 tagggagtca gttgaaattc tattctgatc ttattctgtg gtgtcttttg cagcccagac 4620 aaatgtggtt acacacttt taagaaatac aattctacat tgtcaagctt atgaaggttc 4680
     aaatgtggtt acacactttt taagaaatac aattctacat tgtcaagctt atgaaggttc 4680 caatcagatc tttattgtta ttcaatttgg atctttcagg gattttttt ttaaattatt 4740 atgggacaaa ggacatttgt tggaggggtg ggagggagga acaatttta aatataaac 4800 attcccaagt ttggatcagg gagttggaag ttttcagaat aaccagaact aagggtatga 4860 aggacctgta ttggggtcga tgtgatgcct ctgcgaagaa ccttgtgtga caaatgagaa 4920 acattttgaa gtttgtggta cgacctttag attccagaga catcagcatg gctcaaaggg 4980 cagctccgtt tggcagtgca atggtataaa tttcaagctg gatatgtcta atgggtatt 5040 aaacaataaa tgtgcagttt taactaacag gatattaat gacaaccttc tggttggtag 5100 ggacatcgt ttctaaatgt ttattatgta caatacagaa aaaaatttta taaaattaag 5160 caatgggaa ctgaatggaa cagaatctt tagtcaatca 5220
       caatgtgaaa ctgaattgga gagtgataat acaagtcctt tagtcttacc cagtgaatca 5220 ttctgttcca tgtctttgga caaccatgac cttggacaat catgaaatat gcatctcact 5280 ggatgcaaag aaaatcagat ggagcatgaa tggtactgta ccggttcatc tggactgccc 5340
                                                                                                                                                                                Page 38
```

```
cagaaaaata acttcaagca aacatcctat caacaacaag gttgttctgc ataccaagct 5400 gagcacagaa gatgggaaca ctggtggagg atggaaaggc tcgctcaatc aagaaaaattc 5520 ttttggaaaa tctgccgtgg gcctccaga tagctcattt ggggaagctt ttttggaaaattt gcaagagtga cagtggattg catttctttt gggggaagctt tctttggtg 5640 gttttgtta ttataccttc ttaagttttc aaccaaggtt tgcttttgtt ttggattact ttgtttaaa agatttcat acttttacct tccatggctc tttttaagat tgatactttt 5820 ttgttataca agattttcat acttttacct tccatggctc tttttaagat tgatactttt 5820 ttgttataca agatttctg caacactgta caccataaaaa atacggtaag gatactttac 5880 aagaggggc tgatattctg caacactgta caccataaaaa atacggtaag gatactttac 5880 tggttgttgga aaaagtcaca ttgccattaa actttccttg tctgtctagt taatattgtg 6000 aagaaaaata aagtacagtg tgagatactg
```

```
<210> 290
<211> 10987
<212> DNA
<213> Homo sapiens
```

		•			•		
	<400> 290				cactataaca	ctactacace (	50
		gcttctgaaa .	ctaggcggca	gaggcggagc	accongrage	ctgctgcgcc (	120
	tctactacac	ctcgggtgtc	ttttgcggcg	graggregee	gccygyagaa	gcgtgagggg aactgcacct	180
	ctagagcaga	cttatttacc	aagcattgga	ggaatatcgt	aggiaaaaai	gcctattgga agcagattta	รีกด
	tccaaagaga	ggccaacatt	ttttgaaatt	tttaagacac	gctgcaacaa	agcagattta :	360
	nnaccaataa						
	gaacctgcag	aagaatctga	acataaaaac	aacaattacg	aaccaaacct	atttaaaact	420 420
	ccacaaaaaa						
•	aggetaacte	taccactata	ccaatctcct	gtaaaagaat	tagataaatt	caaattagac aactaaaatq	540 600
	***********	atottcccaa	tagtagacat	aaaagtcttc	gcacagtgaa	aactaaaatg aagtcctgtt	660
	ODSOTOCOO	togatectga	tatotcttog	tcaagttctt	tagctacacc	acccaccctt tcctcatgat	840
	ccattagatt	tacatytayt	acaccagaag	tootctcaac	/taaccctttc	aggtctaaat aaatatttca	1440
	aaggaagttg	taccgcccc	. ggcccgcgaa	catatttctt	catotoacca	aaatatttca ttcagagaat	1500
	aagcaggcaa	tatctggaac	ttctccageg	getteetat	caanttttt	aggtcatatg	1800
	atattcagaa	taagagaatc	accidadyay	acctctnaa?	atomactoma	aatacatact	1860
	actgatccaa	actttaaaaa	agaaactgaa	ccasattta	ttoataatoo	aatacatact aagctggcca	1920
	acaattctga	a ggaaatgtto	Lagaaatya				
				a ggacagtgt	g aaaatgatt	c aaaaagcaaa t acaacattca	2460
	aaagtggaai	í acagtgatá	c tgactttca	a tcccagaaa	a gretttat	a tgatcatgaa a cctagtcatg	2580
	tetaatatt	nattaacca	a aaatattcc	c atggaaaag	a atcaagatg	t atgtgcttta	2760
	ccttcaana	a anntacaat	t caaccaaaa	c acaaaccu	a gagemmee	a aaaaaatcaa	1 2820
	ccccaaya			Page	39		

•	•		9740-0001PC			
gaagaaacta	cttcaatttc	aaaaataact	gtcaatccag	actctgaaga	acttttctca	2880
gacaatgaga	ataattttot	cttccaaqta	gctaatgaaa	ggaataatct	tgctttagga	294U ·
aatactaagg	aacttcatga	aacagacttg	acttgtgtaa	acqaacccat	tttcaagaac	3000
tctaccatgg	ttttatatag	agacacaggt	gataaacaag	caacccaagt	gtcaattaaa	<i>3060.</i>
aaagatttoo	tttatottct	tacagaggag	aacaaaaata	gtgtaaagca	gcatataaaa	3170
atgactctag	atcaaaattt	aaaatcqqac	atctccttga	atatagataa	aataccagaa	3780
aaaaataato	attacatoaa	caaataggca	ggactcttag	gtccaatttc	aaatcacagt	3240
tttggaggta	acttcagaac	aucttcaaat	aaqqaaatca	agctctctga	acataacatt	3300
aagaagagca	aaatottctt	caaagatatt	gaagaacaat	atcctactag	tttagcttgt	3360
attaaaatta	taaatacctt	ggcattagat	aatcaaaaga	aactgagcaa	gcctcagtca	3420 .
attaatacto	tatctocaca	tttacagagt	agtgtagttg	tttctgattg	taaaaatagt	3480
catataaccc	ctcagatgtt	attttccaaq	caggatttta	attcaaacca	taatttaaca.	334U .
cctagccaaa	aggcagaaat	tacagaactt	tctactatat	tagaagaatc	aggaagtcag	3600:
tttgäattta	ctcagtttag	aaaaccaagc	tacatattgc	agaagagtac	atttgaagtg	3660
cctgaaaacc	agatgactat	cttaaagacc	acttctgagg	aatgcagaga	tgctgatctt	3/20
catgtcataa	tgaatgcccc	atcgattggt.	caggtagaca	gcagcaagca	atttgaaggt	3/80
acagttgaaa	ttaaacggaa	gtttgctggc	ctgttgaaaa	atgactgtaa	caaaagtgct	3840
tctggttatt	taacagatga	aaatgaagtg	gggtttaggg	gcttttattc	tgctcatggc	3900
acaaaactga	atotttctac	taaaactcta	caaaaaacta	tgaaactgtt	tagtgatatt	3960
gagaatatta	gtgaggaaac	ttctgcagag.	gtacatccaa	taagtttatc	ttcaagtaaa	4020
tgtcatgatt	ctgttgtttc	aatgtttaag	atagaaaatc	ataatgataa	aactgtaagt	4080
gaaaaaaata	ataaatgcca	actgatatta	caaaataata	ttgaaatgac	tactggcact	4140
tttgttgaag	aaattactga	aaattacaag	agaaatactg	aaaatgaaga	taacaaatat	4200
actgctgcca	gtagaaattc	tcataactta	gaatttgatg	gcagtgattc	aagtaaaaat	4200
gatactgttt	gtattcataa	agatgaaacg	gacttgctat	ttactgatca	gcacaacata	4320
tgtcttaaat	tatctggcca	gtttatgaag	gagggaaaca	ctcagattaa	agaagatttg	4300
tcagatttaa	cttttttgga	agttgcgaaa	gctcaagaag	catgtcatgg	taatacttca	4500
aataaagaac	agttaactgc	tactaaaacg	gagcaaaata	taaaagattt	tgagacttct	4500
gatacatttt	ttcagactgc	aagtgggaaa	aatattagtg	LCyccadaya	gtcatttaat	4500
aaaattgtaa	atttctttga	tcagaaacca	gaagaartyc	#220##2##2	cttaaattct	4680
gaattacatt	ctgacataag	aaayaacaaa	atecesatta	atactaga	ggaaacagac	4740
atagttaaac	acaaaatact	gadayadayı	greetagreg	. gractygaaa	tcaactagtg	4800
accttccagg	gacaacccya	acytyatyda 	aayaccaaay	ctttmmacaa	gttgggtttt agtgaaaaac	4860
catacagcia	gcyyyaaaaa	agitaaaatt	gcaaaggaac	ottttagcca	tcaatgggca	4920
ctttttgatg	addadyayca	aggiactagi	nacettnaat	tancatotoa	gaccattgag	4980
adyaccccaa	ccccaaanto	taaanaaatn	canaattctc	tcaataatga	taaaaacctt	5040
attacayciy	agetatant	occacctaao	ctcttaagtg	ataatttato	tagacaaact	5100
gettetattg	aaacatcaaa	aagtatcttt	ttoaaaotta	aagtacatga	aaatgtagaa	5160
aaanaaacan	caaaaaatcc	tocaacttot	tacacaaatc	agtcccctta	ttcagtcatt	5220
gaaaattcag	ccttagcttt	ttacacaaqt	tataataaaa	aaacttctgt	gagtcagact	5280
trattactto	aagcaaaaaa	atgacttaga	gaaggaatat	ttgatggtca	accagaaaga	5340
ataaatacto	cagattatgt	aggaaattat	ttgtatgaaa	ataattcaaa	cagtactata	5400
actaaaaata	acaaaaatca	tctctccgaa	aaacaagata	cttatttaag	taacagtagc	5460
atgictaaca	gctattccta	ccattctgat	gaggtatata	atgattcagg	atatctctca	5520
aaaaataaac	ttgattctgg	tattgagcca	gtattgaaga	atgttgaaga	tcaaaaaaac	2280
actagttttt	ccaaagtaat	atccaatgta	aaagatgcaa	atgcataccc	acaaactgta	5700
aatgaagata	tttgcgttga	ggaacttgtg	actagetett	caccitycaa	aaataaaaat	5760
gcagccatta	aattgtccat	atttatat	teacatera	casttasasa	acctgcattt	5820
aggatagcca	gtggtaaaat	tanageget	1 cacatyaaa	. caactaaaaa	agtgaaagac atcaaaaatt	5880
atatttacag	acagilicay	- Laady Laatt	aayyaaaaca	atgagaataa	ggatattctt	5940
tgccaaacga	#201#22#02	tasstatsac	acocattcac	atgatttaga	tgctgacatt	6000
cataacticic		acataaccaa	acgedetede	nattonanaa	agtttctaaa	6060
cayaytyaay	adallicata atastattaa	tttanaaact	tranatatat	otaaatotao	tatagggaag	6120
cttcataant	cantiticati	tocaaatact	totoggattt	ttagcacagc	aagtggaaaa	6180
tetatecana	tatcanatno	ttcattacaa	aacgcaagac	aagtottttc	tgaaatagaa	6240
datantacca	accapatett	ttccaaanta	ttotttaaaa	otaacdaaca	ttcagaccag	6300
rtraraanan	agedageeee	tactatacot	actccagaac	atttaatatc	ccaaaaaggc	6360
ttttcatata	atotootaaa	ttcatctoct	ttctctagat	ttagtacago	aagtggaaag	6420
caagtttcca	ttttagaaaa	ttccttacac	aaagttaagg	gagtottaga	ggaatttgat	6480
ttaatcagaa	ctgagcatag	tcttcactat	tcacctacgt	: ctagacaaaa	tgtatcaaaa	6540
atacttcctc	atattaataa	gagaaaccca	gagcactgtg	ı taaactcaga	aatggaaaaa	6600
acctocagta	aagaatttaa	attatcaaat	aacttaaatg	ı ttgaaggtgg	ttcttcagaa	6660
aataatcact	ctattaaaot	ttctccatat	ctctctcaat	: ttcaacaaga	caaacaacag	6720
ttggtattag	gaaccaaagt	ctcacttatt	gagaacattc	: atgttttggg	ı aaaagaacag	6780
acttcaccta	aaaacqtaaa	aatooaaatt	ootaaaacto	, aaactttttc	: tgatgttcct	6840
gtgaaaacaa	atatagaagt	ttgttctact	ta <b>ctccaaag</b>	, attcagaaaa	ctactttgaa	6900
		-	Page 4	10		

```
39740-0001PCT.txt
 gaagattatt ttggtaagga aagtttatgg actggaaaag gaatacagtt ggctgatggt 7980 ggatggctca taccctccaa tgatggaaag gctggaaaag aagaatttta tagggctctg 8040 tggacactc caggtgtgga tccaaagctt attctagaa tttgggtta taatcactat 8100
actificate gaagcagaaa acaagcttat gcatatactg 9/80 actagaaatg atcccaagtg gtccaccca actaaagact gtacttcagg gccgtacact 9840 gctcaaatca ttcctggtac aggaaacaag cttctgatgt cttctcctaa ttgtgagata 9900 tattatacaaa gtcctttatc actttgtatg gccaaaagga agtctgtttc cacacctgtc 9960 tcaacaagaa tgacttcaaa gtcttgtaaa ggggagaaag agattgatga ccaaaagaac 10020 tgcaaaaaga gaagagcctt ggatttcttg agtagactgc ctttacctcc acctgttagt 10080 cccatttgta catttgttc tccggctgca cagaaggcat ttcagccacc aaggagttgt 10140 ggcaccaaat acqaaacacc cataaagaaa acaagccttat gcatatactg 9/80
    ggcaccaaat acgaaacacc cataaagaaa aaagaactga attctcctca gatgactcca tttaaaaaaat tcaatgaaat ttctctttg gaaagtaatt caatagctga cgaagaactt
   ttacaatcaa caaaatggtc atccaaactc aaacttgaga aaatatcttg ctttcaaatt 10980
                                                                           Page 41
```

```
gacacta
```

10987

```
<210> 291
 <211> 1552
  <212> DNA
  <213> Homo sapiens
gcccgtacac accgtgtgct gggacacccc acagtcagcc gcatggctcc cctgtgcccc 60
    tgtgagaagc cagccagagg catctgaggg ggagccggta actgtcctgt cctgctcatt 1500 atgccacttc cttttaactg ccaagaaatt, ttttaaaata aatatttata at 1552
    <211> 1578
     <212> DNA
     <213> Homo sapiens
  <400> 292
acgaacaggc caataaggag ggagcagtgc ggggtttaaa tctgaggcta ggctggctct 60
tctcggcgtg ctgcggcgga acggctgttg gtttctgct gttgtaggtc cttggctggt 120
cgggctccgag tcaccaggaa ctcgaaaatt aatgctgaaa ataaggcgaa ggaagccatg 180
gcaggcgcaa agcgcgttcc taccgccct gctgcaacct ccaagcccgg actgaggcca 300
agaacagctc ttggggacat tggtaacaaa gtcagtgaa aactgcaggc caaaatgcct aggtaacaac ttcagctact ggaaaagtca ttgataaaaa actaccaaaa 420
cctttgaaa aggtacctat gctggtgca gtgccagtgt ctgagccagt gccagagcca 480
gttgatactg cctctccaag cccaatggaa acatctggat gtgccagtg ctgagccagt gccagagcca 480
gttgatactg cctctccaag cccaatggaa acatctggat gtgcccctgc agaagaagac 600
ctgtgtcagg ctttctctga tgtaattctt gcagtaaatg atgtggatgc agaagaagagc 660
gctgatccaa acctttgtag tgaatatgtg aaagatattt atgcttact gggaacaact 720
gaggaagaga aagcagcag accaaaatac ctactggat gggaagtcac tggaacaact 720
gaggaagaga aagcagtcag accaaaatac ctactgggt gggaagtcac tggaacaact 720
gaggaagaga aagcagtcag accaaaatac ctactgggt gggaagtcac tggaacaact 720
accatgtaca tgactgtct cattattgat cggttcatgc agaataattg tgtgcccaag 900
aagatgctgc agactggttgg tgtcactgc atgtttattg caagcaaata tgaagaaatg 960
taccctccag aaattggtga agactctaag gctttaaact ttggtctgg tcggcctcta 1080
cctttgcact tccttcggag agcactaaa accactaag ccacacatc 1140
    <400> 292
     cctttgcact tccttcggag agcatctaag attggagagg ttgatgtcga gcaacatact 1140 ttggccaaat acctgatgga actaactatg ttggactatg acatggtgca ctttcctcct 1200 tctcaaattg cagcaggagc tttttgctta gcactgaaaa ttctggataa tggtgaatgg 1260 acaccaactc tacaacatta cctgtcatat actgaagaat ctcttctcc agttatgcag 1320
      cacctggcta agaatgtagt catggtaaat caaggactta caaagcacat gactgtcaag 1380 aacaagtatg ccacatcgaa gcatgctaag atcagcactc taccacagct gaattctgca 1440 ctagttcaag atttagccaa ggctgtggca aaggtgtaac ttgtaaactt gagttggagt 1500
                                                                                                                                                       Page 42
```

```
aaaaaaaaa aaaaaaaa
<210> 293
<211> 3195
<212> DNA
<213> Homo sapiens
1020
                                             1080
 gcgttttgtt gagcatgaca cctgcagcag gaatatatgt gtgcctattt gtgtggacaa
 aaatatttac acttagggtt tggagctatt caagaggaaa tgtcacagaa gcagctaaac caaggactga gcaccctctg gattctgaat ctcaagatgg gggcagggct gtgcttgaag gccctgctgaa gcaccctctgtt agggccttgg ttcaataaag cactgagcaa gttgagaaaa
                                              3060
                                              3120
                                              3180
                                              3195
 aaaaaaaaa aaaaa
  <210> 294
 <211> 3737
  <212> DNA
  <213> Homo sapiens
                          Page 43
```

```
<400> 294
 ggcgtccgcg cacacctccc cgcgccgccg ccgccaccgc ccgcactccg ccgcctctgc 60
ccgcaaccgc tgagccatcc atgggggtcg cgggccgcaa ccgtcccggg gcggcctggg 120
aattattaac agatgagaag tcttgccaag atgtggatga gtgctctttg gataggacct 1200 gtgaccacag ctgcatcaac caccctggca catttgcttg tgcttgcaac cgagggtaca 1260 ccctgtatgg cttcacccac tgtggagaca ccaatgagtg cagcatcaac aacggaggct 1320 gtcagcaggt ctgtgtgaac acagtgggag gctagagg cctctaccc acagtgggaac 1380
gcattttatg tccaaatgga accttccaaa atgaggaagg acaaatgact tgtgaaccat 2100
 gcccaagacc aggaaattct ggggccctga agaccccaga agcttggaat atgtctgaat 2160 gtggaggtct gtgtcaacct ggtgaatatt ctgcagatgg ctttgcacct tgccagctct 2220 gtgccctggg cacgttccag cctgaagctg gtcgaacttc ctgcttcccc tgtggaggag 2280 gccttgccac caacatcag ggagctactt cctttcagga ctgtgaaacc agagttcaat 2340 gttcacctgg acatttctac aacaccaca ctcaccacta tattcgttgc ccagtggaa 2400
 gttcacctgg acattctac aacaccacca ctcaccgatg tattcgttgc ccagtgggaa cataccagcc tgaatttgga aaaaataatt gtgtttcttg cccaggaaat actacgactg actttgatgg ctccacaaac ataacccagt gtaaaaacag aagatgtgga ggggagctgg
                                                                                                                                        2400
                                                                                                                                       2460
                                                                                                                                       2520
  gagatttcac tgggtacatt gaatccccaa actacccagg caattaccca gccaacaccg 2580 agtgtacgtg gaccatcaac ccaccccca agcgccgcat cctgatcgtg gtccctgaga 2640 tcttcctgcc catagaggac gactgtgggg actatctggt gatgcggaaa acctcttcat 2700 ccaattctgg gacaacatag gacagccgg agacctacgg agaccaccac gccaccc 2760
  ccaggtcaaa gaagctgtgg attcagttca agtccaatga agggaacagc gctagagggt 2820 tccaggtccc atacgtgaca tatgatgagg actaccagga actcattgaa gacatagttc 2880 gagatggcag gctctatgca tctgagaacc atcaggaaat acttaaggat aagaaactta 2940 tcaaggctct gtttgatgtc ctggcccatc cccaggaacta tttcaagtac acagcccagg 3000
 agcacttctg gagacat
```

<210> 295 <211> 2042

Page 44

```
<212> DNA
 <213> Homo sapiens
<400> 295
ggggccagtc gttcgccgga aagcatttgt ctcccacctc atcataacaa caattaattt 60
   <210> 296
<211> 2547
    <212> DNA
    <213> Homo sapiens
   ttgaggctca gcagtctcat ggcagcagtg cctgttcaca gccccatggc agcgttaccc 840 agtcccaagg ctcctcca cagtcccagg gcatatccag ctccttacc agcacgatgc 900 caaactccag ccagtcctct cactccagct ctgggacact gagctcctta gagacagtgt 960 accactagga accttattct attcctgagg accaagaacc tgaggaccaa gaacctgagg 1020 agctcaccc tgccccctgg gctcgattat agggcccttca ggatggattt gccaatcttg 1080 agcacatgct gaacactac tgggttggaa tgacaactac tggtttgga gaacatacag caagaaacac tttcggatt 1200 aaccctttot aaatacaga ctttaaggaaaca cctttaagaa cctttaagaaaca cctttaagaaca cctttaagaaaca cctttaagaacac cccatccttt aacacacat 1320
      gaacctttgt aaatacagag cttgtaggga aaggaaaacg ccgtcctttg aataacaatt 1320
                                                                          Page 45
```

```
39740-0001PCT.txt
aaaaatacac aaattagcta ggcatggtgg actcgcctgt aatctcacta cacaggaggc 2460
adadatatat adattaytta yytatyytyy attryctyt adtitiatta tacaggaggc 2400 tyaggcagga gaatcactty aacctggag gcggatytty aagtgagcty agattycacc 2520 actgcactcc agtctggyty agagtgagac tcagtcttaa aaaaatatyc ctttttgaag 2580 cacgtacatt ttgtaacaaa gaactgaagc tcttattata ttattayttt tyatttaaty 2640 ttttcagccc atctccttc atattctgy gagacagaaa acatyttcc ctacacctct 2700 tygcattccat cctcaacacc caactytcc gatgcaatga acacttaata aaaaacagtc 2760 cattagts
gattggtc
 <210> 298
<211> 1358
<212> DNA
 <213> Homo sapiens
<210> 299
  <211> 4407
  <212> DNA
  <213> Homo sapiens
  tttcgactcg cgctccggct gctgtcactt ggctctctgg ctggagcttg aggacgcaag 60 gagggtttgt cactggcaga ctcgagactg taggcactgc catggcccct gtgctcagta 120
   <400> 299
  ttctgccatt cctgtcccca cggaaggtta tagtaaaagg tgggagaatt gttgctatgc 1320 agtttgttcg gacagagcaa gatgaaactg gaaaatggaa tgaagatgaa gatcagatgg 1380 tccatctgaa agccgatgtg gtcatcagtg cctttggttc agttctgagt gatcctaaag 1440
                                                              Page 47
```

```
39740-0001PCT.txt
taaaagaagc cttgagccct ataaaattta acagatgggg tctcccagaa gtagatccag 1500 aaactatgca aactagtgaa gcatggggtat ttgcaggtgg tgatgtcgtt ggtttggcta 1560 acactacagt ggaatcggtg aatgatggaa agcaagcttc ttggtacatt cacaaatacg 1620 tacagtcaca atatggagct tccgttctg ccaagcctga actacccctc ttttacactc 1680
ctattgatct ggtggacatt agtgtagaaa tggccggatt gaagtttata aatccttttg 1740 gtcttgctag cgcaactcca gccaccagca catcaatgat tcgaagagct tttgaagctg 1800 gatggggttt tgccctcacc aaaactttct ctcttgataa ggacattgtg acaaatgttt 1860 cccccagaat catccgggaa accacctctg gccatagat tagaccttgga caaagctcct 1920
                                                                                                                                                                                                               1800
 ttctgaatat tgagctcatc agtgagaaaa cggctgcata ttggtgtcaa agtgtcactg 1980
aactaaaggc tgacttccca gacaacattg tgattgctag cattatgtgc agttacaata 2040 aaaatgactg gacggaactt gccaagaagt ctgaggattc tggagcagat gccctggagt 2100 taaatttatc atgtccacat ggcatgggag aaagaggaat gggcctggcc tgtgggcagg 2160
taaatttatc atgtccacat ggcatgggag aaagaggaat gggcctggcc tgtgggcagg 2160 atccagagct ggtgcggaac atctgccgct gggttaggca agctgttcag attccttttt 2220 ttgccaagct gaccccaaat gtcactgata ttgtgagcat cgcaagagct gcaaaggaag 2280 gtggtgccaa tggcgttaca gccaccaaca ctgtctcagg tctgatggga ttaaaatctg 2340 atggcacacc ttggccagca gtggggattg caaagcgaac tacatatgga ggagtgtctg 2400 ggacagcaat cagacctatt gctttgagag ctgtgacctc cattgctcgt gctctgcctg 2460 gattcccat tttggctact ggtggaattg actctgcta aagtggtctt cagtttctc 2520 atagtggtg ttccgtctc caggtatgca gtgccattca gaatcaggat ttcactgtga 2580 tcgaagacta ctgcactggc ctcaaagccc tgctttatct gaaaagcatt gaagaactac 2640 aagactggaa tggaaaaga ccagttccac 2700
 aagactggga tggacagagt ccagctactg tgagtcacca gaaagggaaa ccagttccac 2700
 gtatagctga actcatggac aagaaactgc caagttttgg accttatctg gaacagcgca 2760 agaaaatcat agcagaaaac aagattagac tgaaagaaca aaatgtagct ttttcaccac 2820 ttaagagaag ctgtttatc cccaaaaggc ctattcctac catcaaggat gtaataggaa 2880 aagcactgca gtaccttgga acatttggtg aattgagcaa cgtagagcaa gttgtggcta 2940 tgattgatga agaaatgtgt atcaactgtg gtaatgcta catgacctgt aatgattctg 3000 gctaccaggc tatacagttt gatccagaaa cccacctgcc caccataacc gacacttgta 3060 caggctgtac tctgtggctc agtgtttgcc ctattgtcga ctgcatcaaa atggtttcca 3120 cagacaacacc ttatgacca aagagagaggcg tacccttatc totgaaccac ttatgacca aagagagaggcg tacccttatc totgaaccac ttatgacca aagagagaggcg tacccttatc
 agtgāaātta agcattttga aacāaagtac tetttāacat acaagaāaat gtatecaāgg 3600
  aaacatttta tcaataaaaa ttacctttaa ttttaatgct gtttctaaga aaatgtagtt 3660 agctccataa agtacaaatg aagaaagtca aaaattattt gctatggcag gataagaaag 3720 cctaaaattg agtttgtgga ctttattaag taaaatcccc ttcgctgaaa ttgcttattt 3780
  ttggtgttgg atagaggata gggagaatat ttactaacta aataccattc actactcatg 3840 cgtgagatgg gtgtacaaac tcatcctctt ttaatggcat ttctctttaa actatgttcc 3900 taaccaaatg agatgatagg atagatcctg gttaccactc ttttactgtg cacatatggg 3960 ccccggaatt ctttaatagt caccttcatg attatagcaa ctaatgtttg aacaaagctc 4020
  aaagtatgca atgcttcatt attcaagaat gaaaaatata atgttgataa tatatataa 4080 gtgtgccaaa tcagtttgac tactctctgt tttagtgttt atgtttaaaa gaaatatatt 4140 ttttgttatt attagataat attttgtat ttctctattt tcataatcag taaatagtgt 4200 catataaact catttattc ctcttcatgg catcttaatt atgaatctat aagtagtaa 4260
   tcagaaagta acaatctatg gcttatttct atgacaaatt caagagctag aaaaataaaa 4320 tgtttcatta tgcactttta gaaatgcata tttgccacaa aacctgtatt actgaataat 4380
                                                                                                                                                                                                                  4407
   atcaaataaa atatcataaa gcatttt
   <210> 300
   <211> 5532
    <212> DNA
   <213> Homo sapiens
   <400> 300
   gccgcgctgc gccggagtcc cgagctagcc ccggcgccgc cgccgcccag accggacgac 60
   aggccacctc gtcggcgtcc gccgagtcc ccgcctcgcc gccaacgcca caaccaccgc 120 gcacggcccc ctgactccgt ccagtattga tcgggagagc cggagcgagc tcttcgggga 180 gcagcgatgc gaccctccgg gacggccggg gcagcgctcc tggcgctgct ggctgcgctc 240 tgcccggcga gtcggctct ggaggaaaag aaagtttgcc aaggcacaagt taacaagctc 300
   acgcagttgg gcacttttga agatcatttt ctcagcctcc agaggatgtt caataactgt 360 gaggtggtcc ttgggaattt ggaaattacc tatgtgcaga ggaattatga tctttccttc 420 ttaaagacca tccaggaggt ggctggttat gtcctcattg ccctcaacac agtggagcga 480 attcctttgg aaaacctgca gatcatcaga ggaaatagt actacgaaaa ttcctatgcc 540 ttagcagtct tatctaacta tgatgcaaat aaaaccggac tgaaggagct gcccatggaga 600
   aatttacagg aaatcctgca tggcgccgtg cggttcagca acaaccctgc cctgtgcaac 660
                                                                                                                       Page 48
```

39740-0001PCT.txt gtggagagca tccagtggcg ggacatagtc agcagtgact ttctcagcaa catgtcgatg 720 

```
39740-0001PCT.txt
ttctcgcaaa aacgtatctc ctaatttgag gctcagatga aatgcatcag gtcctttggg 4800 gcatagatca gaagactaca aaaatgaagc tgctctgaaa tctcctttag ccatcacccc 4860 aacccccaa aattagtttg tgttacttat ggaagatagt tttctcttt tacttcactt 4920 caaaagcttt ttactcaaag agtatatgtt ccctcaggt cagctgccc caaaccccct 4980 ccttacgctt tgtcacacaa aaagtgtct tgccttgagt catctattca agcacttaca 5040 gctctggca caacagca ttttacacgt gccaataga gtaccatta agcacttaca 5040 gctctggca caacagca ttttacacgt
 gctctggcca caacagggca ttttacaggt gcgaatgaca gtagcattat gagtagtgtg 5100 aattcaggta gtaaatatga aactagggtt tgaaattgat aatgctttca caacatttgc 5160 agatgtttta gaaggaaaaa agttccttcc taaaataatt tctctacaat tggaagattg 5220
 gaagattcag ctagttagga gcccatttt tcctaatctg tgtgtgccct gtaacctgac 5280 tggttaacag cagtcctttg taaacagtgt tttaaactct cctagtcaat atccaccca 5340 tccaatttat caaggaagaa atggttcaga aaatattttc agcctacagt tatgttcagt 5400 cacacacaca tacaaaatgt tccttttgct tttaaagtaa tttttgactc ccagatcagt 5460
  cagagecect acageattőt taagaaagta tttgatťttt gteteaatga aaaťaaaact 5520
  atattcattt cc
  <210> 301
<211> 1528
   <212> DNA
   <213> Homo sapiens
   <400> 301
   cggcgagcga gcaccttcga cgcggtccgg ggaccccctc gtcgctgtcc tcccgacgcg 60
   găcccgcgtg ccccaggcct cgcgctgccc ggccggctcc tcgtgtccca ctcccggcgc 120
  acgccctccc gcgagtcccg ggcccctccc gcgcccctct tctcggcgcg cgcgcagcat 180 ggcgcccccg caggtcctcg cgttcgggct tctgcttgcc gcggcgacgg cgacttttgc 240 cgcagctcag gaagaatgtg tctgtgaaaa ctacaagctg gccgtaaact gctttgtgaa 300 taataatcgt caatgccagt gaacttaagg tgggggacaa aatactgtca tttgctcaaa 360
   gctggctgcc aaatgtttgg tgatgaaggc agaaatgaat ggctcaaaac ttggggagaag 420 agcaaaacct gaaggggccc tccagaacaa tgatgggctt tatgatcctg actggatga 480 gagcgggctc tttaaggcca agcagtgcaa cggcacctcc acgtgctggt gtgtgaacac 540
   tgctggggtc agaagaacag acaaggacac tgaaataacc tgctctgagc gagtgagaac 600 ctactggatc atcattgaac taaaacacaa agcaagagaa aaaccttatg atagtaaaag 660 tttgcggact gcacttcaga aggagatcac aacgcgttat caactggatc caaaatttat 720 cacgagtatt ttgtatgaga ataatgtat cactattgat ctggttcaaa attcttctca 780
  cacgagtatt ttgtatgaga ataatgttat cactattgat ctggttcaaa attcttctca 780 aaaaactcag aatgatgtgg acatagctga tgtggcttat tattttgaaa aagatgttaa 840 aggtgaatcc ttgtttcatt ctaagaaaat ggacctgaca gtaaatgggg aacaactgga 900 tctggatcct ggtcaaactt taatttatta tgttgatgaa aaagcacctg aattctcaat 960 gcagggtcta aaagctggtg ttattgctgt tattgggtt gtggtgatag cagttgttgc 1020 tggaattgtt gtgctggta tttccagaaa gaagagaatg gcaaagtatg agaaggctga 1080 gataaaggag atgggtgaga tgcataggga actcaatgca taactatata atttgaagat 1140 tatagaagaa gggaaatagc aaatggacac aaattacaaa tgtggtgcg tgggacgaag 1200 acatcttga aggtcatgag ttgaaactgg cttgaaactgg cttgaaactggaaactggaaactggaaactggaaactggaaactggaaactgaaactggaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaa
    gtactcaaaa tataagcagc ttgaaactgg ctttaccaat cttgaaattt gaccacaagt 1320 gtcttatata tgcagatcta atgtaaaatc cagaacttgg actccatcgt taaaattatt 1380 tatgtgtaac attcaaatgt gtgcattaaa tatgcttcca cagtaaaatc tgaaaaactg 1440 atttgtgatt gaaagctgcc tttctattta cttgagtctt gtacatacat actttttat 1500
     gagctatgaa ataaaacatt ttaaactg
     <210> 302
     <211> 1856
     <212> DNA
      <213> Homo sapiens
    ctgacttggc aggactgtgc aattgtcaga aggccgtggg gagtggggggc cagtgcctgc 60 agcctgcct gcctctca caggccctta gagcatcgcc aggtgcagag ctccacagct 120 ctcttccca aggagtaatc agagggtgag aacgtggagc ctggtggaca ggtgaaagca 180
    ctgggatctt tctgcccaga aaggggaaag ttgcacattt atatcctaga gggaagcgac 240 agcagtgctt ctccctgtgc tgaggtacag gagccatgtg gctagaaatc ctcctcactt 300 cagtgctggg ctttgccatc tactggttca tctcccggga caaagaggaa actttgccac 360 ttgaagatgg gtggtggggg ccaggcacga ggtccgcagc cagggaggac gacagcatcc 420
     gccctttcaa ggtggaaacg tcagatgagg agatccacga cttacaccag aggatcgata 480 agttccgttt cacccacct ttggaggaca gctgcttcaa ctatggcttc aactccaact 540 acctgaagaa agtcatctcc tactggcgga atgaatttga ctggaagaag caggtggaga 600
      ttctcaacag ataccetcae ttcaagacta agattgaagg getggacate cacttcatee 660
      acgtgaagcc ccccagctg cccgcaggcc ataccccgaa gcccttgctg atggtgcacg 720
                                                                                                                                                             Page 50
```

```
39740-0001PCT.txt
accccaact ccgtgtggta agcaacatgg ctttgatgat aaacgacttt actcta
<210> 303
<211> 6450
<212> DNA
<213> Homo sapiens
```

39740-0001PCT.txt ctgataagca ctttttaaat ggctctaaga ataagccaca gcaaagaatt taaagtggct 2580 cctttaattg gtgacttgga gaaagctagg tcaagggttt attatagcac cctcttgtat tcctatggca atgcatcctt ttatgaaagt ggtacacctt aaagctttta tatgactgta gcagagtatc tggtgattgt caattcactt ccccctatag gaatacaagg ggcacacagg ggaaggcaga tcccctagtt ggccaagact tatttaact tgatacactg cagattcaga 2640 2700 2760 cagtcattta tgcctaaagc ctggtgatta ttcatttaaa tgaagatcac atttcatatc 4320 aacttttgta tccacagtag acaaaatagc actaatccag atgcctattg ttggatattg 4380 aatgacagac aatcttatgt agcaaagatt atgcctgaaa aggaaaatta ttcagggcag 4440 ctaattttgc ttttaccaaa atatcagtag taatatttt ggacagtagc taatgggtca 4500 gtgggttctt tttaatgttt atacttagat tttcttttaa aaaaattaaa ataaaacaaa 4560 aaaaatttct aggactagac gatgtaatac cagctaaagc caaacaatta tacagtggaa ggttttacat tattcatcca atgtgtttct attcatgtta agatactact acatttgaag 4680 tgggcagaga acatcagatg attgaaatgt tcgcccaggg gtctccagca actttggaaa 4740 tctctttgta ttttacttg aagtgccact aatggacagc agatattttc tggctgatgt 4800 tggtattggg tgtaggaaca tgatttaaaa aaaaaactct tgcctctgct ttcccccact 4860 ctgaggcaag ttaaaatgta aaagatgtga tttatctggg gggctcaggt atggtgggga 4920 agtggattca ggaatctggg gaatggcaaa tatattaaga agagtattga aagtatttgg 4980 aggaaaatgg ttaattctgg gtgtgcacca aggttcagta gagtccactt ctgccctgga gaccacaaat caactagctc catttacagc catttctaaa atggcagctt cagttctaga gaagaaagaa caacatcagc agtaaagtcc atggaatagc tagtggtctg tgtttcttt 5040 5100 5160 čącčattące tagettąceg taatgattet ataatgecat catgeageaa ttatgagagg 5460 ttagagtact ccttccctg catgacactg attacaaata ctttcctatt catactttcc 5520 aattatgaga tggactgtgg gtactgggag tgatcactaa caccatagta atgtctaata 5580 ttcacaggca gatctgcttg gggaagctag ttatgtgaaa ggcaactaaa gtcatacagt 5640 agctcaaaag gcaaccataa ttctctttgg tgcaagtctt gggaggcgtga tctagattac 5700 actgcaccat tcccaagtta atcccctgaa aacttactct caactggagc aaatgaactt 5760 tggtcccaaa tatccatctt ttcagtagcg ttaattatgc tctgttcca aactgcattc 5820 ctttccaatt gaattaaagt gtggcctcgt ttttagtcat ttaaaattgt tttctaagta 5880 attgctgct ctattatggc acttcaattt tgcactgtct tttcagattc 220222221 5040 attgctgcct ctattatggc acticaatit tgcacigtct tttgagatic aagaaaaatt tctattcatt tttttgcatc caattgtgcc tgaacttta aaatatgtaa atgctgccat 6000 gttccaaacc catcgtcagt gtgtgttt agagctgtgc accctagaaa caacatactt 6060 gtcccatgag caggtgcctg agacacagac ccctttgcat tcacagagag gtcattggtt 6120 atagagactt gaattaataa gtgacattat gccagtttct gttctctac aggtgataaa 6180 caatgcttt tgtgcactac atactcttca gtgtagagct cttgtttat gggaaaaggc 6240 tcaaatgcca aattgtgtt gatggattaa tatgccctt tgccgatgca tactattact 6300 gatgtgactc ggtttgtcg cagctttgct ttgtttaatg aaacacactt gtaaacctct 6360 ctatttgaactt gaaaaagaat caagcgggat gcctgagcac ctgtaaacaa ttttctcaac 6420 ctatttgaact ttcaaataaa gaattaaact 6450 ctatttgatg ttcaaataaa gaattaaact

Page 52

```
<210> 304
<211> 3336
<212> DNA
<213> Homo sapiens
 <220>
 <221> unsure
 <222> (0)...(0)
<223> n = A, T, C or G
cgcagcatca agcaagagat ggaggaaaag gagaattgtc acctggagca gcgacaggtt 720 aaggttgagg agccttcgag accatcagcg tcctggcaga actctgtgtc tgagcggcca 780
 tttaagacac ccattaagga aacgctgccc atctcctcca ccccgagcaa atctgtcctc 1920
   cccagaaccc ctgaatcctg gaggctcacg ccccagcca aagtaggggg actggattc 1980 agcccagtac aaacctccca gggtgcctct gaccccttgc ctgaccccct ggggctgatg 2040 gatctcagca ccactcctt gcaaagtgct ccccccttg aatcaccgca aaggctcctc 2100 agttcagaac ccttagacct catctccgtc ccctttggca actcttctcc ctcagatata 2160 agcctcccca aaggctccca caaggctccca aaggctccca aaggctccca aaggctccca aaggctccca aaggctccca aaggctccca aaggctcccca aaggctcccc cccagatata 2160 agcctcccca aaggctccca aaggctccca aaggctccca aaggctcccc cccagatata 2220
   agttcagaac ccttagacct catctccgtc ccctttggca actcttctc ctcagatata 2160 gacgtccca agccaggctc cccggagcca caggtttctg gccttgcagc caatcgttct 2220 ctgacagaag gcctggtcct ggacacaatg aatgacagcc tcagcaagat cctgctggac 2280 attattcctg agctacagta gagccctgcc cttgccctg tgctcaagct gtcaccaa ctgggccctg acaacatcaa ctggtcccag 2340 ttattcctg agctacagta tgcacccaa gcctctgagt gaggacagca ggcagggact 2460 gtctgctcc tcatagctcc ctgctgcctg attatgcaaa agtagcagtc acaccctagc 2520 cactgctggg accttgtgt ccccaagagt atctgattcc tctgctgcc ctgcaggag 2580 ctgaagggtg ggaacaacaa aggcaatggt gaaaagagat taggaacccc ccagcctgtt 2640 tagtataaat tctccaaatt atcctctaat tataaatgta agcttattc cttagatca 2700 tagtataaa ctgccagaag gtgggtagga gtgggtagga ttgacctgggg tttcaattga cttctgttcc 2820
     tatccagaga ctgccagaag gtgggtagga tgacctgggg tttcaattga cttctgttcc 2820 ttgctttag ttttgataga agggaagacc tgcagtgcac ggttcttcc aggctgaggt 2880 acctggatct tgggtcttc actgcaggga cccagacaag tggatctgct tgccagagtc 2940
     ctttťtgccc ctčcctgcca cctčccčgtg tttcčaagtč agčtttcčtg caagaagaaa
     tcctggttaa aaaagtcttt tgtattgggt caggagttga atttggggtg ggaggatgga
tgcaactgaa gcagagtgtg ggtgcccaga tgtgcgctat tagatgtttc tctgataatg
     tccccaatca taccagggag actggcattg acgagaactc aggtggaggc ttgagaaggc cgaaagggcc cctgacctgc ctggcttcct tagcttgccc ctcagctttg caaagagcca ccctaggccc cagctgaccg catgggtgtg agccagcttg agaacactaa ctactcaata
                                                                                                                                                                                               3180
                                                                                                                                                                                                3240
                                                                                                                                                                                               3300
                                                                                                                                                                                                3336
      aaagcgaagg tggaccnaaa aaaaaaaaa aaaaaa
                                                                                                              Page 53
```

```
<210> 305
                     2365
 <211>
  <212> DNA
  <213> Homo sapiens
<400> 305
 tcccagcctt cccatccccc caccgaaagc aaatcattca acgacccccg accctccgac 60
  gccactttgc aaaggagctc actgtggtgt ctgtgttca accactgaat ctggaccca 1680 tctgtgaata agccattctg actcatatcc cctattaac agggtctcta gtgctgtgaa 1740 aaaaaaaaat cctgaacatt gcatataact tatattgtaa gaaatactgt acaatggggg 1860 aaataggtg gaaattaaga agaaactagg tctgatattc aaatggacaa actgccagtt 1920 ttgttcctt tcactggcca cagttgttg atgcattaaa agaaaataaa aaaaagaaaa 1980 aagagaaaag aaaaaaaaag aaaaaagttg taggcgaatc atttgtcaa agctgttggc 2040 cctctgcaaa agagcctttt tctaggcca catcagtgta ccgttcacca gttgccattg 2100 agggttcag tataattcaa agcaccaaaa taagaaaaga tgtagatta tttcatcata 2220 ttgttgtt gaacaagtc ctgttgtt tataattca agcaccaaaa taagaaaaga ctgcttaagaa ctgcttctt 2280 tcgttgtt
     <210> 306
     <211> 1117
     <212> DNA
      <213> Homo sapiens
     <400> 306
     gcaccaacca gcaccatgcc catgatactg gggtactggg acatccgcgg gctggcccac 60 gccatccgcc tgctcctgga atacacagac tcaagctatg aggaaaagaa gtacacgatg 120 ggggacgctc ctgatatga cagaagcag tggctgaatg aaaaattcaa gctgggcctg 180
     găctttccca atctgcccta cttgattgat ggggctcacă agatcaccca gagcăăcgcc
    gactttccca atctgcccta cttgattgat ggggctcaca agatcaccca gagcaacgcc 240 atcttgtgct acattgccg caagcacaac ctgtgtgggg agacagaaga ggagaagatt 300 cgtgtggaca ttttggagaa ccagaccatg gacaaccata tgcagctggg catgatctgc 360 tacaatccag aatttgagaa actgaagcca aagtacttgg aggaactccc tgaaaagcta 420 aggcttact cagagtttct ggggaagcgg ccatggttg caggaaacaa gatcacttt 480 gtagatttc tcgtctatga tgtccttgac ctccaccgta tatttgagcc caactgctg 540 ggcctacatga aggcccttcac agacctgtg tcccagctgg tgaagatctct 600 gcctacatga aggccctga aggccttga aggccttgga ggcccatac tcagcctg ttccaaagat ggccttgga ggcccatac tcagcctgct 720 gccaggctg tgcagcgag tgggagtgag gagcccatac tcagcctgct 720 ctcctctattat tcccatctt actccaaga cttcattgc cctcttcact ccccctaaac 840 page 54
                                                                                                                                                                                                                                       240
                                                                                                                                    Page 54
```

```
ccctgtccca tgcaggccct ttgaagcctc agctacccac tatccttcgt gaacatcccc 900 tcccatcatt acccttccct gcactaaagc cagcctgacc ttccttcctg ttagtggttg 960 tgtctgcttt aaagcctgcc tggcccctcg cctgtggagc tcagccccga gctgtccccg 1020 tgttgcatga aggagcagca ttgactggtt tacaggccct gctcctgcag catggtccct 1080 gcctaggcct acctgatgga agtaaagcct caaccac
                                                  39740-0001PCT.txt
<211> 1266
<212> DNA
 <213> Homo sapiens
attgat
  <210> 308
<211> 2162
<212> DNA
   <213> Homo sapiens
   gggctgcgct gtccagctgt ggctatggcc ccagccccga gatgaggagg gagagaacta 60 ggggcccgca ggcctgggaa tttccgtccc ccaccaagtc cggatgctca ctccaaagtc 120
```

```
39740-0001PCT.txt
atcctgagtg gtctggcggt tttttcttct aactgacttc tgctttcac ggcgtgtgct 1680 gggcccggat ctccaggccc tggggaggga gcctctggac ggacagtggg gacattgtgg 1740 gtttggggct cagagtcgag ggacggggtg tagcctcggc atttgcttga gtttctcac 1800 tcttggctct gactgatcc tgcttgtgca ggccagtgga ggctcttggg cttgggagaac 1860 acgtgtgtct ctgtgtatgt gtctgtgtg ctgcgtccgt gtctgtcaga ctgttctgcct 1920 gtcctggggt ggctaggag tgggtctgac cgttgtatgg tttgacctga tatactccat 1980 tctcccctgc gcctcctcct ctgtgtttt tccatgtccc cctcccaact ccccatgcc 2040 agttttacc catcatgcac cctgtacagt tgccacgtta ctgccttttt taaaaatata 2100 attgacagaa accaggtgcc ttcagaggct ctctgatta aataaacctt tcttgtttt 2160 tt
   <210> 309
                            3933
   <211>
   <212> DNA
   <213> Homo sapiens
<400> 309
    gaacctgatg ctttaacttt gctggcccca gccgctggag acacaatcat atctttagat 1500 tttggcagca acgacacaga aactgatgac cagcaacttg aggaagtacc attatataat 1560 gatgtaatgc ccccccac caacgaaaaa ttacagaata taaatttggc aatgtctcca 1620
    ttacccaccg ctgaaacgcc aaagccactt cgaagtagtg ctgaccctgc actcaatcaa 1680 gaagttgcat taaaattaga accaaatcca gagtcactgg aacttcttt taccatgccc 1740 cagattcagg atcagacacc tagtccttcc gatggaagca ctagacaaag ttcacctgag 1800 cctaatagtc ctgaagtgaata tttttat gtggatagtg atatggtcaa tgaattcaag 1860
     ttggaattgg tagaaaact ttttgctgaa gacacagaag caaagaaccc attttctact 1920 caggacacag atttagactt ggagatgtta gctccctata tcccaatgga tgatgacttc 1980 cagttacgtt ccttcgatca gttgtcacca ttagaaagca gttcccaaagca ccctgaaagc 2040 gcaagtcccc aaagcacagt tacagtattc cagcagactc aaagcacaga acctactgct 2100
    gcaagtcctc aaagcacagt tacagtattc cagcagactc aaatacaaga acctactgct 2100 aatgccacca ctaccactgc caccactgat gaattaaaaa cagtgacaaa agaaccgtatg 2160 gaagacatta aaatattgat tgcatctcca tctcctaccc acatacataa agaaactact 2220 agtgccacat catcaccata tagagatact caaagtcgga cagcctcacc aaacagagca 2280 ggaaaaggag tcatagaaca gacagaaaaa tctcatccaa gaagccctaa cgtgttatct 2340 gtcgctttga gtcaaagaac tacagttcct gaggaagaac taaatccaaa gatactactaca ggattggaa cattattaca gcagccagac gatcatgcag gtcactttt tagagaata aactagtgaa aaggatgaa acttagtgaa cagaatggaa tggagcaaaa gcagccagac cagaatggaa tggagcaaaa gacaattatt 2580 caccaggtga aagaatact cagagcttg gatcaagta actgagcag cagaaaccta 2700 ctgcagggtg aagaatact cagagcttg gatcaagta actgagctt ttcttaattt 2760 cattctttt tttggacact ggtggctcac taccaaacct ggttagttca atttttgatc 2880
      atctaattt agaagcctgg ctacaatact gcacaaactt ggttagttca atttttgatc 2880 ccctttctac ttaatttaca ttaatgctct tttttagtat gttctttaat gctggatcac 2940 agacagctca ttttctcagt tttttggtat ttaaaccatt gcattgcagt agcatcattt 3000 taaaaaaatgc accttttat ttatttattt ttggctagg agtttatccc tttttcgaat 3060
                                                                                                                                                                          Page 56
```

```
tattttaag aagatgccaa tataatttt gtaagaaggc agtaaccttt catcatgatc 3120 ataggcagtt gaaaaatttt tacacctttt ttttcacatt ttacataaat aataatgctt 3180 tgccagcagt acgtggtagc cacaattgca caatatatt tcttaaaaaa taccagcagt 3240 tactcatgga atatatctg cgtttataaa actagtttt aagaagaaat tttttttggc 3300 ctatgaaatt ggtaaacctg gaacatgaca ttgttaatca tataataatg attcttaaat 3360 gctattactagaa ggtatgtggc atttattgg ataacattct caattcagag aaatcatctg 3480 atgttctat aggcagact gtaaacaaga agaaaacaat tctgctacc ctgttggtat 3600 aaagaatattt tgagcagact gtaaacaaga aaaaaaaaat catgcattct tagcaaaatt 3660
                                                                                                               39740-0001PCT.txt
 treatgeraa tarigigida eligatatida accidadigi eligetidee eligitygida 3660 aaagatatti tgagcagact gtaaacaaga aaaaaaaaat catgcattet tagcacaaaat 3720 geetagtatg ttaattiget caaaatacaa tgittgatti tatgcactti gregetatta 3720 acateettit titeatgtag atticaataa tigagtaati tagaageat tattitagga 3780 atatatagti geetagtag aaateetigit titeetatgt acategtaca aattitieat 3840 teetitiget etitigigita ggatetaaca etaactgtat tgittigita catcaaataa 3900 acateetteta tagaaaaaaa aaa
  acatcttctg tggaaaaaaa aaaaaaaaaa aaa
   <210> 310
<211> 2872
   <212> DNA
<213> Homo sapiens
        ttacatgttg ggaggaggag ataagttata gggagctgga tttcaaacgg tggtccaaga 2520 ttcaaaaatc ctattgatag tggccatttt aatcattgcc atcgtgtgct tgttcatcc 2580 agtgttatgc actttccaca gttggtgtta gtatagccag agggtttcat tattattct 2640 ctttgcttc tcaatgttaa tttattgcat ggtttatct ttttctttac agctgaaatt 2700 gctttaaatg atggttaaa ttacaaatta aattggaat ttttatcaat gtgattataa 2760
         gctttaaatg atggttaaaa ttacaaatta aattgggaat ttttatcaat gtgattgtaa 2760
                                                                                                                                       Page 57
```

WO 03/078662 PCT/US03/07713

```
39740-0001PCT.txt
ttaaaaatat tttgatttaa ataacaaaaa taataccaga ttttaagccg cggaaaatgt 2820
tcttgatcat ttgcagttaa ggactttaaa taaatcaaat gttaacaaaa aa
 <210> 311
 <211> 926
 <212> DNA
 <213> Homo sapiens
 <400> 311
ggggcccatt ctgtttcagc cagtcgccaa gaatcatgaa agtcgccagt ggcagcaccg 60 ccaccgccgc cgcgggcccc agctgcgcg tgaaggccgg caagacagcg agcggtgcgg 120 gcgaggtggt gcgctgtctg tctgagcaga gcgtggccat ctcgcgctgc cggggcgccg 180 gggcgcgcct gcctgccctg ctggacgagc agcaggtaaa cgtgctgctc tacgacatga 240 acggctgtta ctcacgcctc aaggaggctgg tgccaccct gccccagaac cgcaaggtga 300
926
 aataatttag atggtgaaaa aaaaaa
 <210> 312
 <211> 4989
 <212> DNA
 <213> Homo sapiens
 <400> 312
 tttttttttt ttttgagaaa gggaatttca tcccaaataa aaggaatgaa gtctggctcc 60
 ggaggagggt ccccgacctc gctgtggggg ctcctgtttc tctccgccgc gctctcgctc 120
 tggccgacga gtggagaaat ctgcgggcca ggcatcgaca tccgcaacga ctatcagcag 180 ctgaagcgcc tggagaactg cacggtgatc gagggctacc tccacatcct gctcatctcc 240 aaggccgagg actaccgcag ctaccgcttc cccaagctca cggtcattac cgagtacttg 300
ctgctgttcc gagtggctgg cttcgagagc ctcggagacc tcttcccaa cctcacggtc 360 atccgcggct ggaaactctt ctacaactac gcctggtca tcttcgagat gaccaatctc 420 aaggatattg ggctttacaa cctgaggaac attactcggg gggccatcag gattgagaaa 480 aatgctgacc tctgttacct ctccactgtg gactggtcc tgatcctgga tgcggtgtcc 540 aataactaca ttgtggggaa taagccccca aaggaatgtg gggacctgtg tccagggacc 600 atggaggaga agccgatgtg tgagaagacc accatcaaca atgagtacaa ctaccgctgc 660 tggaccacaa accgctgcca gaaaatgtgc ccaagcacgt gtgggaagcg ggcgtgcacc 720 gagaacaatg agtgctgcca ccccgagtgc ctgggcagct gcagcgcgcc tgacaacgac 780 accgctgtg tagcttgccg ccactactac tatgccggt tcctggcca 840
gagaacaatg agtgctgcca ccccgagtgc ctgggcagct gcagcgcgcc tgacaacgac 780 acggcctgtg tagcttgccg ccactactac tatgccggtg tctgtgtgcc tgcctgcccg 840 cccaacacct acaggtttga gggctggcgc tgtgtggacc gtgacttctg cgccaacatc 900 ctcagcgccg agagcagcga ctccgagggg tttgtgatcc acgacggcga gtgcatgcag 960 gagtgccct cgggcttcat ccgcaacggc agccagagca tgtactgcat cccttgtgaa 1020 ggtccttgcc cgaaggtctg tgaggaagaa aagaaaacaa agaccattga tcctgttact 1080 tctgctcaga tgctccaagg atgcaccatc ttcaagggca atttgctcat taacatccga 1140 cggggggaata acattgctc agagctggag aacttcatgg ggctcatcga ggtggtgaccg 1200 ggctacgtga agatccgcca ttctcatgcc tggctcctt tgtccttcct acaaaacctt 1260 cgcctcatcc taggagagga gcagctagaa gggaattact ccttctacgt cctcgacac 1320
 cgcctcatcc taggagagga gcagctagaa gggaattact ccttctacgt cctcgacaac 1320 cagaacttgc agcaactgtg ggactgggac caccgcaacc tgaccatcaa agcagggaaa 1380 atgtactttg ctttcaatcc caaattatgt gtttccgaaa tttaccgcat ggaggaagtg 1440
 acggggacta aagggcgcca aagcaaaggg gacataaaca ccaggaacaa cgggggagaga 1500 gcctcctgtg aaagtgacgt cctgcatttc acctccacca ccacgtcgaa gaatcgcatc 1560 atcataacct ggcaccggta ccggcccct gactacaggg atctcatcag cttcaccgtt 1620 tactacaagg aagcaccctt taagaatgtc acagagtatg atgggcagga tgcctgcggc 1680
 tccaacagct ggaacatggt ggacgtggac ctcccgcca acaaggacgt ggagcccggc 1740 atcttactac atgggctgaa gccctggact cagtacgccg tttacgtcaa ggctgtgacc 1800 ctcaccatgg tggagaacga ccatatccgt ggggccaaga gtgagatctt gtacattcgc 1860 accaatgctt cagttccttc cattcccttg gacgttcttt cagcatcgaa ctcctcttct 1920 cagttaatcg tgaagtggaa ccctccctct ctgcccaacg gcaacctgaa ttactacatt 1980 gtgcgctggc agcggcagcc tcaggacggc tacctttacc ggcacaatta ctgctccaaa 2040 gacaaaaatcc ccatcaggaa gtatgccgaa gacaccatcg acattgagga ggtcacaagag 2100
  aaccccaaga ctgaggīgtg īggtīgggāg aaagggcctī gctgcgccīg ccccaaaācī 2160
                                                                                                                       Page 58
```

```
39740-0001PCT.txt
gaagccgaga agcaggccga gaaggaggag gctgaatacc gcaaagtctt tgagaatttc 2220 ctgcacaact ccatctcgt gccaagacct gaaaggaagc ggagagatgt catgcaagtg 2280 gccaacacca ccatgtccag ccgaagcagg aacaccacgg ccgcagacac ctacaacatc 2340 accgaccgg aagagctgga gacagagtac ccttctttg agagcagagt ggataacaac 2460 tgcaaccacg aggctgagaa gctggctgc agcgcctcca acttcgtctt tgcaaggact 2520 atgcccgcag aaggagcaga tgacattcct gggccagtga cctgggagcc aaggcctgaa 2580 aactccatct ttttaaagtg gccggaacct gagaatccca atggattgat tctaatgtat 2640 gaaataaaat acggatcaca agttgaggat cagcgaaaca 2700
ggaaaaataa ttgccacaag tccagctggg aagccctttt tatcagtttg aggaagtggc 4560 tgtccctgtg gccccatcca accactgtac acacccgcct gacaccgtgg gtcattacaa 4620 aaaaacacgt ggagatggaa attttacct ttatctttca cctttctagg gacatgaaat 4680 ttacaaaggg ccatcgttca tccaaggctg ttaccattt aacgctgcct aattttgcca 4740 aaatcctgaa ctttctcct catcggccg gcgctgattc ctcgtgtccg gaggcatggg 4800 tgagcatggc agctggttgc tccatttgag agacacgctg gcgacacact ccgtccatcc 4860 gactgccct gcgtgctgc tcaaggccac aggcacacag gtctcattgc ttctgactag 4920 attattatt ggggggaactg gacacaatag gtctttctct cagtgaaggt ggggagaagc 4980 ataatcatt
                                                                                                                                                                                                                          4989
     tgaaccggc
     <210> 313
     <211> 12515
     <212> DNA
     <213> Homo sapiens
     <400> 313
    ctaccgggcg gaggtgagcg cggcgccggc tcctcctgcg gcggactttg ggtgcgactt 60 gacgagcggt ggttcgacaa gtggccttgc gggccggatc gtcccagtgg aagagttgta 120 aatttgcttc tggccttccc ctacggatta tacctggcct tcccctacgg attatactca 180
    acttactgtt tagaaaatgt ggcccacgag acgcctggtt actatcaaaa ggagcggggt 240 cgacggtcc cactttccc tgagcctcag cacctgcttg tttggaaggg gtattgaatg 300 tgacatccgt atcagcttc ctgttgtgtc aaaacaacat tgcaaaattg aaatccatga 360
                                                                                                                                                                                                                          300
     gčaggaggča atattacata atitcagitc cacaaatcca acacaagtaa atgggtctgt 420
     tattgatgag cctgtacggc taaaacatgg agatgtaata actattattg atcgttcctt 480 caggtatgaa aatgaaagtc ttcagaatgg aaggaagtca actgaatttc caagaaaaat 540 acgtgaacag gagccagcac gtcgtgtctc aagatctagc ttctcttctg accctgatga 600
     gaaagctcaa gattccaagg cctattcaaa aatcactgaa ggaaaagttt caggaaatcc 660 tcaggtacat atcaagaatg tcaaagaaga cagtaccgca gatgactcaa aagacagtgt 720 tgctcaggga acaactaatg ttcattcctc agaacatgct ggacgtaatg gcagaaatgc 780
                                                                                                                             Page 59
```

39740-0001PCT.txt agctgatccc atttctgggg attttaaaga aatttccagc gttaaattag tgagccgtta 840 tggagaattg aagtctgttc ccactacaca atgtcttgac aatagcaaaa aaaatgaatc 900 tcccttttgg aagctttatg agtcagtgaa gaaagagttg gatgtaaaat cacaaaaaga 960 aaatgtccta cagtattgta gaaaatctgg attacaaact gattacgcaa cagagaaaga 1020 aagtőctgat ggittacagg gggagaccca actgttggtc icgcgtaagt caagaccaaa 1080 aagtgctgat ggtttacagg gggagaccca actgttggtc tcgcgtaagt caagaccaaa 1080 atctggtggg agcggccacg ctgtggcaga gcctgcttca cctgaacaag agcttgacca 1140 gaacaagggg aagggaagag acgtggagtc tgttcagact cccagcaagg ctgtgggcgc 1200 cagctttcct ctctatgagc cggctaaaat gaagacccct gtacaatatt cacagcaaca 1260 aaattctcca caaaaacata agaacaaaga cctgtatact actggtagaa gagaatctgt 1320 gaatctgggt aaaagtgaag gcttcaaggc tggtgataaa actcttactc ccaggaagct 1380 tcaactaga aatcgaacac cagctaaagt tgaagatgca gctgactctg ccactaagcc 1440 ggaaactgaa attcacaatg agccatttt aactctgtgg ctcactcaag ttgagaggaa 1560 gatccaaaag gattccctca gcaagcctga gaaattggg actacagctg gacagatgtg 1620 gatccaaaag gattcctta gcaagcctga gaaattgggc actacagctg gacagatgtg 1620 ctctgggtta cctggtctta gttcagttga tatcaacaac tttggtgatt ccattaatga 1680 gagtgaggga atacctttga aaagaaggcg tgtgtccttt ggtgggcacc taagacctga 1740 actattgat gaaaacttgc ctcctaatac gcctctcaaa aggggaggaag ccccaaccaa 1800 aagaaaggtct ctggtaatgc acactccacc tgtcctgaag aaaatcatca aggaacagcc 1860 tcaaccatca ggaaaacaag agtcaggttc agaaatccat gtggaagtga aggcacaaag 1920 cttggttata agccttccag ctctagtcc taggaaaact ccagttgcca gtgatcaacg 1980 ccgtaggtcc tgcaaaacag ccctgcttc cagcagcaaa tctcagacag aggttcctaa 2040 gagaggagga gaaagagtgg caacctgcct tcaaaagaga gtgtctatca gccgaagtca 2100 acatgatatt ttacagatga tatgttccaa aagaagaagt ggtgcttcgg aagcaaatct 2160 gattgttgca aaatcatggg cagatgtagt aaaacttggt gcaaaacaaa cacaaactaa 2220 agtcataaaa catggcctc aaaggtcaat gaacaaaagg caaagaagac ctgctactcc 2280 aaagaagcct gtgggcgaag ttcacagtca atttagtaca ggccacgcaa actctccttg 2340 taccataata atagggaaag ctcatactga aaaagtacat gtgcctgctc gaccctacag 2400 agtgctcaac aacttcattt ccaaccaaaa aatggacttt aaggaagatc tttcaggaat 2460 agctgaatg ttcaagaccc cagtgaagga gcaaccgcag ttgacaagca catgtcacat 2520 cgctatttca aattcagaga atttgcttgg aaaacagttt caaggaactg attcaggaga 2580 agaacctctg ctcccacct cagagagttt tggaggaaat gtgttcttca gtgcacagaa 2640 tgcagcaaaa cagccatctg ataaatgctc tgcaagccct cccttaagac ggcagtgtat 2700 tagaggaaaat ggaaacgtag caaaaacgcc caggaacacc tacaaaatga cttctctgga 2760 gacaaaaact tcagatactg agacagagcc ttcaaaaaaca gtatccactg taaacaggtc 2820 aggaaggtct acagagttca ggaatataca gaagctacct gtggaaagta agagtgaaga 2880 aacaaaacaa gaagtgaaga tgaaggaag tgaaggaag taaaaaaagaggct cagaaggaaa cactactaca 2940 acaaaggaga gaaggagaga tgaaggaaat agaaagacct tttgagacat ataaggaaaa 3000 tattgaatta aaagaaaacg atgaaaagat gaaagcaatg aagagatcaa gaacttgggg 3060 gcagaaatgt gcaccaatgt ctgacctgac agacctcaag agcttgcctg atacagaact 3120 catgaaagac acggcacgtg gccagaatct cctccaaacc caagatcatg ccaaggcacc 3180 aaagagtgag aaaggcaaaa tcactaaaat gccctgccag tcattacaac cagaaccaat aaacacccca acacacacaa aacaacagtt gaaggcatcc ctggggaaag taggtgtgaa agaagagctc ctagcagtcg gcaagttcac acggacgtca ggggagacca cgcacacgca cagaagcca gcaggagatg gcaagagcat cagaacgttt aaggagtctc caaagcagat 3300 3420 cctggaccca gcagcccgtg taactggaat gaagaagtgg ccaagaacgc ctaaggaaga ggcccagtca ctagaagacc tggctggctt caaagagctc ttccagacac caggtccctc tgaggaatca atgactgatg agaaaactac caaaatagcc tgcaaatctc caccaccaga atcagtggac actccaacaa gaacaacaa atgaccaga ataagcaga acacacaga gaacacaca 3480 3600 tgtagaggaa gaattettag cacteaggaa actaacacca teageaggga äägeeätget tacgcccaaa ccagcaggag gtgatgagaa agacattaaa gcatttatgg gaactccagt gcagaaactg gacctggcag gaactttacc tggcagcaaa agacagctac agactcctaa ggaāaaggcc caggctctag aagacctggc tggctttaaa gagctcttcc agactcctgg 3900 tcacaccgag gaattagtgg ctgctggtaa aaccactaaa ataccctgcg actctcaca 3960 gtcagaccca gtggacaccc caacaagcac aaagcaacga cccaagagaa gtatcaggaa 4020 agcagatgta gagggagaac tcttagcgtg caggaatcta atgccatcag caggcaaagc 4080 catgcacacg cctaaaccat cagtaggtga agagaaagac atcatcatat ttgtgggaac 4140 tccagtgcag aaactggacc tgctagagaa cttaaccag agcaagagaa 4260 tcctaaggaa gaggcccagg ctctggaaga cctgactggc tttaaagagc tcttccagac 4260 ccctggtcat actgaagaag cagtggctgc tggcaaaact actaaaatgc cctgcgaatc 4320 ttctccacca gaatcagcag acaccccaac aagcacaaga aggcagccca agacaccttt 4380 ggagaaacag gacgtacaga aggagctctc agccctgaag aagctcacac agacatcagg 4440 ggaaaccaca cacacagata aagtaccagg aggtgaggat aaaagcatca acgcgtttag 4500 ggaaactgca aaacagaaac tggacccagc agcaagtgta actggtagca agaggcaccc 4560 aaaaactaag gaaaaggccc aacccctaga agacctggct ggctggaaag agctcttcca 4620 gacaccagta tgcactgaca agcccacgac tcacgagaaa actaccaaaa tagcctgcag 4680 atcacaacca gacccagtgg acacaccaac aagctccaag ccacagtcca agagaagtct 4740 caggaaagtg gacgtagaag aagaattctt cgcactcagg aaacgaacac catcagcagg 4800 caaagccatg cacacaccca aaccagcagt aagtggtgag aaaaacatct acgcatttat 4860 Page 60

```
39740-0001PCT.txt
 gggaactcca gtgcagaaac tggacctgac agagaactta actggcagca agagacggct 4920
 gggaactica gtycayaaac tyyactiyat ayayaactia actyycayca agayacygct 4920 acaaactcct aaggaaaagg cccaggctct agaagacctg gctggcttta aagagctctt 4980 ccagacacga ggtcacactg aggaatcaat gactaacgat aaaactgcca aagtagcctg 5040 caaatcttca caaccagacc tagacaaaaa cccagcaagc tccaagcgac ggctcaagac 5100 atccctgggg aaagtgggcg tgaaagaaga gctcctagca gttggcaagc tcacacagac 5160 atccctgggg aaagtgggcg caaagaaga gctcctagca gattggcaagc tcacacagac 5220
ayayıcılla yeayıcaayı teacacaac areayyyyaa accacygaty cayacaaya 6400 accagcaggt gaagataaag gcatcaaagc attgaaggaa tctgcaaaac agacaccggc 8520 tccagcagca agtgtaactg gcagcaggag acggccaaga gcacccaggg aaagtgccca 8580 agccatagaa gacctagctg gcttcaaaga cccagcagca ggtcacactg aagaatcaat 8640 gactgatgac aaaaccacta aaataccctg caaatcatca ccagaactag aagacaccgc 8700
        aacaagctca aagagacggc ccaggacacg tgcccagaaa gtagaagtga aggaggagct 8760 gttagcagtt ggcaagctca cacaaacctc aggggagacc acgcacaccg acaaagagcc 8820 ggtaggtgag ggcaaaggca cgaaagcatt taagcaacct gcaaagcgga acgtggacgc 8880 ggtaggtgag ggcaaaggca cgaaagcact aaggagacct aaggagagag ccaaagcgca 8880
         agaagatgta attggcagca ggagacagcc aagagcacct aaggaaaagg cccaaccct 8940
                                                                                                             Page 61
```

	39740-0001PCT.txt								
	accaacttcc	aananctete	traaararra	ggccacactg	aggaactggc	9000			
ggaagaccty	actastsact	ttacaancoc	tccaaaacaa	acacctgaca	ntonaaaacc	9060			
aaatggtgct	getgataget	ttataaycyc	ccctaaagcaa	acaccegaca	nanacntont	9120			
tctaaaaata	tccayaayay	22±c2c222	cassagease	gaacccgtgg	ccccactocc	9180			
aagcaccaga	gaccctgtaa	aattataaay	catalageage	acttccctgc	tacactacat	9240			
cttcaagagg	ggaggtggca	aagatggaag	cyccacggga	accaagaggc	costtactes	9240			
gccagcacca	gaggaaattg	tggaggagct	gccagccagc	aagaagcaga	gggttgetee	9300			
cagggcaaga	ggcaaatcat	ccgaacccgt	ggtcatcatg	aagagaagtt	tgaggactic	9300			
tacaaaaaaa	attoaaccto	cagaagagct	gaacagcaac	gacatgaaaa	ccaacaaaga	9420			
onaararaaa	ttacaadact:	caatccctaa	aaataaqqqa	atatccctgc	gctccagacg	9460			
ccaagataag	actoaoocao	aacagcaaat	aactgaggtc	tttgtattag	cagaaagaat	9540			
anaaataaac	agaaatgaaa	agaagcccat	gaagacctcc	ccagagatgg	acattcagaa	9000			
tccanatgat	agaacccaga	aacccatacc	taqaqacaaa	gtcactgaga	acaaaayyiy	9000			
cttgaggtct	octagacaga	atgagagete	ccaqcctaaq	gtggcagagg	agagcggagg	.9/20			
thenesenses	acaaaaattc	tcatocaoaa	tcagaaaggg	aaaggagaag	caggaaattc	9/80			
agactccatg	tacctaaaat	caagaaagac	aaaaagccag	cctgcagcaa	gcactttgga	9840			
nancaaatct	otocagagag	taacocogag.	tatcaagagg	tgtgcagaaa	atccaaagaa	9900			
gactaaggac	aatotototo	tcaagaaaat	aacaaccaga	agtcataggg	acagtgaaga	9960			
tatttgacag	aaaaatcgaa	ctgggaaaaa	tataataaag	ttagttttgt	gataagttct	10020			
anthoganttt	·ttotcataaa	ttacaaqtqa	attctdtaad	taaqqctqtc	agtetgetta	TOOOO			
2000220222	actttogatt	tactagatct	gaatcogctt	cataaactcc	actoggagca	10140			
ctoctoooct	cctggactga	gaatagttga	acaccagaga	ctttgtgaag	gagtctgggc	10200			
caanntttnc	cctcancttt	ocadaatdaa	occttgaggt	ctgtcaccac	ccacaoccac	10260			
cctacancan	cettaactat	gacacttgcc	acactototo	gtcgtttgtt	tocctatott	10320			
ctcacageag	contancana	aacaactatc	ctcatctatc	ccaacactga	gcaggcactc	10380			
ontagage	aatnaatnna	taagcgcacg	gatgaatgga	gcttacaaga	tctatctttc	10440			
contactacy	ogocatttoo	tececaaatt	aaggetattg	gacatctgca	caggacagtc	10500			
ctattttta	totectttee	tttctnaaaa	taaaatttta	tgctttggag	aatgactcgt	10560			
gageacatet	ttannacca	anantnactt	tctotaaooa	gtgactcgtg	acttacctta	10620			
gaycacaccc	astacttttc	taactagggt	toctctcacc	tgagacattc	tccacccaca	10680			
gicicitygg	attactett	ntnonccate	acnaceteaa	actggctcct	aatctccagc	10740			
+++cc+c+c3	ttassactt	consantita	ctooctctac	tcccgcctgt	tttctttcta	10800			
netetateta	acaacaaa	occacccant	acannaantn	acaccagtac	tctataaaac	10860			
acticiating	ttagecegae	tagacactca	ocacettean	ccacgatttc	aggatcoctt	10920			
actactacc	coctacetee	nazateteet	ttnaanccca	gacatctttc	tccaacttca	10980			
ccttgtgage	tataactcot	tcatcttcat	ttactttcca	ctttgccccc	tatectetet	11040			
gacttytaga	22tc202022	tancconco	teccecanat	cacctgtctg	gattcctccc	11100			
gigilicica	ccttaccaga	tagecegeea	ceceeagae	cagacagggt	anctotecce	11160			
calleacted	cctatacaga	cantacceta	tetecaentt	tgtttcccca	atatctaaca	11220			
caaaacgtgc	tancatcata	antacttact	naatnaatno	agaaatcagc	gatactgact	11280			
gggagccagg	tooctoccat	aatacttgcc	tracancotr	atccatgatc	graaggaga	11340			
tytactatat	acttangaga	gatayyytte	annoncanno	aggggacatc	toaccettc	11400			
atgacatte	geregaggga	gggaatagaa	cannncanaa	caggggaggg	tattcaaaaa	11460			
acayyyctyt	ttaggggtata	cactttonaa	antatazaac	ataaatgctt	ccttctacot	11520			
agagtggctt	cascagagg	20t20022to	ttactataat	caagttgttc	taacacttta	11580			
aggccaaccc	taaaatttt	cctcacatan	22222####	tccagccata	tacctataaa	11640			
gacttagtag	chattatyaa	ccccacacag	ttagaattca	gctctaacca	naaatettae	11700			
gtggaatatt	cigillagia	tetereceta	atanatacaa	tatttcaana	ncacnetaan	11760			
tgaagtatgt	caycacciti	actattacta	gradytacay	tatttcaaga	taannoctac	11820			
ggtggtttt	attitacagg	gcigityaty	acygyctaaa	aatgttcatt	aaagggccac	11880			
ccccgtgttt	aatagatgaa	caccaccic	acacaacccc	ccttggtact	22212000	11940			
gagatctgac	. addidCTGCC	tacttcttd	gyctyactyy	atttgagaac ttccaagtga	atttccatot	12000			
ccatttccac	. catygtatgg	tadcilcict	yayılılayı	. ticcaayiya	innacctatac	12060			
aataggacat	. ccccattaaa	cataggigi	cttacactaa	tcgcctccca	accatctcct	12120			
gatctggtcc	cecageetet	teessesses	acacactccc	ctčtgtacct	cetocetoo	12180			
gcctccctta	ggcaggcacc	LCCAACCACC	acacacicc	tgctgttttc	ttaannaan	12240			
actttcccac	cagccccacc	aagaccattt	catteteet	tgagctcagc	. claayyyayy	12300			
cttcttgcct	. gtgggttccc	TCacccccat	gccigicctc	căggctgggg	cayyttilla	12360			
gtttgcctgg	aattgttctg	tacctctttg	cagcacgtag	tgttgtgaaa	l claayilali	12/20			
aattgagttt	ctggctcccc	tcctggggtt	graagttitg	ttcattcatg	ayyyetyati	12/20			
gtatttcct	gttactgtat	cccagtgacc	agccacagga	gatgtccaat	. aaaytatyt <u>i</u>	12515			
atgaaatggt	ćttaaaaaaa	aaaaaaaaaa	addad			14717			

<210> 314 <211> 2444 <212> DNA <213> Homo sapiens

```
<210> 315
<211> 732
   <212> DNA
    <213> Homo sapiens
   <400> 315
   tgctgcgaac cacgtgggtc ccgggcgcgt ttcgggtgct ggcggctgca gccggagttc 60 aaacctaagc agctggaagg aaccatggcc aactgtgagc gtaccttcat tgcgatcaaa 120
    ccagatgggg tccagcgggg tcttgtggga gagattatca agcgttttga gcagaaagga 180
ttccgccttg ttggtctgaa attcatgcaa gcttccgaag atcttctcaa ggaacactac 240
   gttgacctga aggaccgtcc attctttgcc ggcctggtga aatacatgca ctcagggccg 300 gtagttgcca tggtctggga ggggctgaat gtggtgaaga cgggccgagt catgctcggg 360 gagaccaacc ctgcagact caagcctggg accatcgtg gagacttctg catacaagtt 420 ggcaggaaca tatacatgg cagtgattct gtggagagtg cagagaagga gatcggcttg 480 ggcaggaaca tatacatgg cagtgattct gtggagagtg cagagaagga gatcggcttg 480 tatacaagga cagtgattac accataga 540
    tggtttcacc ctgaggaact ggtagattac acgagctgtg ctcaggaactg gatctatgaa 540 tgacaggagg gcagaccaca ttgctttca catccattc ccctccttcc catgggcaga 660 ggaccaggct gtaggaaatc tagttatta caggaacttc atcataattt ggagggaagc 660 tcttggaggt gtgaggttctc cctgtacagt gttaccatcc ccgaccatct gattaaaatg 720 727
    cttcctccca gc
     <210> 316
     <211> 2422
     <212> DNA
     <213> Homo sapiens
```

```
<400> 316
gtcagcctcc cttccaccgc catattgggc cactaaaaaa aggggggctcg tcttttcggg 60 gtgtttttct cccctcccc tgtccccgct tgctcacggc tctgcgactc cgacgccggc 120
aaggtttgga gagcggctgg gttcgcggga cccgcgggct tgcacccgcc cagactcgga 180
aatcacaaac ccctagaggg caagtacgag tggcaagagg tggagaaggg cagcttgccc 720 gagttctact acagacccc gcggcccccc aaaggtgcct gcaaggtgcc ggcgcaggag 780 agccaggatg tcagcgggag ccgcccggcg gcgcctttaa ttggggctcc ggctaactct 840 gaggacacgc attggtgga cccaaagact gccgtcgg acagccagac ggggttagcg 900
gaggacacgc attruggigga cccaaagact galccycly acayclayac yyyyttaycy 900 gagcaatgcg caggaataag gaagcgacct gcaaccgacg attructac tcaaaacaaa 960 agagccaaca gaacagaaga aaatgtttca gacggttcc caaatgccgg ttctgtggag 1020 cagacgcca agaagcctgg cctcagaaga cgtcaaacgt aaacagctcg aattaagaat 1080 attttaaaaa tacatacgc tgacttcatg gaatggacat cctgtataag cactgaaaaa 1200 caacaacaca ataacactaa aattttaggc actcttaaat gatctgcctc taaaagcgtt 1260 ggatgtagca ttatgcaatt aggtttttcc ttatttgctt cattgtacta cctgtgtata 1320
taggatgtagca tratgcaatt aggittitic trattiggit cattgtacta cetytydda 1520 tagttittac ettitatgta gcacataaac titggggaag ggagggcagg gtggggetga 1380 ggaactgacg tggagcgggg tatgaagagc tigcittgat tracagcaag tagataaata 1440 titgacitgc atgaagaga gcaatitigg ggaagggtit gaatigtit etitaaagat 1500 gtaatgtee titcagagac agetgatact teattaaaa aaatcacaaa aattgaaca 1560 etiggetaaag ataatigeta titatitita caagaagtit atteteatit gggagatetg 1620
 gtgatctccc aagctatcta aagtttgtta gatagctgca tgtgggctttt ttaaaaaagc 1680 aacagaaacc tatcctcact gccctcccca gtctctctta aagttggaat ttaccagtta 1740 attactcagc agaatggtga tcactccagg tagtttgggg caaaaatccg aggtgcttgg 1800 gagttttgaa tgttaagaat tgaccatctg ctttattaa atttgttgac aaaatttct 1800
 cattttttt tcacttcggg ctgtgtaaac acagtcaaaa taattttaaa tccctcgata 1920 tttttaaaga tctgtaagta acttcacatt aaaaaaatgaa atattttta atttaaagct 1980 tactctgtc atttatccac aggaaagtgt tatttttaaa ggaaggttca tgtagagaaa 2040
 agcacacttg taggataagt gaaatggata ctacatcttt aaacagtatt tcattgcctg 2100
 tgtatggaaa aaccatttga agtgtacctg tgtacataac tctgtaaaaa cactgaaaaa 2160 ttatactaac ttattatgt taaaagattt tttttaatct agacaatata caagccaaag 2220 tggcatgttt tgtgcatttg taaatgctgt gttgggtaga ataggttttc ccctcttttg 2280 ttaaataata tggctatgct taaaaggttg catactgagc caagtataat tttttgtaat 2340 gtggaaaaa gatgccaatt attgttacac attaagtaat caataaagaa aacttccata 2400 gctaaaaaa aacaagaaa aacaagaaa 23222
  gctaaaaaaa aaaaaaaaaa aa
  <210> 317
  <211> 5061
   <212> DNA
   <213> Homo sapiens
  <400> 317
  atggctcaga tatttagcaa cagcggattt aaagaatgtc cattttcaca tccggaacca 60
 acaagagcaa aagatgtgga caaagaagaa gcattacaga tggaagcaga ggctttagca 120 aaactgcaaa aggatagaca agtgactgac aatcagagag gctttgagtt gtcaagcagc 180 accagaaaaa aagcacaggt ttataacaag caggattatg atctcatggt gtttcctgaa 240 tcagattccc aaaaaagagc attagatatt gatgaaaaa agctcacca agctgaactt 300
  gagaaactat tgctggatga cagtttcgag actaaaaaaa cacctgtatt accagttact 360 cctattctga gcccttcctt ttcagcacag ctctatttta gacctactat tcagagagga 420 cagtggccac ctggattacc tgggccttcc acttatgctt taccttctat ttatccttct 480 acttacagta aacaggctgc attccaaaat gcccaagaatgcc cacttttcca 540
  tctacagaac ctatatattt aagtcttccg ggacaatctc catatttctc atatcctttg 600 acacctgcca caccctttca tccacaagga agcttaccta tctatcgtcc agtagtcagt 660 actgacatgg caaaactatt tgacaaaata gctagtacat cagaattttt aaaaaatggg 720 aaagcaagga ctgattgga ggtaacagat tcaaaagcaagga ctgattcca gcaacttcca gcaacttcca ggtactcca 780
  aagtctgagg atatcagtaa atttgactgg ttagacttgg atcctctaag taagcctaag 840 gtggataatg tggaggtatt agaccatgag gaagagaaaa atgtttcaag tttgctagca 900 aaggatcctt gggatgctgt tcttcttgaa gagagatcga cagcaaattg tcatcttgaa 960 agaaaggtga atggaaaatc cctttctgtg gcaactgtta caagaagcca gtctttaaat 1020 attcgaacaa ctcagcttgc aaaagcccag ggccatatat ctcagaaaga cccaaatggg 1080 accagtagtt tgccaactgg aagttctctt cttcaagaag ttgaagtaca gaatgaggag 1140
                                                                                                                      Page 64
```

				•		
:		39	9740-0001PC	T.txt		1200
	tttgtcgatc (	-sttacaaaa 1	toaagacca	aatttccata	taccaatcac	1200
atggcagctt.	tttgicyaic c	accacaca (	110303000	aaanaaacat	atocooagaa	1260
cocacaaacc	caggctattt ( tgaaggtctc (	ittaagicca	jicacagege	addydddacat	tacttttaco	1320
aatoctagto	tgaaggtctc (	cattgacatt 🤉	gaaggattic	agctactage		1380
aatgctuges.	gttctactgt a	agaaatcatt a	ataatgcaag	ccctttgctg	ggtacatyat	1360
tgtgatgtya	aagtagatgt	toocanctat (	attctaaaaq	tttqtqqtca	agaggaagtg	1440
gacttgaatc	aagtagatgt 1	tiggeagetat	gadcatattC	aaaactotco	aaaatgggac	1500
ctocadaata	gactacaact	eggaagicai i	yaycacaccc	atcassatct	uncccuaaca	1560
2020223113	gactacaact (	cttgaccttc	agtgcaatgt	yccaaaacci	ggcccgaaca	1620
acayaaacta	atgaaacacc	cotogattta (	aacaaacacc	tgtatcaaat	agaaaaaccc	1020
gcagaayary	ccatgacgag	ocaccetott (	naanaactct	tagattctta	tcacaaccaa	T980
tgcaaagaag	ctcttcaaat	acaccccgcc	ca c caa à cao	tagatcaagt	aattaaagct	<b>1740</b> . •
otagaactgg	tctgtagtgc	tgaaaaccaa	caccyaycay.	++accattac	agaatcagta	1800
912302222	tctatagtac '	tttagatggt 🔻	gtcgagactc	ttyccartac	agaattagta	1060
gtaagaaaaa	agagagcagt	taatottoca	aggagtaaaa	ctgctgatgt	gacticitig	1000
aagaayctaa	agagagcagt	caggagttca	actangoget.	cacttaatcc	tgaaaatcct	1920
tttggaggag	gcataaacca	Caygageeca	acaatttata	atcttctcag	actccataca	1980
ottcaaqtaa	gcataaacca	attaactgca	gcaacctarg	accetectag	ada adcatad	2040
aattetoota	gcataaacca ggagtcctac	agactgtgcc	caaagtagca	agagtyttaa	ggaagcacgg	2100
aacccggca	agcagctcca	offactatt	tttactactc	atggaatttc	aagtaattyy	2100
actacaacay	agcagctcca atgaaaaata	ctacttoata	tattcactat	ctcacaatqq	aaaggatctt	2160
gtatcaaatt	atgaaaaata ttcaatcaaa	Clacityata	26++262202	atttcttcta	tcttattaaa	2220
tttaaaccta	ttcaatcaaa	gaaggttyyc	acttacaaya	+00000000000000000000000000000000000000	atcanttett	2280
taggatgaac	taatcatttt	tcctatccag	atatcacaat	Lyccartaga	accageeeee	2340
tyggatgate	tttttggaat	tttaaatcag	agcagtggaa	gttcccctga	ttctaataay	2340
caccitacic	gaccagaagc	+++00000333	atttctttac	ctctttataa	ctttagacgg	2400
cagagaaagg	gaccayaayc	LLigggeada	ctttaaactt	catcacatac	aaattctott	2460
rttttaacat	gaccagaagc gtggaactaa ttaccaaaaa	acttctatat	CLLLygacte	tactactaca	aattaattt	2520
cctooaacao	ttaccaaaaa	aggatatgtc	atggaaagaa	Lagryciaca	ggccgacccc	2580
-ctggaacag	catttgatat	tatttataca	actcctcaag	ttgacagaag	cattatacay	2360
ccttciccig	caccegacac	2020224021	ataaaaggga	aacttcttga	tattcttcat	2640
caacataact	tagaaacact cacttggact	ayayaacyac	~~+~~~~	++++2+0003	gaaacgttat	2700
aaagactcat	cacttggact	ttctaaagaa	galadayett		3330100333	2760
tattacttca	aacacccaaa	ttatcttcct	aaaatattag	caagegeeee	aaactygaaa	2020
latigeteea	ttgccaaaac	ttäctcatto	cttcaccagt	ggcctgcatt	gtacccacia	2020
tggggtaacc	ttgccaaaac aacttcttga	++62222+++	octoatcago	aagtaagato	cctagctgtg	2880
attgcattgg	aacttctiga	LLCaaaaccc	getgateass	ttcttccaca	otttotacaa	2940
acctogatto	aacttcttga	tgatgatgag	Ctaacayate		otcesonoes	3000
actttaaaat	aggccattag	cttgaatagt	tcattagtgc	aattccttt	geccagggea	3060
ye ce egada e	tccagatage	acacaattta	tattggcttc	: tcaaagatgo	cctgcatyai	3000
ttgggaaata	ccagacage	caacatatt	ttagatacto	tcctgtcagt	: aggaggaaaa	3120
gtacagttta	tccagatagc gtacccgata aagaacttct	cgaacacgcc	2225440426	anctittage	aggagtagca	3180
caacttagag	aagaacttct ggcaggctag	aaaacayacy	adactigua	. ++c+ccaaa	aantatooaa	3240
naaaaantaa	gacagactag	tggatcagcc	agacaggiru	Licitedad	augtatggaa	3300
gaaaaagcad	cctttttca	gaaaaataaa	taccatctcc	: ctctcaagc	aagiciagig	3300
Cyaytacay	taaatattaa	atcatattcc	ticticautt	ctaatgctg1	t ccccctaaaa	3360
gcaaaagaat	taaatattaa tgaatgctga	section and	naanaaatta	atotcatoti	t taaqqttqqt	3420
gtcacaatgg	, tgaatgctga	CCCCCCggga	gaagaaacc	202112100	taanatctoo	3480
gaagatette	ggcaagatat	gttagcttta	cagatyata	ayactatyy	- +aacaaaaa	3540
c++>>>0	ggcaagatat ggactagatct	gaggatggta	attttcaaa1	t gtctctcaa	Lugcayayay	2600
Citaaayaa	gactagatct g tggagctggt	tectactice	gataccctca	a ggaaaatcc	a agtggaatai	. 3000
cgaggcarg	g tggagctggt g gatcctttaa	2025222				
ggtgtgacag	g gateetttaa	ayataaacca	- cetttate	t attectata	c tggatgctg1	3720
fictgaagaa	g aatatgaaaa	ggcttcagag	adcitiate		t octtco220	3780
מדפטרנפרנ	g aatatgaaaa t atgttttagg	catctgtgat	cgacacaat	g acaalalaa	t gettegaag.	2840
gragecace	t atgittitagg a tgittcacat	toactitoga	aagtttttg	g gacatgcac	a gatgttigg	2000
acgggacaca	a tgtttcacat a gggatcgggc	+cc++++0+0	ctoacctct	a atatoocat	a tgtcattaa¹	t 3900
agcttcaaa	a gggatcgggc a agcccaccat		ttattata	acctctact	o tcapoccta	c 3960.
gagagtaaa	a agcccaccat	tegiticay	Ligitiging	g ucceessor	t nattcette	a 4020
aacttoata.	a agcccaccat a gaaagcagac	: aaaccttttt	cttaaccic	L LLLactya		4080
anottacca	a gaaagcagac g aacttacaag	ı tattcaagat	ttgaaatac	g ttagagaty	c acticaacc	- 4140
gggctacca	g aacttacaag g acgcagaago	tacaattttc	· tttactagg	c ttattgaat	c aagtttggg	a 4140
caaactaca	g acycayaayc		cacaacett	n ctcadcttc	a tttttctgg	t 4200
agcattgcc	g acgcagaago a caaagtttaa a atgatgagco	Cilcicati	. cacaaccet	a assestant	c ctttagaca	a 4260
cřtectřet	a atgatgagco	: catcctttca	I TTTTCACCL	a aaacataca	2 666243133	a 4320
gatggtcga	a atgatgagco a tcaaggaagt	: ctctatttt	: acatatcat	a agaaataca	a cccayacaa	- 4200
yatygttga	a tcaaggaagt t atgtagtcc	aattttataa	aaaaaacaq	a ttgaaccat	c atttgtctt	C 4360
cattatatt	t atgtagtccg g tcgaatttca		, gaaggaarg	a otättattt	t tccactttq	g 4440
cgaacattt	g tegaattte	gyaacitta	. aataageee	a cacacata	Onstatens s	ă 4500
· aanttacca	g tcgaatttca g gctttccta	ı taggatggtı	t Ctaggaaya	a Cacacacac	d dgacgcag-	+ 4560
UCC333300	g gctttcctaa a aaattgagti	t aaacautta	: ttacagagt	t tgatgaatg	ji iiiaaiyya	+ 4600
yccaaaayy	a aaattgagti t gtgatcttg	ttotacttt	ttccaccct	t tacttcgtc	ja tgagaaagc	L 4020
gragcagag	i gracticy		teetteant	c ctactccad	g ccaaatagg	a 4680
gaagggata	ig ctaggtctg	agatycayy	. aataatact	c ttttcatc	t gotgatgca	t 4740
ggagctoto	a aattatcca	t ctcttaccg	a aatggtact		33.34.3CC	a 4800
atraaanat	a aattatcca c ttgttactg	a agatggagc	t gacccaaat	ic catalytic	a aacacacci	+ 4860
c++cc-c-	c ttgttactg	r afrcăăaco	t aaaaccaaa	ia tttcacga:	aa aacgaggaa	4000
ciccagai	a accacada	t tutatacau	t goatatano	a aagaaacc	ct aagacagcg	ja 4920
ccgacatto	a accacaaaa a atgaaatgc	t tytatatay	- +c+c+acar	no agaatttt	tt cttaaataa	a 4980
gaacttcaa	a atgaaatgc ac taagtgtac	t cagtgcaga	a ccccigcgg	an continue	to otatraori	a 5040
otaacccto	ac taagtgtac gc ctttgaaag	a tttcaactt	g agcaaagag	ya cyyttaad	cy graceage	รักครั
actacacc	a catacttgt	a a				2001
actycygco	10 - 50 - 50 - 50 - 50 - 50 - 50 - 50 -	==				

```
<210> 318
 <21:1> 3014
 <212> DNA
  <213> Homo sapiens
 <400> 318
 ctgaccagcg ccgccctcc ccgcccccga cccaggaggt ggagatccct ccggtccagc 60 cacattcaac acccactttc tcctcctct gcccctatat tcccgaaacc ccctcctct 120
gtacaaagcg gagggcgcc cgcccaagca gggcccgttc gcgccgccgc cctgcaaggc 1620 gccgggcgcg agcggctgcc tgctcccgcg ggacggcctg ccctcaacct ccgcctctgc 1680 cgccgccgcc ggggcggcc ccgcgctcta ccctgcactc ggcctcaacg ggctcccgca 1740 gctcggctac caggacggctg tgctcaagga gggcctgcc caggatctacc cgccctatct 1800 caactaccag agtctatca agccggatt cagaagccag ccagagccca caatacagct tcgagtcatt 1860
   acctcagaag atttgtttaa tctgtgggga tgaagcatca ggctgtcatt atggtgtcct 1920 tacctgtggg agctgtaagg tcttctttaa gagggcaatg gaagggcagc acaactactt 1980 atgtgctgga agaaatgact gcatcgttga taaaatccgc agaaaaaact gcccagcatg 2040
   tcgccttaga aagtgctgtc aggctggcat ggtccttgga ggtcgaaaat ttaaaaagtt 2100 caataaagtc agagttgtga gagcactgga tgctgttgct ctccacagc cagtgggcgt 2160 tccaaatgaa agccaagcc taagccagag attcactttt tcaccaggtc aagacataca 2220 gttgattcca ccactgatca acctgttaat gagcattgaa ccagatgtga tctatgag 2280
    acatgacaac acaaaacctg acacctccag ttctttgctg acaagtctta atcaactagg 2340 cgagaggcaa cttctttcag tagtcaagtg gtctaaatca ttgccaggtt ttcgaaactt 2400 acatattgat gaccagtaa ctctcattca gtattcttgg atgagcttaa tggtgtttgg 2460
   acatattgat gaccagataa ctctcattca gtattcttgg atgagcttaa tggtgtttgg 2460 tctaggatgg agatcctaca aacacgtcag tgggcagatg ctgtattttg cacctgatct 2520 aatactaaat gaacagcgga tgaaagaatc atcattctat tcattatgcc ttaccatgtg 2580 gcagatccca caggagtttg tcaagcttca agttagccaa gaagagttcc tctgtatgaa 2640 agtattgtta cttcttaata caattccttt ggaagggcta cgaagtcaaa cccagtttga 2700 ggagatgagg tcaagctaca ttagagagct catcaaggca attggtttga ggcaaaaagg 2760 agttgtgcg agctcacagc gtttctatca acttacaaaa cttcttgata acttgcatga 2820 tctgtcaaa caactccatc tgtactgatg aatacatt atccagtccc gggcactgag 2880 tgttgaattt ccagaaatga tgtctgaagt tattgctgca caattaccca agatattggc 2940 agggatggg aaaccccttc tctttcataa aaagtgaatg tcatctttt cttttcataa aaagtgaatg tcatctttt cttttcataa aaagtgaatg tcatctttt cttttcataa aaagtgaatg tcatctttt cttttcataa 3000
     ağggātggtg aaačccctīc tctttcatāa aaagīgaātg tcatcttttt cītttaaāga
                                                                                                                                                                                                                     3000
     attaaatttt gtgg
     <210> 319
     <211> 2148
      <212> DNA
     <213> Homo sapiens
     <400> 319
     gcttcagggt acagctccc cgcagccaga agccgggcct gcagcgcctc agcaccgctc 60 cgggacaccc cacccgcttc ccaggcgtga cctgtcaaca gcaacttcgc ggtgtggtga 120 actctctgag gaaaaaccat tttgattatt actctcagac gtgcgtggca acaagtgact 180
                                                                                                                           Page 66
```

```
39740-0001PCT.txt
   tgttgaāaat aaagagaagc aatgtgaagc aaaaaaaaaa aaaaaaaa
  <210> 320
<211> 540
   <212> DNA
   <213> Homo sapiens
  <210> 321
<211> 2346
   <212> DNA
    <213> Homo sapiens
   <400> 321
gcacgaggct gcggcgggtc cgggcccatg aggcgacgaa ggaggcggga cggcttttac 60
ccagccccgg acttccgaga cagggaagct gaggacatgg caggagtgtt tgacatagac 120
ctggaccagc cagaggacgc gggctctgag gatgagctgg aggagggggg tcagttaaat 180
gaaagcatgg accatggggg agttggacca tatgaacttg gcatggaaca ttgtgagaaa 240
tttgaaatct cagaaactag tgtgaacaga gggccagaa aaatcagacc agagctacttc gggtacttgg taaagggggc tatggaagag ttttcaagt aggacatgg ttttcaagt atgaaggtgc taaaaaggcg atgaggagaa atatttgcc atgagagaga atattccata tcgtggatt aattatgcc tttcagactg gtggaaaact ctacctcatc 540
cttgagtatc tcagtggagg agaactatt atgcagttag aaagaagaggg atatttatg 600
gaagacactg cctgcttta cttggcagaa atcccatgg ctttggggca tttacaaca 660
Page 67
    <400> 321
                                                                            Page 67
```

```
39740-0001PCT.txt
aaggggatca tctacagaga cctgaagccg gagaatatca tgcttaatca ccaaggtcat'720 gtgaaactaa cagactttgg actatgcaaa gaatctattc atgatggaac agtcacacac 780 acattttgtg gaacaataga atacatggcc cctgaaatct tgatgagaag tggccacaat 840 cgtgctgtgg attgggagg tttgggagcac ttaatgtatg acatgctgac tggagcaccc 900
  ccattcactg gggagaatag aaagaaaaca attgacaaaa tcctcaaatg taaactcaat 960
ttgcctcct acctcaca agaagccaga gatctgctta aaaagctgct gaaaagaaat 1020 gctgcttctc gtctgggagc tggtcctggg gacgctggag aagttcaagc tcatccattc 1080 tttagacaca ttaactggga agaacttctg gctgaaagg tggagcccc ctttaaacct 1140 gtcgacagc cagatgact aacttcagt gaaagtgca agtttacacg tcagacacct 1200 gtcgacagc cagatgact aacttcagt gaaagtgca atcaggtct tctgggttt 1260 acatatgtgg ctccatctgt acttgaaagt gtgaaagaaa agttttcctt tgaaccaaaa 1320 atccgatcac ctcgaagatt tattggcagc ccacgaacac ctgtcagcc agtcaaattt 1380 acceptaga atttctggg aatttctggg aagaaggaac cagaaaacc tcagaacacct 1440
tctcctgggg atttctgggg aagaggtgct tcggccagca cagcaaatcc caatggaaac aagtggcata gagcagatgg atgtgacaat gagtggggaa 1500 gcatcggcac cacttccaat acgacagccg aactctgggc catacaaaaa acaagctttt 1560 cccatgatct ccaaacggcc agagcacctg cgtatgaatc tatgacagag caatgctttt 1620 aagactcaaaa tgacagttc agagagtcaa tgtcattaca tagaacactt cggacacaagg 1740 aaaaataaac gtggattta aaaaatcaat caatggtgca aaaaaaaaact taatagacag ttatacaagg atttcatgt tgatgaccg aaactggtgca aaactgacct ttatcaagg atttcatgt tgatgaccg aaactggtgca aagggtaacc ttctaacaaggaagcaaaa tagcaaga tttcatag ggaaggcaaa gacaaaagaa acttaccaat tacttgcac tactgaacca ttctatagaaca tacttgcaac taaaggacaaa tagcagacaa tggatgttca aggtggaaacaa tagcagacaa tggaagcaaaa ggaaggcaaaagg aacttaccaat tgatgttta aggttgtgaa accttggaacca tttttttata taaatatata tttttcaaat agattttta cgtgcaaaca 2100 aacttctgt ttcttctct ggtgaaataa taaaatgcaa atgaatcatt ttttcagtaa ccaagccaga 2220 caacttctgt ttctctctt ggtgaaataa tagaatgaa atgaatcatt ttttcagtaa ccaagccaga 2220 caacttctgt ttctctctt ggtgaaataa tagaatgaa atgaatcatt ttttcagtaa cccaagccc 2340 gagcct
   tctcctgggg attictgggg aagaggtgct tcggccagca cagcaaatcc tcagacacct 1440
    gagcct
    <210> 322
<211> 2420
      <212> DNA
      <213> Homo sapiens
   tccgggcgg cccccggcag ccagcgcgac gttccaaaat cgaacctcag tggcggcgct 60 cggaagcgga actctgccgg ggccgcccg gctacattgt ttcctcccc cgactccctc 120 ccgcccctt ccccgcctt tcttccctcc gcgacccggg ccgtgcgtc gtcccctgc 180 ctctgcctgg cggtccctc tcccctcc ttgcacccat acctcttgt accgcaccc 240 ctggggaccc ctgcgcccct ccccccc ctgacccat acctctttgt accgcaccc 240 ctggggaccc gcggcgaggt ggcccggacc gcagtgccc aagagagctc taatggtacc 360 aagtgacagg ttggctttac tgtgactcgg ggacgccaga gctcctgaga agatgtcagc 420 aatacaggcc gcctggccat ccggtacaga atgtattgcc aagtacaact tccacggcac 480 tgccgagag gacctgcct tctgcaaaaaa agacgtctc accattataa ccattataa ccattataa 540
      <400> 322
    tgccgagcag gacctgcctt tctgcaaagg agacgtgctc accattgtgg ccgtcaccaa 540 ggaccccaac tggtacaag ccaaaaacaa ggtgggccgt gagggcatca tcccaggcaa 600 ctacgtccag aagcgggagg gcgtgaaaggc gggtaccaaa ctcagcctca tgccttggtt 660 ccacggcaag atcacacggg agcaggctga gcggcttctg tacccgccgg agacaggcct 720 gttcctggtg cgggagagca ccaactaccc cggagactac acgctgtgg tgagctgcga 780 cggcaaggtg gagcactacc gcatcatgta ccatgccagc aagctcagca tcgacgagga 840 ggtgtacttt gagaacctca tgcagctggt gagcactac acctcagacg cagatggact 900 ctgtacggc ctcattaaac caaaaggtcat gagaagcaca gtagcagca agatgaact 960 ctgtacggc ctcattaaac caaaaggtcat gagaagcaca gtagcagca agatgaactt 960
    ctgtacgcg ctcattaaac caaaggtcat ggagggcaca gtggcggccc aggatgagtt 960 ctaccgcagc ggctgggccc tgaacatgaa ggagctgaag ctgctgcaga ccatcgggaa 1020 gggggagttc ggagacgtga tgctgggcga ttaccgaggg acacaaagtcg ccgtcaagtg 1080 cattaagaac gacgccactg cccaggcctt cctggctgaa gcctcagtca tgacgcaact 1140 gcggcatagc aacctggtgc agctcctggg ccttgtggac tacctgcgg ggcggagact gtccctcaa gtctctgtg ggcggagact gtccctcaa gtctctgcta gagacttgcg ggcggagact tcaggggac ccttgtggac agcctggag ggcacaacat tcgtgcatcg agacctggct ggcccaagg tcagggacac gtccctcac agacctggct ggcccaagg tcagggacac ggccctaagg gccccaatg tcagggacac ggccctcaaggact tcagggact taggccaagg gccctgaagg gccccgcaatg tgctgggacaccgggact tcaagtggac agccctggac ggccctgaagg gccccaatg tgctgggacaccggaccca 1440 ggagacacgggc aagctgccaagg ggagtttcgg aacccttctc tgggaaatct tgggaaatct tgggcaaact ttgggaaatct tgggaaatct tgggaaatct tgggaaatct tgggaaatct tgggaaatct tgggaaatct tgggaaacctggac agaagggcta 1620 caagatggat gccccgaag gccccgaag gccccgaag ggaggcta 1620 caagatggat gccccgaag gccccgaag gccccgaag gaaagggcta 1620 caagatggat gccccgaag gccccgaag gccccgaag gaaagactgct 1680
       čťgťacgcgc čtčattaaac caaaggtčat ggagggcaca gtggcggccc aggatgagtt 960
      caagatggat gcccccgacg gctgcccgcc cgcagtctat gaagtcatga agaactgctg 1680 gcacctggac gccgccatgc ggccctcctt cctacagctc cgagagcagc ttgagcacat 1740 caaaacccac gagctgcacc tgtgacggct ggcctccgcc tgggtcatgg gcctgtgggg 1800 actgaacctg gaagatcatg gacctggtgc ccctgctcac tgggcccgag cctgaactga 1860 gccccagcgg gctggcggc cttttcctg cgtcccaccctc cggccccgtc 1920
```

```
39740-0001PCT.txt
2420
   accacgccat gaggaaaaaa
    <210> 323
   <211> 2253
    <212> DNA
    <213> Homo sapiens
 quadrated general control of the con
   ggcttatttt títáaaaçát tggágtcata gcatgtgtgt aáactttaaá tátgcaaatá
        aataagtatc tatgtctaaa aaaaaaaaaa aaa
        <211> 1619
         <212> DNA
         <213> Homo sapiens
        <400> 324
         ggacagagaa agagccaaga acaaaattgc aaaggaaacc aacaataaga agaaagaatt 420
                                                                                                                                                           Page 69
```

```
39740-0001PCT.txt
tgaggaaact gcgaagaaag tgcgccgtgc catcgagcag ctggctgcca tggattgagg 480 cctctggccg gagctgcctg gtcccagagt ggctgcacca cttccagggt ttattccctg 540 gtgccaccag ccttcctgtg ggccccttag caatgtctta ggaaaggaaga tcaacatttt 600 caaattagat gttcaactg tgctcctgtt ttgtcttgaa agtggcacca gaggtgcttc 660 tgcctgtgca gcgggtgctg ctggtaacag tggctgcttc tctctctct tctcttttt 720 gggggctcat ttttgctgtt ttgattcccg ggcttaccag gtgagaagtg agggaggaag 780 gtgaaatgtgt cccttttgct agagctgaca gctttgtcg cgtgggcaga gccttccaca 840 ggggcctgtt tgttttgtg gacttgtag gctgcacag tcctgagtgt ggacttggcaggttttt tgttgttgtg gactgcacag ttatttttt ggtagatgca tgcatggc 1020 gtgatgagag aatggagaca gagtccctgg ctcctcactagtgc ttttttttt ggtagatgca tgacttgtt 1020 gaatttgtt aggaattgtaa ttcacagaat agcacaaact acaattaaaa ctaagcacaa 1140 agccattcta agtcattggg gaaccgggtg gaacttcagg tggatgagga gacagaatag 1200
  agccattcta agtcattggg gaaacggggt gaacttcagg tggatgagga gacagaatag agtgatagga agcgtctggc agatactcct tttgccactg ctgtgtgatt agacaggccc agtgagccgc ggggcacatg ctggccgctc ctccctcaga aaaaggcagt ggcctaaatc
                                                                                                                                                                                                                                                                                        1260
  cttttaaat gacttggctc gatgctgtgg gggactggct gggctgctgc aggccgtgtg 1380 tctgtcagcc caaccttcac atctgtcacg ttctccacac gggggagaga cgcagtccgc 1440 ccaggtcccc gctttctttg gaggcagcag ctcccgcagg gctgaagtct ggcgtaagat 1500 gatggatttg atccgcctc ctcctgtca tagagctgca gggggggagaga cgcagtctgca 1560
   ğctggaaacc tctggaggtc atctcggctg ttcctgagaa ataaaaagcc tgtcatttc
   <210> 325
<211> 5010
    <212> DNA
    <213> Homo sapiens
  <400> 325
ggcggctcgg gacggaggac gcgctagtgt gagtgcgggc ttctagaact acaccgaccc 60
tcgtgtcctc ccttcatcct gcggggctgg ctggagcggc cgctccggtg ctgtccagca 120
gccataggga gccgcacggg gagcgggaaa gcggtcgcgg ccccaggcgg ggcggccggg 180
atggagcggg gccgcagcc tgtggggaag gggctgtgg ggcgcctcga gcggctgcag 240
gttcttctgt gtggcagttc agaatgatgg atcaagctag atcagcattc tctaacttgt 300
ttggtggaga accattgtca tatacccggt tcagcagtag atcagcagta tcggcaagta 360
acagtcatgt ggagatgaaa cttgctgtag agaagaagaa aaatgctgac aataacacaa 420
aggccaatgt tttcttgatt ggatttatga ttggctactt gggctattgt aacaggggtag 540
aaccaaaaac tgagtgtga agactggcag gaaccgagtc tccagtgagg gaggagccag 600
gagaggactt ccctgcagca cgtcgcttat attagggatga aattcatatg 720
   <400> 325
   agaaggactt ccctgcagca cgtcgcttat attgggatga cctgaagaga aagttgtcgg 600 agaaactgga cagcacagac ttcaccagca ccatcaagct gctgaatgaa aattcatatg 720 tccctcgtga ggctggatct caaaaagatg aaaatcttgc gttgtatgtt gaaaatcaat 780 ttcgtgaatt taaactcagc aaagtctggc gtgatcaaca ttttgttaag attcaggtca 840 aagacagcgc tcaaaactcg gtgatcatag ttgataagaa cggtagactt gtttacctgg 900 tggagaatcc tggggggttat gtggcgtata gtaaggctgc aacagttact ggtaaactgg 960 tccatgctaa ttttggtact aaaaaagatt ttgaggattt atacactcct gtgaatggat 1020 ctatagtgat tgcagagca gggaaaatca cctttgcaga aaaggttgca aatgctgaaa 1080 gcttaaatgc aattggtgt ttgatataca tggaccagac taaatttccc attgttaacg 1140 cagaactttc attctttgga catgctcatc tggggacaagg tgacccttac acacctggat 1200
    cagaactttc attetttgga catgetcate tggggacagg tgaccettae acacctggat 1200 tccettcett caatcacact cagtttcac catcteggte atcaggattg cetaatatae 1260 ctgtccagac aatetecaga getgetgeag aaaagetgtt tggggaatatg gaaggagact 1320 gtccetetga etggaaaaca gactetacat gtaggatggt aacetecagaa ageaagaatg 1380
    tgaagctcac tgtgagcaat gtgctgaaag agataaaaat tcttaacatc tttggagtta 1440 ttaaaggctt tgtagaacca gatcactatg ttgtagttgg ggcccagaga gatgcatggg 1500 gccctggagc tgcaaaatcc ggtgtaggca cagctctcct attgaaactt gcccagatgt 1560
     tctcagatat ggtcttaaaa gatgggtttc agcccagcag aagcattatc tttgccagtt 1620
    ggagtgctgg agactttgga tcggttggtg ccactgaatg gctagaggga tacctttcgt 1680 ccctgcattt aaaggctttc acttatatta atctggataa agcggttctt ggtaccagca 1740 acttcaaggt tctgccagc ccactgttgt atacgcttat tgaggaaaaca atgcaaaatg 1800
     tgaagcatcc ggttactggg caatttctat atcaggacag caactgggcc agcaaagttg 1860 agaaactcac tttagacaat gctgcttcc ctttccttgc atattctgga atcccagcag 1920 tttctttctg tttttgcgag gacacagatt atccttattt gggtaccacc atggacacct 1980 ataaggaact gattgagagg attcctgagt tgaaacaaag ggcaacagagg 2040
      tcgcťggtca gttcgtgaťť aaactaáccc atgatgttga áttgaacctg gactatgaga 2100
     ggtacaacag ccaactgctt tcatttgtga gggatctgaa ccaatacaga gcagacataa 2160 aggaaatggg cctgagttta cagtggctgt attctgctcg tggagacttc ttccgtgcta 2220 cttccagact aacaacagat ttcgggaatg ctgagaaaac agacagattt gtcatgaaga 2280
     aactcaatga tcgtgtcatg agagtggagt atcacttcct ctctccctac gtatctccaa 2340 aagagtctcc tttccgacat gtcttctggg gctccggctc tcacacgctg ccagctttac 2400 tggagaactt gaaactgcgt aaacaaaata acggtgcttt taatgaaacg ctgttcagaa 2460
                                                                                                                                                                 Page 70
```

```
39740-0001PCT.txt
accagitigged to transport to tr
    accagttggc tctagctact tggactattc agggagctgc aaatgccctc tctggtgacg 2520
        aattatcgga agcagtgcct tccataatta tgacagttat actgtcggtt tttttaaat 3540 aaaagcagca tctgctaata aaacccaaca gatactggaa gttttgcatt tatggtcaac 3600 acttaagggt tttagaaaac agccgtcagc caaatgtaat tgaataaagt tgaagcatag 3720 aatttagagat gaattaaatt taattagggg tgaccaagtt atccaaaggt gaccattgc aaaatttaat agctcagtt atccaaggtg gtactcctgc aaaattttat agctcagtt atccaaggtg tttcctaaa gtacctttgt cacaatccta acacattatc gggagcagtg 3900 accagtaatg 3720 aaaatttcca gtaccattgt cacaatccta acacattatc gggagcagtg 3900 accattgc tataaaaga acaaggtagt ttttacctac cacagtgtct ggaggagcagtg 3900 accattattctccaattgc actaagggtg taagtaatta tcggggaacag tgtttcccat 4020 attttcctaa atgcaatgac atcttcaaag cttgaagatc gttagtacct aacaattttg ggaaattca accactgtaa aatgaaatta tcggggacagtg 3900 accattgggtg ggaaaattca accactgtaa atggtagtact aacaatgtatc 4080 attgggttt tgttacctt atggttctc acggtcctct acttaatgag acaagttta accactatat tggttgctat tgacaagtca ttttaatta tcacattatt tgcatgtac 4260 acatttaaa cttagtgcgg acaagttta accagaatt tggggaagga gagtcccctg aaggtctgac 4440 aggggactttg tatagaaggt ttgggggaagga gagtcccctg aaggtctgac 4440 aggggactttg tatagaaggt ttgggggaagga gagtcccctg aaggtctgac 4440
              ctcctataaa cttagtgcgg acaagttta atccagaatt gaccttttga cttaaagcag 4380 agggactttg tatagaaggt ttgggggatga gagtccctg aaggtctgac 4440 cgtctgct acccattcgt ggtgatcaat taaatgtagg tatgaataag ttcgaagctc 4500 cgtgagtgaa ccatcatata aacgtgtagt acagctgttt gtcatagggc agttggaaac 4560 ggcctcctag ggaaaagtc atagggtctc ttcaggttct tagtgtcact tacctagatt 4620 atccctctt ttatcttgga ctgacattta gcgtagctaa ggtagaaaaggt catagctgag 4740 attcctggtt cgggtgtac gcacacgtac ttaatacaaa gcatgtggaa ggatccttc aggaaaaggt 4800 ataacacaat atgaatacag ggcatgcatt ttgagagag gagtctctc aggaaaaccct 4860 atcctggtt aagggttgag ttactccta tcaagccagt acgtgctaac aggactcaata 4920 ttcctgaatg aaatatcaga ctagtgacaa gctcctggtc ttgagatgtc ttcctgttaa 4980 ggagttagggc cttttggagg taaaaggtaa 5010
```

```
39740-0001PCT.txt
agatatcctg gaaaacattc acgaggtgat ggaaatcaaa ttcaaaggcg tggacaatga 1020 ggatgaccat ggccgtggag atctggggcg cctcaagaag cagaaggatc accacaaccc 1080 tcatctaatc ctcatgatga ttccccaca ccggctcgac aacccgggcc aggggggtca 1140 gaggaagaag cgggctttgg acaccaatta ctgcttccgc aacttggagg agaactgctg 1200 tggacgccc ctctacattg acttccgaca gggatctgggc tggaagtggg tccatgaacc 1260
 tgtgcgccc ctctacattg acttccgaca ggatctgggc tggaagtggg tccatgaacc 1260 taagggctac tatgccaact tctgctcagg cccttgccca tacctccgca gtgcagacac 1320 aacccacagc acggtgctgg gactgtacaa cactctgaac cctgaagcat ctgcctcgcc 1380 ttgctgcgtg ccccaggacc tggagccct gaccatcctg tactatgttg ggaggacccc 1440 caaagtggag cagctctcca acatggtggt gaagtcttgt aaatgtagct gagagcccca 1560 acacaagcaa caaacctcac tgagggcct ggagcccaca accttcgctgac ctgcggaaac 1560 ggctgagatg gaggtttcct tttggaacaca cactgcctga ctgcccgctc ccgggcaaat 1620 ggctgagatg gggtttcgt tttggaacaca accttctggct ccgggcaaat 1620 ggtaaagaaa ggctgaacac ttcttcttg ctggctctga gaatcacggt 1680 cggtaacgaca gacagagggg atggggatag aggaaaggga tggtaagttg agatgttgtg 1800 tggcaatggg attgggcta ccctaaaggg agaaggaagg gcagagaatg gctgggtcag 1860
 tggcaatggg atttgggcta ccctaaaggg agaaggaagg gcagagaatg gctgggtcag 1860 ggccagactg gaagacactt cagatctgag gttggatttg ctcattgctg taccacatct 1920 gctctaggga atctggatta tgttatacaa ggcaagcatt tttttttta aagacaggtt 1980
 gctctaggga atctggatta tgttatacaa ggcaagcatt tttttttta aagacaggtt 1980 acgaagacaa agtcccagaa ttgtatctca tactgtctgg gattaagggc aaatctatta 2040 ggtcatgcag ttcctggcc atcaactga ttgggccttt tggatatgct gaacgcagaa 2160 gaaagggtgg aaatcaaccc tctcctgtct gccctctggg tccctcctct cacctctcc 2220 tcgatcatat ttccccttgg acacttggt agacgcctt caggtcagga tgcacatttc 2280 tggattgtg tccatgcag ccttgggca tattgggtct tccccactt ccccccact cacctcccaag 2340 accctgtgt cattggtgt tccttggaagc aggtgctaca acactgtgagg cattcgggga 2400 aggtgcacat gtgccacaca gtgacttggc ccagacgca tagactgagg tataaagaca 2460 agtatgaata ttactctcaa aatctttgta taaataaata tttttggggc atcctggatg 2520 atttcatctt ctggaatat gtttctagaa cagtaaaaagc cttattctaa
atttcatctt ctggaatatt gtttctagaa cagtaaaagc cttattctaa ggtg
   <210> 327
<211> 1421
    <212> DNA
    <213> Homo sapiens
   acttactgcg ggacggcctt ggagagtact cgggttcgtg aacttcccgg aggcgcaatg 60 agctgcatta acctgccac tgtgctgcc ggctcccca gcaagacccg ggggcagatc 120 caggtgattc tcgggccgat gttctcagga aaaagcacag agttgatgag acgcgtccgt 180 cgcttccaga ttgctcagta caagtgcctg gtgataagt atgccaaaga cactcgctac 240 agcagcagtt tctgcacaca tgaccggaac accatggagg cgctgcccgc ctgcctgctc 300 cgagacgtgg cccaggaggc cctgggggg gctgtcatag gcatcgacga ggggcagttt 360 ttccctgaca tcatggagtt ctgcgaggc atggccaacg ccgggaagac cgtaattgtg 420 gctgcactgg atggcactg atggccactg ccaggaagac cctggagaaa ccatctgaa cctgatacca 480
    <400> 327
    gctgcactgg atgggacctt ccagaggaag ccatttgggg ccatcctgaa cctggtgccg 480 ctggccgaga gcgtggtgaa gctgacggcg gtgtgcatgg agtgcttccg ggaagccgcc 540 tataccaaga ggctcgcca agagaaggag gtcgaggtga ttggggagc agacaagtac 600
    cactcogtgt gtcggctctg ctacttcaag aaggcctcag gccagcctgc cgggccggac 660 aacaaagaga actgcccagt gccaggaaag ccaggggaag ccgtggctgc caggaagctc 720 tttgcccac agcagattct gcaatgcagc cctgccaact gagggacctg caagggccgc 780 ccgctcctt cctgccactg ccgctactg gacgctctt gcatgctgc ccagccactc 840
    caggaggaag tcgggaggcg tggagggtga ccacaccttg gccttctggg aactctcctt 900 tgtgtggctg ccccactgc cgcatgctc ctcctctct acccactggt ctgcttaaag 960 cttcctctc agctgctgg acgatcgcc aggctggagc tggccccgct tggtggcctg 1020 ggatctggca cactcctct ccttggggtg agggatctggca cactcctct ccttggggtg agggatctagg
    cctgcttctt cccctctgcg gctttcactg ctgagtttct gttctcctg ggaagcctgt 1140 gccagcacct ttgagccttg gcccacactg aggcttaggc ctctctgct gggatgggct 1200 cccacctcc cctgaggatg gcctggattc acgccctctt gtttcctttt gggctcaaag 1260 cccttcctac ctctgggat ggtttccaca ggaacacac ttgctgggac ttggatcca ggggctatc tcttcaagtg tggagagggc 1380 aggctcacc cctctgctg aggcttatca ggggcttatc tcttcaagtg tggagagggc 1380
      ăğggtccacg ccictgcigt agcitatgaa aitaactaat t
      <210> 328
      <211> 4604
       <212> DNA
       <213> Homo sapiens
      <400> 328
      ggaacagctt gtccacccgc cggccggacc agaagccttt gggtctgaag tgtctgtgag 60 acctcacaga agagcacccc tgggctccac ttacctgccc cctgctcctt cagggatgga 120
      ggcaatggcg gccagcactt ccctgcctga ccctggagac tttgaccgga acgtgccccg 180
                                                                                                                                                                Page 72
```

```
39740-0001PCT.txt
ttataactga aggagaaggt gccccaaaat gcaagatttt ccacaagatt cccagagaca 4320
ggaaaatcct ctggctggct aactggaagc atgtaggaga atccaagcga ggtcaacaga 4380 gaaggcagga atgtgtggca gatttagtga aagctagaga tatggcagcg aaaggatgta 4440 aacagtgcct gctgaatgat ttccaaagag aaaaaaagtt tgccagaagt ttgtcaagtc 4500 aaccaatgta gaaagctttg cttatggtaa taaaaatggc tcatacttat atagcactta 4504
 ctttgtttgc aagtactgct gtaaataaat gctttatgca aacc
<210> 329
<211> 2076
 <212> DNA
 <213> Homo sapiens
<400> 329
cggggaaggg gagggaggag ggggacgagg gctctggcgg gtttggaggg gctgaacatc 60 gcggggtgtt ctggtgtcc ccgccccgcc tctccaaaaa gctacaccga cgcggaccgc 120 ggcggcgtcc tccctcgccc tcgcttcacc tcgcgggctc cgaatgcggg gagctcggat 180 gtccggttc ctgtgaggct tttacctgac acccgccgc tttccccggc actggctggg 240 agggcgccct gcaaagttgg gaacgcggag ccccggcacc gctccgcgc cctccggct 300
gcccaggggg ggtcgccggg aggagcccgg gggagaggga ccaggagggg cccgcggcct 360 cgcaggggcg cccgcgccc cacccctgc cccgccagcg gaccggtcc ccacccccgg 420 tccttccacc atgcacttgc tgggcttctt ctctgtggcg tgttctctgc tcgccgctgc 480
gctgctcccg ggtcctcgcg aggcgcccgc cgccgccgcc gccttcgagt ccggactcga 540 cctctcggac gcggagcccg acgcgggcga ggccacggct tatgcaagca aagatctgga 600 ggagcagtta cggtctgtgt ccagtgtaga tgaactcatg actgtactct acccagaata 660 ttggaaaatg tacaagtgtc agctaaggaa aggaggctgg caacataaca gagaacaggc 720 caacctcaac tcaaggacag aagagactat aaaatttgct gcagcacatt ataatacaga 780
gatcttgaaa agtattgata atgagtggag aaagactcaa tgcatgccac gggaggtgtg 840 tatagatgtg gggaaggagt ttggagtcgc gacaaacacc ttctttaaac ctccatgtgt 900 gtccgtctac agatgtgggg gttgctgcaa tagtgagggg ctgcagtgca tgaacaccag 960
 cacgagetae etcageaaga egitatitga aattacagig ectetetete aaggeeccaa 1020
accagtacca atcagttttg ccaatcacac ttcctgccga tgcatgtcta aactggatgt 1080 ttacagacaa gttcattcca ttattagacg ttcctgcca gcaacactac cacagtgtca 1140 ggcagcgaac aagacctgcc ccaccaatta catgtggaat aatcacatct gcagatgcct 1200
ggctcaggaa gattttatgt tttcctcgga tgctggagat gactcaacag atggattcca 1260 tgacatctgt ggaccaaaca aggagctgga tgaagagacc tgtcagtgtg tctgcagagc 1320 ggggcttcgg cctgccagct gtggacccca caaagaacta gacagaaact catgccagtg 1380
 tgtctgtaaa aacaaactct tccccagcca atgtggggcc aaccgagaat ttgatgaaaa 1440
cacatgccag tgtgtatgta aaagaacctg ccccagaaat caacccctaa atcctggaaa 1500 atgtgcctgt gaatgtacag aaagtccaca gaaatgcttg ttaaaaggaa agaagttcca 1560 ccaccaaaca tgcagctgtt acagacggcc atgtacgaac cgccagaagg cttgtgagcc 1620
aggattitca tatagtgaag aagtgtgtcg ttgtgtccct tcatattgga aaagaccaca 1680 aatgagctaa gattgtactg ttttccagtt catcgattit ctatatgga aaactgtgtt 1740 gccacagtag aactgtctgt gaacagagag acccttgtgg gtccatgcta acaaagacaa 1800 aagtctgtct ttcctgaacc atgtggataa ctttacagaa atggactgga gctcatctgc 1860 aaaaggcctc ttgtaaagac tggttttctg ccaatgacca aacagccaag attttcctct 1920 tgtgattict ttaaaagaat gactatataa tttatttcca ctaaaaatat tgtttctgca 1980 tcattttta tagcaacaaga aatggataa accctgtg atcaatatt ttatatcatg 2046
 caaaatatgt ttaaaataaa atgaaaattg tattat
                                                                                                                                                                                                                2076
 <210> 330
<211> 2819
 <212> DNA
 <213> Homo sapiens
 <400> 330
 ctgggcccag ctcccccgag aggtggtcgg atcctctggg ctgctcggtc gatgcctgtg 60
ccactgacgt ccaggcatga ggtggttcct gccctggacg ctggcagcag tgacagcagc 120 agccgccagc accgtcctgg ccacggcct ctctccagc cctacgacca tggactttac 180 cccagctcca ctggaggaca cctcctcacg ccccaattc tgcaagtggc catgtgagtg 240
cccagctcca ctggaggaca cctcctcacg cccccaattc tgcaagtggc catgtgagtg 240 cccgccatcc ccaccccgct gcccgctggg ggtcagcctc atcacagatg gctgtgagtg 300 ctgtaagatg tgcgctcagc agcttgggga caactgcacg gaggctgcca tctgtgaccc 360 ccaccggggc ctctactgtg actacagcgg ggaccgcccg aggtacgcaa taggagtgtg 420 tgcacaggtg gtcggtgtgg gctgcgtcct ggatggggtg cgctacaaca acggccagtc 480 cttccagcct aactgcaagt acaactgcac gtgcatcgac ggcgcggtgg gctgcacacc 540 actgtgcccc cgagtgcgc ccccgcgtct ctggtgcccc cacccgggc gcgtgagcat 600 acctggccac tgctgtgagc agtgggtatg tgaggacgac gccaagaggc cacgcaagaa 660 cgcaccccgt gacacaagga ccttcgatgc tgtgggtgag gtggaggcat ggcacaggaa 720 ctgcatagcc tacacaagcc cctggagccc ttgctccacc agctgcggcc tgggggtctc 780
                                                                                                                    Page 74
```

```
39740-0001PCT.txt
cacteggate tecaatgtta aegeceagtg etggeetgag caagagagee geetetgeaa 840
 gttgagaagt tcccattatt atttctgttc ttacaaatgt gaaacggaag ctcatagagg 2640 tgagaaaact caaccagagt cacccagttg gtgactggga aagttaggat tcagatcgaa 2700 attggactgt ctttataacc catatttcc ccctgtttt agagcttcca aatgtgtcag 2760
 aataggaaaa cattgcaata aatggcttga ttttttaaaa aaaaaaaaa aaaaaaaaa
 <210> 331
 <211> 2540
 <212> DNA
 <213> Homo sapiens
```

```
39740-0001PCT.txt
tagcatttgc taccaagtag gaaaaaaaat gtacatggca gtgttttagt tggcaatata 1680 atctttgaat ttcttgattt ttcagggtat tagctgtatt atccatttt tttactgtta 1740
tttaattgaa accatagact aagaataaga agcatcatac tataactgaa cacaatgtgt 1800 attcatagta tactgattta atttctaagt gtaagtgaat taatcatctg gatttttat 1800 tctttcaga taggcttaac aaatggagct ttctgtatat aaatgtggag attagagtta 1920 atctcccaa tcacataatt tgttttgtgt gaaaaaggaa taaattgttc catgctggtg 1980 gaaaaggga taaacacgga cgtgtgcgaa atatgttgt taggatttt gccattgttg 2100 tgtaaagggattt taatgataga atactatcag gccaacatgt actgacatgg aaagatgtca 2160
gagatatgtt aagtgtaaaa tgcaagtggc gggacactat gtatagtctg agccagatca 2220 aagtatgtat gttgttaata tgcatagaac gagagatttg gaaagatata caccaaactg 2280 ttaaatgtgg tttctcttcg gggagggggg gattggggga ggggcccag aggggttta 2340 gaggggcctt ttcactttcg actttttca ttttgttctg ttcggattt ttataagtat 2400 gtagaccccg aagggttta tgggaactaa catcagtaac ctaacccccg tgactatcct 2460 gtgctcttcc tagggagctg tgttgttcc cacccaccac ccttccctct gaacaaatgc 2520
 ctgagtgctg gggcactttg
 <210> 332
<211> 1474
 <212> DNA
 <213> Homo sapiens
 <400> 332
 aaaaagaaat caagaatgca attttattta caatagtcac gccggaaata cctagaaata 60
 aatttaactg aggatgtaaa agacctctac aaggagagtt caatgcgtag cgggagcgga 120
 gagctgaccc cagagagccc tgggcagccc cacctccgcc gccggcctag ttaccatcac 180
 accccggaga gcccgcagct gccgcagccg gccccagtca ccatcaccgc aaccatgagc 240 agcgaggccg agacccagca gccgccgcc gccccccgc cccccgc cctcagcgc 300 gccgacacca agcccggcac taccggagcg gcgcagggag cggtggcccg ggcgcccag 360
 ggagatggag agactgtgga gtttgatgtt gttgaaggag aaaagggtgc ggaggcagca 600 aatgttacag gtcctggtgg tgttccagtt caaggcagta aatatgcagc agaccgtaac 660 cattatagac gctatccacg tcgtaggggt cctccacgca attaccagca gtgggggaaaa gaacgaggga tcggagagtg ctcccgaagc caggcccaac 780 cagccacagt attccaaccc tcctgtgcag ggagaagtga tggaggggg tggcaggag aacaaggtag accagtgagg cagatatgta tcggagggtgc tgacaaccag 900 ggtgcaggag cctcctcgc caaaaggcag cagatatgta tcgggggatat agaccacgat 960 cagatatcaag gagatgagac ccaaaggtcag cctaaaggcag acggcaatga agaagataaa 1020 gaaaatcaag gagatgagac cccagaaaac cctaaaccac aagatggcaa agaagacaaaa 1140 gaaccggg cttaccatct ctaccatcat ccggtttagt catccaacaa gaagaaaatat 1260 gaaattccag caataagaaa tgaacaaaa attggagctg aagacctaaa qtqcttqctt 1320
 gaaattccag caataagaaa tgaacaaaag attggagctg aagacctaaa gtgcttgctt 1320 tttgcccgtt gaccagataa atagaactat ctgcattatc tatgcagcat ggggttttta 1380 ttatgtttta cctaaagacg tctctttttg gtaataacaa accgtgtttt ttaaaaaaagc 1440 ctggttttc tcaatacgcc tttaaaggaa ttcc 1474
  <210> 333
  <211> 4079
  <212> DNA
  <213> Homo sapiens
  <400> 333
  ggagcggcgg gcgggcggga gggctggcgg ggcgaacgtc tgggagacgt ctgaaagacc 60
  aacgagactt tggagaccag agacgcgct ggggggacct ggggcttggg gcgtgcgaga 120 tttcccttgc attcgctggg agctcgcga gggatcgtc catggccggg gctcggagcc 180 gcgacccttg gggggcctcc gggatttgct acctttttgg ctccttgctc gtcgaactg 240 tcttctcacg ggctgtcgcc ttcaatctgg acgtgaggg tgccttgcgc aaggagggcg 300
  agccaggcag cctcttcggc ttctctgtgg ccctgcaccg gcagttgcag ccccgacccc 360 agagctggct gctggtggt gctccccagg ccctggctct tcctgggcag caggcgaatc 420 gcactggagg cctcttcgct tgcccgttga gcctggagga gactgactgc tacagagtgg 480
  ācatcgāccā gggagctgat atgcaāaagg āaagcāagga gaaccagtgg ttgggagtcā 540
  gtgttcggag ccaggggct gggggcaaga ttgttacctg tgcacaccga tatgaggcaa 600 ggcagcgagt ggaccagatc ctggagacgc gggatatgat tggtcgctgc tttgtgctca 660 gccaggacct ggccatccgg gatgagttgg atggtgggga atggaagttc tgtgagggac 720 gcccccaagg ccatgaacaa tttgggttct gccagcaggg cacagctgcc gccttctccc 780
                                                                                                             Page 76
```

```
39740-0001PCT.txt
  <210> 334
  <211> 3373
  <212> DNA
  <213> Homo sapiens
  <400> 334
  ggtggcaact tctcctctg cggccgggag cggcctgcct gcctccctgc gcacccgcag 60 cctccccgc tgcctccta gggctccct ccggccgcca gcgcccatt ttcattcct 120
  Page 77
```

```
39740-0001PCT.txt
acgccgcgc cgcggagcag ccgtgcccgc cgcccgggcc cgccgccagg gcgcacacgc 420 tcccgcccc ctacccggcc cggggag tttgcacctc tccctgccg ggtgctcgag 480 ctgccgttgc aaagccaact ttggaaaaag tttttgggg gagacttggg ccttgaggtg 540 cccagctcg cgctttccga ttttgggggc ctttccagaa aatgttgcaa aaaagctaag 600 cccagcacaa aaagccaaca cccagcaa aaagccaaca 600
cccagctccy cgclilicya tittygygyc ctttcayad aatgligda daaagctaag 600 ccggcgggca gaggaaaacg cctgtagccg gcgagtgaag acgaaccatc gactgccgtg 660 ttccttttcc tcttggaggt tggagtccc tgggcgccc cacacggcta gacgcctcgg 720 ctggttcgcg acgcagccc ccggccgtgg atgctgcact cgggctcggg atccgccag 780 gtagccggc gcgggcgcg gccggggca tgcggctga ccccccc agcgacggag 840 ccggggccgg ggggggcgc tgagcgcag ccgcgctga gaggcctga 900 gcgcctgatc gccgcggacc tgagccgag ccaccccct ccccagccc ccaccctgg 960 ccggggcga acgcaccag tctaccagtc caggacccag ccaccccc ccaccctgg 960
 cgcgggggg gcgcgctcga tctacgcgtc cggggccccg cgggggccggg cccggagtcg 1020 gcatgaatcg ctgctgggcg ctcttcctgt ctctctgctg ctacctgcgt ctggtcagcg 1080 ccgaggggga ccccattccc gaggagcttt atgagatgct gagtgaccac tcgatccgct 1140
ccgaggggga ccccattcc gaggagcttt atgagatgct gagtgaccac tcgatccgct 1140 cctttgatga tctccaacgc ctgctgcacg gagaccccgg agaggaagat ggggccgagt 1200 tggacctgaa catgacccg tcccactctg gaggcgagct ggagagcttg gctcgtggaa 1260 gaaggagcct gggttccctg accattgctg agccggccat gatcgccgag tgcaagacgc 1320 gcaccgaggt gttcgagatc tcccggcgcc tcatagaccg caccaacgcc aacttcctgg 1380 tgtggccgcc ctgtgtggag gtgcagcgc gctccggctg ctgcaacaac cgcaacgtgc 1440 agtgccgcc caccaaggtg cagctgcgac ctgtccaggt gagaaagatc gagattgtgc 1500 ggaagaagcc aatctttaag aaggccacgg tgacgctgga agaccacctg gcatgcaagt 1560 gtgagacagt ggcagctgca cggcctgtga cccgaagccc ggggggttcc caggagcagc 1620 gagccaaaac gccccaaact cgggtgacca ttcggacggt gcgagtccgc cggccccca 1680 agggcaaaca ccggaaattc aagcacacc atgacaagac qqcactqaag gagacccttg 1740
 agggcaagca ccggaaattc aagcacacgc atgacaagac ggcactgaag gagacccttg 1740 gagcctaggg gcatcggcag gagagtgtg gggcagggtt atttaatatg gtatttgctg 1800 tattgcccc atggggtcct tggagtgata atattgttc cctcgtccgt ctgtctcgat 1860
agtctgctcc accaaggggc tcttgaaccc cttattaagg ccccagatga ccccagtcac 2640 tcctctctag ggcagaagac tagaggccag ggcagcaagg gacctgctca tcatattcca 2700 acccagccac gactgccatg taaggttgtg caggggtgt actgcacaag gacattgtat 2760 gcagggagca ctgttcacat catagataaa gctgattgt atatttatta tgacaatttc 2820
   tggcagatgt aggtaaagag gaaaaggatc cttttcctaa ttcacacaaa gactccttgt 2880 ggactggctg tgcccctgat gcagcctgtg gctggagtgg ccaaatagga gggaggactgt 2940 ggtaggggca gggaggaac actgctgtcc acatgacctc catttcccaa agtcctctgc 3000
   tccagcaact gcccttccag gtgggtgtgg gacacctggg agaaggtctc caagggaggg 3060 tgcagccctc ttgcccgcac ccctcctgc ttgcacactt ccccatcttt gatccttctg 3120 agctccacct ctggtggctc ctcctaggaa accagctcgt gggctgggaa tgggggagag 3180 aagggaaaag atcccaaga ccccttggg tgggatctga gctccacct cccttccca 3240 ctactgcact ttccccttc ccgccttcca aaacctgctt ccttcagttt gtaaagtcgg 3300
                                                                                                                                                                                                                                              3360
    tgattātatt titgggggct ticctittat tittaāatg taaaatītat ītataītcēģ
                                                                                                                                                                                                                                               3373
    tätttaaagt tgt
    <210> 335
    <211> 2304
     <212> DNA
     <213> Homo sapiens
    <400> 335
    gtccccgcag cgccgtcgcg ccctcctgcc gcaggccacc gaggccgccg ccgtctagcg 60
     čecegačetě gěcačeatga gagecetget ggegegeetg ettetetgeg teetggtegt 120
    gagcgactcc aaaggcagca atgaacttca tcaagttcca tcgaactgtg actgtctaaa 180 tggaggaaca tgtgtgtcca acaagtactt ctccaacatt cactggtgca actgcccaaa 240 gaaattcgga gggcagcact gtgaaataga taagtcaaa acctgctatg aggggaatgg 300 tcactttac cgaggaaagg ccagcactga caccatgggc cggccctgcc tgccctggaa 360 tcactttac cgaggaaagg cagcactga taggagaagg taggaagg cagcactga taggagaagg cagcatgaa 360
    ctctgccact gtccttcagc aaacgtacca tgcccacaga tctgatgctc ttcagctggg 420 cctggggaaa cataattact gcaggaaccc agacaaccgg aggcgaccct ggtgctatgt 480 gcaggtgggc ctaaagccgc ttgtccaaga gtgcatggtg catgactgcg cagatggaaa 540 aaagccctcc tctcctccag aagaattaaa atttcagtgt ggccaaaaga ctctgaggcc 600
                                                                                                                                        Page 78
```

```
39740-0001PCT.txt
atcaataaaa tgtgattttt ctga
   <210> 336
   <211> 1876
   <212> DNA
   <213> Homo sapiens
   <40U> 330
cgcggccgcg gttcgctgtg gcgggcgct gggccgccgg ctgtttaact tcgcttccgc 60 tggcccatag tgatctttgc agtgaccag cagcatcact gtttcttggc gtgtgaagat 120 aacccaagga attgaggaag ttgctgagaa gagtgtgctg gagatgctct aggaaaaaat 180 tgaatagtga gacgagttcc agcgcaaggg tttctggttt gccaagaaga aagtgaacat 240 tgaatagtga gacaacagcc tgccacctta cgctcagggc ttggcctccc ctcagggtgc 300 catggatcas accaacagc tgccaccta cgctcaggcc tatggcctcc gactgacccc 360
  aaaaaaaaa aaaaaa
```

<210>

<211>

6633

## 39740-0001PCT.txt

```
<212> DNA
<213> Homo sapiens
<400> 337
ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccctgattgc 60
gtaagagcaa aaagcgaagg cgcaatctgg acactgggag attcggagcg cagggagttt 120 gagagaaact tttatttga agagaccaag gttgaggggg ggcttattc ctgacagcta 180 tttacttaga gcaaatgatt agttttagaa ggatggacta taacattgaa tcaattacaa 240
aacgcggttt ttgagcccat tactgttgga gctacaggga gagaaacagg aggagactgc 300 aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg 360 cggaataaca tcggaggaga agtttccag agctatgggg acttccatc cggcgttcct 420 ggtcttaggc tgtcttcta cagggcttag cctaatcatc tgccagcttt cattaccctc 480
tatcettca aatgaaaatg aaaaggttgt gcagctgaat teatcettt etetgagatg 540 ctttggggag agtgaagtga getggcagta eeccatgtet gaagaagaga geteegatgt 600 ggaaateaga aatgaagaaa acaacagegg eetttttgtg aeggtettgg aagtgageag 660 tgeeteggeg geceacaaag ggttgtacae ttgetattae aaccaeete agacagaaga 720
gaatgagctt gaaggcaggc acatttacat ctatgtgcca gacccagatg tagcctttgt 780 acctctagga atgacggatt atttagtcat cgtggaggat gatgatctg ccattatacc 840 ttgtcgcaca actgatcccg agactcctgt aaccttacac aacagtgagg gggtggtacc 900 tgcctcctac gacagcagac agggctttaa tggcacttc actgtagggc cctatatctg 960
 tgaggccacc gtcaaaggaa agaagttcca gaccatccca tttaatgttt atgctttaaa 1020
agcaacatca gagctggatc tagaaatgga agctcttaaa accgtgtata agtcagggga 1080 aacgattgtg gtcacctgtg ctgttttaa caatgaggtg gttgaccttc aatggactta 1140 ccctggagaa gtgaaaggca aaggcatcac aatgctggaa gaaatcaaag tcccatccat 1200
caaattggtg tacactttga cggtccccga ggccacggtg aaagacagtg gagattacga 1260 atgtgctgcc cgccaggcta ccagggaggt caaagaaatg aagaaagtca ctattctgt 1320 ccatgagaaa ggtttcattg aaatcaaacc caccttcagc cagttggaag ctgtcaacct 1380 gcatgaagtc aaacattttg ttgtagaggt gcgggcctac ccacctccca ggatatcctg 1440 gctgaaaaac aatctgact tgattgaaaa tctcactgag atcaccactg atgtggaaaa 1500 gattcaggaa ataaggtatc gaagcaaatt aaagctgatc cgtgctaagg aagaagacag 1560 tggccattat actattgtag ctcaaaattga gattgctgtg aagagctata cttttgaact 1620 gttaactaa gttcctcat ccattctga ctttggaact gattaactaa gttcctcat gattaactaa gttcaccata gctcaactag 1680
 gttaactcaa gttccttcat ccattctgga cttggtcgat gatcaccatg gctcaactgg 1680 gggacagacg gtgaggtgca cagctgaagg cacgccgctt cctgatattg agtggatgat 1740 atgcaaagat attaagaaat gtaataatga aacttcctgg actatttgg ccaacaatgt 1800 ctcaaacatc atcacggaga tccactcccg aggatagata accgtgagg gccgtgtgac 1860
 tttcgccaaa gtggaggaga ccatcgcgt gcgatgcctg gctaagaatc tccttggagc
tgagaaccga gagctgaagc tggtggctcc caccctgcgt tctgaactca cggtggctgc
tgcagtcctg gtgctgttgg tgattgtgat catctcactt attgtcctgg ttgtcatttg
gaaacagaaa ccgaggtatg aaattcgctg gatggctcatt gaatcaatca gcccggatgg
                                                                                                                                                                                                                              1920
                                                                                                                                                                                                                               1980
                                                                                                                                                                                                                               2040
                                                                                                                                                                                                                              2100
 acatgaatat atttatgtgg acccgatgca gctgccttat gactcaagat gggagtttcc 2160 aagagatgga ctagtgcttg gtcgggtctt ggggtctgga gcgtttggga aggtggttga 2220 aggaacagcc tatggattaa gccggtccca acctgtcatg aaagttgcag tgaagatgct 2280 aaaacccacg gccagatcca gtgaaaaaca agctctcatg tctgaactga agataatgac 2340
  tcacctgggg ccacattga acattgtaaa cttgctggga gcctgcacca agtcaggccc catttacatc atcacagagt attgcttcta tggagatttg gtcaactatt tgcataagaa taggggatagc ttcctgagcc accacccaga gaagccaaag aaagagctgg atatctttgg
                                                                                                                                                                                                                               2460
 attgaaccct gctgatgaaa gcacacggag ctatgttatt ttatcttttg aaaacaatgg 2580 tgactacatg gacatgaagc aggctgatac tacacagtat gtccccatgc tagaaaggaa 2640 agaggtttct aaatattccg acatccagag atcactctat gatcgtccag cctcatataa 2700 gaaagaaatct atgtagact cagaaggtcaa actcagatgaa 2760
                                                                                                                                                                                                                               2820
  čctťacttta ttggatťtgt tgagcťtcac ctatcaagtt gcccgaggaa tggagttttt
  ggcttcaaaa aattgtgtc accgtgatct ggctgctcgc aacgtcctcc tggcacaagg 2880 aaaaattgtg aagatctgtg actttggct ggccagagac atcatgcatg attcgaacta 2940 tgtgtcgaaa ggcagtacct ttctgcccgt gaagtggatg gctcctgaga gcatctttga 3000 caacctctac accacatga gtgatgtctg gtcttatggc attctgctct gggagatctt 3060 ttcccttggt ggcacccctt accacggcat gatggtggat tctacttct acaataagat 3120 caagatgggg taccggatgg ccaagcctga cacgctacc agtgaagtct acgagatcat 3180 ggtgaaatgc tggaacagtg agccggagaa gagaccctcc tgagtgagat 3240
   tgtggagaat ctgctgcctg gacaatataa aaagagttat gaaaaaattc acctggactt 3300
  cctgaagagt gaccatcctg ctgtggcacg catgcgtgtg gactcagaca atgcatacat tggtgtcacc tacaaaaacg aggaagacaa gctgaaggac tgggagggtg gtctggatga
  gcagagactg agcgctgaca gtggctacat cattcctctg cctgacattg accctgtccc
                                                                                                                                                                                                                                3480
  tgaggaggag gacctgggca agaggaacag acacagctcg cagacctctg aagagagtgc 3540 cattgagacg ggttccagca gttccacctt catcaagaga gaggacgaga ccattgaaga 3600 catcgacatg atggacgaca tcggcataga ctcttcagac ctggtggaag acagcttcct 3660
                                                                                                                              Page 80
```

```
gtaactggcg gattcgaggg gttccttcca cttctggggc cacctctgga tcccgttcag 3720 aaaaccactt tattgcaatg cggaggttga gaggaggact tggttgatgt ttaaagagaa 3780 gttcccagcc aagggcctcg gggagcgttc taaatatgaa tgaatgggat attttgaaat 3840 gaactttgtc agtgttgcct ctcgcaatgc ctcagtagca tctcagtggt gtgtgaagtt 3900 gaactttgtc agtgttgcct ctcgcaatgc cacagaaggt gaactttgtg cttcaaggac 3960 tggagataga gtccaacaga cacaatttat actgcgacag aacttcagca ttgtaattat 4020 gtgagataga gtccaacaga cacaatttat actgcgacag ctatcttctt togacttcta 4080
                                                                                                                                                                                                                                                    39740-0001PCT.txt
attggtgaga gtccaacaga cacaatttat actgcgacag aacttcagca ttgtaattat 4020 gtaaataact ctaaccaagg ctgtgtttag attgtattaa ctatcttctt tggacttctg 4080 aagagaccac tcaatccatc catgtacttc cctcttgaaa cctgatgtca gctgctgttg 4140 aacttttaa agaagtgcat gaaaaaccat ttttgaacct taaaaggtac tggtactata 4200 acttttgct atcttttta gtgttaagag ataaagaata ataattaacc aaccttgttt 4260 aataagattg ggtcatttag aagcctgaca actcatttc atattgtaat ctatgttat 4320 aatactacta ctgttatcag taatgctaaa tgtgtaataa tgtaacatga tttccctcca 4380 gagaaagcac aatttaaaac aatccttact aagtaggtga tgagtttgac agtttttgac 4440 aattaatat aataacatgt ttctctataa agtatggtaa tagctttagt gaattaaatt 4500 tagttgacaa agtaaaaaqta gtgttgtca qqaaqtcaqa atttttaact 4560
   atttatata aataacatgt ttctctataa agtatggtaa tagctttagt gaattaaatt 4500 tagttgagca tagagaacaa agtaaaagta gtgttgtcca ggaagtcaga atttttaact 4560 tagttgagata ggttcccaa tccatcgtat taaaaaacaa ttaactgccc tctgaaataa 4620 ctagtgctgaa aacaacaaa actcttaagt catgatatatt acccaatgga aaatataatg atcagcaaaa 4740 ctgtgctgaa catacttct catgtatatt tcttcatgc ctgatgaaag ctttggcaac 4800 ctgagaattttttg aatctatgaa cctgaaaagg gtcagaagga tgcccagaca 4860 ctgacaccc tctttcaccc cttacccaa agagaaaagag tttgaaactc gagaccataa 4920 tcagcagcca tctttcaccc cttaccccaa agagaaaagag tttgaaactc gagaccataa 4920 cagagaaccca accctgggt tccatccttg agattctgaa ggatgacatg gattattttctaa acccctggc tgtctcagac ggatgacacca accctgggtt tccatccttg agattctgaa ggatgacatg gaattcaacc acgagagat cctactatt aaccctggc tgtctgatc tgaacattta tgaactttgg gaattcaacc acgagaagt cctactatt aacccttgg tttaaccttgg tttaaccttgg tttaaccttgg tttaaccttgg tttaacctttgg cttcaggtta 5220 gtgacatta atgccatcta acgcaggaag cctactatt tttaactttc cagtcttagc 5280 tttaaccttag gaacacttaa acaggttttc caaaagtaaa gatgctactt 5340 ttgagggctgag aaagctaaag tttggttttg cagaagttttc caaaagtaaa gatgctactt 5340
```

```
39740-0001PCT.txt
cggggcaggg cagggcggct aggccggcca gctcccctt gcccgccagc cagtggccga 600 acccccact ccctgccacc gtcacacagt atttattgtt cccacaatgg ctgggagggg 660 gcccttccag attggggcc ctggggtcc cactcctgt ccatcccag ttgggggctgc 720 gaccgccaga ttctccctta aggaattgac ttcagcaggg gtgggaggct cccagaccca 780 gggcagtgtg gtgggaggg tgttccaaag agaaggcctg gtcagcagag ccgcccccgtg 840 tcccccagg tgctggaggc agactcgagg gccgaattgt ttctagttag gccacgctcc 900 tctgttcagt cgcaaaggtg aacactcatg cggcagcat gggccctctg agcaactgtg 960 g94
  <210> 339
<211> 772
  <212> DNA
   <213> Homo sapiens
<400> 339
agctcgtgcc
gaattcggca cgagccgggt cggagccatg gcggtggcaa attcaagtcc 60
tgttaacccc gtggtgttct ttgatgtcag tattggcggt caggaagttg gccgcatgaa 120
gatcgagctc tttgcagacg ttgtgcctaa gacggccgag aactttaggc agttctgcac 180
cggagaattc aggaaagatg gggttccaat aggatacaaa ggaagcacct tccacagggt 240
cataaaggat ttcatgattc agggtggaga ttttgttaat ggaagtaggta ctggagtcgc 300
cagtatttac cgggggccat ttgcagatga aaattttaaa cttagacact cagctccagg 360
cctgctttcc atggcgaaca gtggtccaag tacaaatggc tgtcagttct tatcacctg 420
ctctaagtgc gattggctgg agaaggtcc aggaagatta ggaaaaatca tcgatggact 480
tctagtgatg agaaagattg agaatgttcc cacaggcccc aacaataagc ccaagctacc 540
tgtggtgatc tcgcagtgtg gggagatgta gtccagacaa agactgaatc aggccttccc 600
tcttctttgg tggtgtttt gggtaaagata atctggactg gcccccgtct ttgcttccct 660
gcctgctgct aggttctac tgtaaataaa gtttttttt
catgaggtca attcaaggcc aggaagcact tccacagggt 240
cagaaatgtcc cacaaatggc tgtcagtct ttacacctg 420
tctagtgatg agaaagattg agaatgttcc cacaggcccc aacaataagc caaagctacc 540
tcttcttgg tggtgtttt gggtaagata atctggactg gcccccgtct ttgcttccct 660
gcctgctgct aggttcaac tgtaaaataaa gtttttttt
attgtcttta agtttcaac tgtaaataaa gtttttttt
   <400> 339
    <210> 340
<211> 919
     <212> DNA
     <213> Homo sapiens
   <400> 340
      taaactatag tcacccgtg
      <210> 341
<211> 7365
      <212> DNA
       <213> Homo sapiens
      ggagttgatc aaggaacctg tctccacaaa gtgtgaccac atattttgca aattttgcat 540 gctgaaactt ctcaaccaga agaaagggcc ttcacagtgt cctttatgta agaatgatat 600
                                                                                                                                                  Page 82
```

```
39740-0001PCT.txt
aaccaaaagg agcctacaag aaagtacgag atttagtcaa cttgttgaag agctattgaa 660 aatcatttgt gcttttcagc ttgacacagg tttggagtat gcaaacagct ataattttgc 720 aaaaaagggaa aataactct ctgaacatct aaaagatgaa gtttctatca tccaaagtat 780
aaaaaaggaa aataactctc ctgaacatct aaaagatgaa gtttctatca tccaaagtat 780 gggctacaga aaccgtgca aaagacttct acagagtgaa cccgaaaatc cttccttgca 840 ggaaaccagt ctcagtgtcc aactctctaa ccttggaact gtgagaactc tgaggacaaa 900 attcttctaacctcaaa agacgtctgt ctacattgaa ttgggatctg aataaggcaa cttattgcag tgtgggagat caagaattgt tacaaatcac 1020 acctcaagga accagggatg aaatcagttt ggattctgca aaaaaaggctg cttgtgaact 1080 attctgagacg gatgtaacaa atactgaaca tcatcaaccc agtaataatg atttgaacac 1140 cactgagaag cgtgcatgtg gagccatgtg gcacaaatac tcatgccagc tcattacagc acgggtagtt ctgcatgtg gagccatgtg gcacaaatac tcatgccagc tcattacagc atgagaacag 1260 cagttatta ccaacagcct ggcttagcaa ggagccaaca taacagatgg gctggaagta aggaacacag 1380 aggagaaaaa gaatggaaaa agaaggaaca tgaaaaggaa ctgagaacct gagaatccta gagaatccta gagaatccta gagaatccta gagaatccta gagaatccta gagaatccta gagatactga 1500 agatgttcct tggataacac taaatagcag cattcagaaa gttaatgagt ggttttccag 1560
```

```
39740-0001PCT.txt
ctacccttcc atcataagtg actcttctgc ccttgaggac ctgcgaaatc cagaacaaag 4740
cacatcagaa aaagcagtat taacttcaca gaaaagtagt gaatacccta taagccagaa 4800
tccagaaggc ctttctgctg acaagtttga ggtgtctgca gatagttcta ccagtaaaaa 4860 taaagaacca ggagtggaaa ggtcatcccc ttctaaatgc ccatcattag atgataggtg 4920 gtacatgcac agttgctctg ggagtcttca gaatagaaac tacccatctc aagaggagct 4980
cattaaggtt gttgatgtgg aggagcaaca gctggaagag tctgggccac acgatttgac 5040 ggaaacatct tacttgccaa ggcaagatct agagggaacc ccttacctgg aatctggaat 5100 cagcctcttc tctgatgacc ctgaatctga tccttctgaa gacagagccc cagagtcagc 5160 tcgtgttggc aacataccat cttcaacctc tgcattgaaa gttccccaat tgaaagttgc 5220 agaatctgcc cagagtccag ctgctgctca tactactgat actgctgggt ataatgcaat 5280
ggaagaaagt gtgagcaggg agaagccaga attgacagct tcaacagaaa gggtcaacaa 5340 aagaatgtcc atggtggtgt ctggcctgac cccagaagaa tttatgctcg tgtacaagtt 5400 tgccagaaaa caccacatca ctttaactaa tctaattact gaagagacta ctcatgttgt 5460
tgccagaaaa caccacatca ctttaactaa tctaattact gaagagacta ctcatgttgt 5460 tatgaaaaca gatgctgagt ttgtgtgta acggacactg aaatatttc taggaattgc 5520 gggaggaaaa tgggtagtta gctatttctg ggtgacccag tctattaaag aaagaaaaat 5580 gctgaatgag catgattttg aagtcagagg agatgtggtc aatgggaagaa accaccaagg 5640 tccaaagcga gcaagagaat cccaggacag aaagatcttc aggggggtag aaatctgttg 5760 tgcttctgtg gtgaaggagc tttcatcatt cacccttggc acaggtgtcc acccaattgt 5820 ggttgtgcag ccagatgcct ggacagagga caatggctc catgcaattg ggcagatgtg 5880 tgaggcacct gtggtgaccc gagagtgggt gttggacagt gtagcactct accaattgt 5840 ggagctggac acctacctga taccccagat ccccacagc cactactgac tgcagccagc 6000 cacaggtaca gagccacag accccaaga tcaactgac aaatggctt tccacagc tgcagccagc 6000 cacaggtaca gagccacag accccaaga tcaactgac aaatggcct tccaagacct tccacagc 6000
cacaggtaca gagccacagg accccaagaa tgagcttaca aagtggcctt tccaggccct 6060 gggagctcct ctcactcttc agtccttcta ctgtcctggc tactaaatat tttatgtaca 6120 tcagcctgaa aaggacttct ggctatgcaa gggtccctta aagattttct gcttgaagtc 6180 tcccttggaa atctgccatg agcacaaaat tattgataatt tttcacctga gaagatttta 6240 aaaccattta aacgccacca attgagcaag atgctgatc attattatc agccctattc 6300 tttctattca ggctgttgtt ggcttagggc tggaagcaca gagtggcttg gcctcaagag 6360 aatagctggt ttccctaagt tacttctct aaaaccctgt gtccacaaag gcagaagtc 6420 aacaccatta aagactgaa aggacgaag aggacgtcaga atcgataag tacaaaag fa480
  agaccettea atggaaggag agtgettggg atcgattatg tgacttaaag teagaatagt 6480
 ccttgggcag ttctcaaatg ttggagtgga acattgggga ggaaattctg aggcaggtat 6540 tagaaatgaa aaggaaactt gaaacctggg catggtggct cacgcctgta atcccagcac 6600 tttgggaggc caaggtgggc agatcactgg aggtcaggag ttcgaaacca gcctggccaa 6660
 catggtgaaa ccccatctct actaaaaata cagaaattag ccggtcatgg tggtggacac 6720 ctgtaatccc agctactcag gtggctaagg caggagaatc acttcagccc gggaggtgga 6780 ggttgcagtg agccaagatc ataccacggc actccagcct gggtgacagt gagactgtgg 6840 ctcaaaaaaa aaaaaaaaaa aggaaaatga aactaggaaa ggtttcttaa agcctgaga 6900
 atatttgcta gatttctaaa gaatgtgttc taaaacagca gaagattttc aagaaccggt 6960 ttccaaagac agtcttctaa ttcctcatta gtaataagta aaatgtttat tgttgtagct 7020 ctggtatata atccattcct cttaaaatat aagacctctg gcatgaatat ttcatatcta 7080 taaaatgaca gatcccacca ggaaggaagc tgttgcttct tttgaggtga ttttttcct 7140 ttgctccctg ttgctgaaac cataccagct cataaataat tttgcttgct gaaggaagaa 7200 aaagtgttt tcataaaccc attatccagg actgttata gctgttgaa ggactaggtc 7260 ttcctagcc cccccagtgt gcaagggcag tgaagacttg attgtacaaa atacgttttg 7320 taaaatgttgt gctgtaaac ctacaaataa acttggaaaca 7365
  taaatgtīgt gctgttāaca ctgcaaataa acttggtagc aaaca
                                                                                                                                                                                                                                                                       7365
   <210> 342
   <211> 10386
   <212> DNA
   <213> Homo sapiens
   <220>
   <221> unsure
<222> (0)...(0)
    <223> n = a, t, c or g
   attgaggact cggaaatgag gtccaagggt agccaaggat ggctgcagct tcatatgatc 60
  attgaggact cggaaatgag gtccaagggt agccaaggat ggctgcagct tcatatgate 60 agttgttaaa gcaagttgag gcactgaaga tggagaactc aaatcttcga caagagctag 120 aagataattc caatcatctt acaaaactgg aaactgaggc atctaatatg aaggaagtac 180 ttaaacaact acaaggaagt attgaagatg aagctatggc ttcttctgga cagattgatt 240 tattagagcg tcttaaagag cttaacttag atagcagtaa tttccctgga gtaaaactgc 300 ggtcaaaaat gtccctccgt tcttatggaa gccgggaagg atctgataca agccgttctg 360 gagagtgcag tcctgttcct atgggttcat ttccaagaag agggtttgta aatggaagca 420 gagaaagtac tggatatta gaagaacttg agaaagagag gtcattgctt cttgctgatc 480 ttgacaaaga agaaaaggaa aaagactggt attccgctca acttcagaat ctcactaaaa 540
                                                                                                                                                      Page 84
```

```
39740-0001PCT.txt
gaatagatag tcttccttta actgaaaatt tttccttaca aacagatatg accagaaggc 600
Page 85
```

39740-0001PCT.txt ttcaggaaaa tgacaatggg aatgaaacag aatcagagca gcctaaagaa tcaaatgaaa 4680 aaccaagtca getgeetgtg tacaaactte taccateaca aaacaggttg caaccecaaa 4920 gťgtaagāaa aaatgcagac tcaāaaaata atttaaatgc tgagagagtt ttctcāgaca 5460 acaaagattc aaagaaacag aatttgaaaa ataattccaa ggacttcaat gataagctcc 5520 caaataatga agatagagtc agaggaagtt ttgcttttga ttcacctcat cattacacgc 5580 ctattgaagg aactccttac tgtttttcac gaaatgattc tttgagttct ctagattttg 5640 atgatgatga tgttgacctt tccagggaaa aggctgaatt aagaaaggca aaagaaaata 5700 atgatgatga tgttgacctt tccagggaaa aggctgaatt aagaaaggca aaagaaaata 5700 aggaatcaga ggctaaagtt accagccaca cagaactaac ctccaaccaa caatcagcta 5760 ataagacaca agctattgca aagcagccaa taaatcgagg tcagcctaaa cccatacttc 5820 agaaacaatc cacttttccc cagtcatcca aagacatacc agacagaggg gcagcaactg 5880 atgaaaagtt acagaatttt gctattgaaa atactccagt ttgcttttct cataattcct 5940 ctctgagttc tctcagtgac attgaccaag aaaccaacaa taaagaaaat gaacctatca 6000 aagagactga gccccctgac tcacagggag aaccaagtaa acctcaagca tcaggctatg 6060 ctctaaatc atttcatgtt gaagataccc cagtttgttt ctcaagaaac agttctctca 6120 cagaaaaaagaa aaagccttca agactcaagg tggtataatga aagaccagatt 6240 tgggtggcat attaggtgaa gatctgacac ttgatttgaa agatatacag agaccagatt 6300 cagaacatgg tctatccct gattcagaaa attttgattg gaagactatt caggaaggtg 6360 tgggtggcat attaggtgaa gatctgacac ttgatttgaa agatatacag agaccagatt 6300 cagaacatgg tctatcccct gattcagaaa attttgattg gaaagctatt caggaaggtg 6360 caaattccat agtaagtagt ttacatcaag ctgctgctgc tgcatgttta tctagacaag 6420 cttcgtctga ttcagattcc atcctttccc tgaaatcagg aatctctctg ggatcaccat 6480 ttcatcttac acctgatcaa gaagaaaaac cctttacaag taataaaggc ccacgaattc 6540 taaaaccagg ggagaaaagt acattggaaa ctaaaaagat agaatctgaa agtaaaggaa 6600 tcaaaggagg aaaaaagtt tataaaagtt tgattactgg aaaagttcga tctaattcag 6660 aaattcagg ccaaatgaaa cagccccttc aagcaaacat gccttcaatc tctcgaggca 6720 ggacaatgat tcatattcca ggagttcgaa atagctcctc aagtacaagt cctgtttcta 6780 aaaaaggccc accccttaag actccagct ccaaaagccc tagtgaaggt caaacagcca 6840 ăăaaaggčcc accccttaag ăctccagcct ccaăaagccc tagtgaaggt caaacagcca 6840 ccacttctcc tagaggagcc aagccatctg tgaaatcaga attaagcct gttgccaggc 6900 agacatccca aataggtggg tcaagtaaag caccttctag atcaggatct agagattcga 6960 cccttcaag acctgccag caaccattaa gtagacctat acagtctcct ggccgaaact 7020 caatttccc tggtagaaat ggaataagtc ctcctaacaa attatctcaa cttccaagga 7080 catcatcccc tagtactgct tcaactaagt cctcaggttc tggaaaaatg tcatatacat 7140 ctccaggtag acagaaggt caacagaacc taacaaaca aacaggtta tcaaagaacc 7260 ccagtagtat tccaagaagt gagtctgcct ccaaaggact aaatcagatg aataatggta 7260 attgagccaa taaaaaggta gaactttcta gaatgtcttc aactaaatca agtggaagtg 7320 aatctgatag atcagaaaga cctgtattag tacgccagtc aactttcatc aaagaagctc 7380 caagcccaac cttaagaaga aaattggagg aatctgcttc atttgaatct ctttctccat 7440 catctagacc agcttctcc actaggtccc aggcacaaac tccagtttta agtccttccc 7560 cacctaatct cagtcccact atagagtata atgatggaag accagcaaag cgccatgata 7620 ttgcacggtc tcattctgaa agtccttcta gacttccaat caataggtca ggaacctgga 7680 aacgtgagca cagcaaacat tcatcatcc ttcctgagt aagacacta 7740 aacgtgagca cagcaaacat tcatcatccc ttcctcgagt aagcacttgg agaagaactg 7740 gaagttcatc ttcaattctt tctgcttcat cagaatccag tgaaaaagca aaaagtgagg 7800 atgaaaaaca tgtgaactct atttcaggaa ccaaacaaag taaagaaaac caagtatccg 7860 caaaaggaac atggagaaaa ataaaagaaa atgaatttc tcccacaaat agtacttctc 7920 agaccgtttc ctcaggtgct acaaatggtg ctgaatcaaa gactctaatt tatcaaatgg 7980 cacctgctgt ttctaaaaca gaggatgttt gggtgagaat tgaggactgt cccattaaca 8040 atcctagatc tggaagatct cccacaggta atactcccc ggtgattgac agtgtttcag 8100 aaaaggcaaa tccaaacatt aaagattcaa aagataatca ggcaaaacaa aatgtgggta 8160 atggcagtgt tcccatgcgt accgtgggtt tggaaaatcg cctgaactcc tttattcagg 8220 tggatgccc tgaccaaaaa ggaactgaga taaaaccagg acaaaataat cctgtccctg 8280 tatcagagac taatgaaagt tctatagtgg aacgtaccc attcagttct agcagctcaa 8340 gcaaacacag ttcacctagt gggactgttg ctgccagagt gactcctttt aattacaacc 8400 caagccctag gaaaagcagc gcagatagca cttcagctcg gccatctcag atcccaactc 8460 cagtgaataa caacacaaag aagcgagatt ccaaaactga cagcacagaa tccagtggaa 8520 cccaaagtcc taagcgccat tctgggtctt accttgtgac atctgttaa aagagagggaa 8580 gaatgaaact aagaacata taagttctaa aagaacttta aagaacttta aagagacttaa aagaacttta aagagacttaa aagaacttta aagagacttta aagagacttta aagagacttta aagagacttta aagagacttaa aagagactta aagagactta aagagacttaa aagagactta aagagactta aagagacttaa aagagacttaa aagagactta aagagacttaa aagagactta aagag tgaaacttta aaagactgaa aaattttgta aataggtttg attcttgtta gagggttttt 8700 Page 86

```
<210> 343
<211> 2191
<212> DNA
<213> Homo sapiens
```

```
tcatgactga acagtcaccg acgagagtgc tgggggaataa aaagggggatc ttcactcggc 1860 agagacaacc aaaaagtgca gcgttccttt tgcgagagag atactggaag attgccaatg 1920 aaaccaggta tcccactca gtagccaagt cacaatgttt ggaaaacagc ccgtttactt 1980 gagcaagaca gtgcctcctt gcgtgtccct tcctcccga gtcagggcga cttccacagc 2040 agcagaacaa gtgcctcctg gactgttcac ggcagaccag aacgtttctg gcctgggttt 2100 tgtggtcatc tattctagca gggaacacta aaggtggaaa taaaagattt tctattatgg 2160 aaataaagag ttggcatgaa agtcgctact g
  aāatāaagag ttggcatgaa agtcgctact g
  <210> 344
  <211> 2776
   <212> DNA
   <213> Homo sapiens
 <400> 344
cagggcagac tggtagcaaa gccccacgc ccagccagga gcaccgccgc ggactccagc 60 acaccgaggg acatgctggg cctgcgccc ccactgctcg ccctggtggg gctgctctcc 120 ctcgggtgcg tcctctca ggagtgcacg aagttcaagg tcagcagctg cccgggaatgc 180 accgagtcgg ggcccggctg cacctggtgc cagaagctga acttcacagg gccgggggat 240 cctgactcca ttcgctgca cacccggcca cagctgctca tgagggggtg tgcggctgac 300 gacatcatgg accccacaag cctcgctgaa acccaaggaag accacaatgg gggccagaaag 360 cagctgtcc cacaaaaagt ggcgctttac ctgcgaccag gccaggcagc agcgttcaac 420 ggggccacctcc ggcgggccaa ttgatgacct caggaatgtc aagaagctag gtggcgacct gctccgggcc 540 ctcaacgaga tcaccgagca ccctgataaa cctgcgaacc catgccccaa caaggagaaa 660
  <400> 344
  ctcaacgaga tcaccgagtc cggccgcatt ggcttcgggt ccttcgtgga caagaccgtg 600 ctgccgttcg tgaacacgca ccctgataag ctgcgaaacc catgcccaa caaggagaaa 660 gagtgccagc ccccgtttgc cttcaggcac gtgctgaagc tgaccaacaa ctccaaccag 720 ctggacgcca tgatgcaggt cgccgctgc ccggagaacc tggatgcacc cgagggtggg 780 ctggacgcca tgatgcagc cgccgctgc ccggagaaacc tcggctggcg caacgtcacg 840 cggctgctgg tgttgccac tgatgacgc ttccatttcg cgggcgacgg aaagctgggc 900 gccatcctga ccccaacga cggccgctgt cacctggagg acaacttgta caagaggagc 960 aacgaatcg actacccatc ggtgggccag ctggcgcaca agctggctga aaacaacatc 1020 cagcccatct tcgcggtgac cagtaggatg gtgaagacct acgagaaact caccgagatc 1080 atccccaact cagccgtgaa caacttgta caacgagatc 1140
   cagcccatct tcgcggtgac cagtaggatg gtgaagacct acgagaaact caccgagatc 1080 atcccaagt cagccgtggg ggagctgtct gaggactcca gcaatgtggt ccatctcatt 1140 aagaatgctt accataga ctcctccagg gtcttcctgg atcacaacgc cctccccgac 1200 accctgaaag tcacctacga ctccttctgc agcaatggag tgacgcacag gaaccagccc 1260 agaggtgact gcaccagga gcagatcaat gtcccgatca ccttccaggt gaaggtcacg 1320 gcaccaggag gcatccagga gcatccagga gcagtcgttt gtcatccggg cgctgggctt cacggacata 1380 gtgaccgtgc aggtcttcc ccagtgtgag tgccggtgc gggaccagag cagagaccgc 1440 atggcaagg cttcttggag tgcggcatct gcaggtgtga cactggctac 1500 attggaaaa actutgagt ccagacaca ggcccagag ccagagaccg 1560
     attgggaaaa actgtgagtg ccagacacag ggccggagca gccaggagct ggaaggaagc 1560 tgccggaagg acaacaactc catcatctgc tcagggctgg gggactgtgt ctgcgggcag 1620 tgcctgtgc acaccagcga cgtccccggc aagctgatat acgggcagta ctgcgagtgt 1680 gacaccatca actgtgagcg ctacaacggc caggtctgcg gcggcccggg gagggggctc 1740 gacactacaggc ctgccccg cgctttgagg gctcagcgtg ccagtggag 1800
    tcagggtata aaatgacatc ccattaatta tattgttaat caatcacgtg tatagaaaaa 2760
        aaaataaaac ttcaat
          <210> 345
         <211> 3160
          <212> DNA
          <213> Homo sapiens
         <400> 345
```

```
<210> 346
<211> 2629
        <212> DNA
         <213> Homo sapiens
       acttgtcatg gcgactgtcc agctttgtgc caggagcctc gcaggggttg atgggattgg 60 ggttttcccc tcccatgtgc tcaagactgg cgctaaagt tttgagcttc tcaaaagtct 120 agagccaccg tccaggagc aggtagctgc tgggctccgg ggacactttg cgttcgggct 180 gggagcgtgc tttccacgac ggtgacacgc ttccctggat tggcagcag actgccttcc 240 gggtcactgc catggaggag ccgcagtcag acctatgcg catgagacac cgtcagcag acctatgcg aaactattc agacctatgg aaactacttc ctgaaaacaa cgttctgtcc cccttgccgt 360 acccaaggaat ggatgattt atgatgatta atgctatccc cggacgatat tggaacaatgg ttcactgaag 420
         <400> 346
         cccaagcaat ggatgatttg atgctgtccc cggacgatat tgaacaatgg ttcactgaag 420 acccaggtcc agatgaagct cccagaatgc cagaggctgc tccccgcgtg gcccctgcac 480
                                                                                                           Page 89
```

```
39740-0001PCT.txt
cagcagetee tacaceggeg geeeetgeac cageeeecte etggeeeetg teatettetg 540 teeetteeca gaaaacetae cagggeaget aeggtteeg tetgggette ttgcattetg 600
 ggacagccaa gtctgtgact tgcacgtact cccctgccct caacaagatg ttttgccaac 660
tggtgcccta tgagccgcct gaggttggct ctgactgtac caccatccac tacaactaca 960 tgtgtaacag ttcctgcatg ggcggcatga accggaggcc catcctcacc atcatcacac 1020 tggaagactc cagtggtaat ctactgggac ggaacagctt tgaggtggct gtttgtgcct 1080 gtcctgggag agaccggcgc acagaggagag agaatctccg caagaaaggg gagcctcacc 1140 acgagctgcc cccagggagc actaagcgag cactgcccaa caacaccagc tcctctcccc 1200 gcttcgagat gttccgagag ctgaatgagg ccttggaact caaggatgcc tggggtgagc 1260 gcttcgagat gttccgagag ctgaatgagg ccttggaact caaggatgcc caggctggga 1320 aggagccagg gggagcagg gctcactcca gccactgaa gtccaaaaag ggtcagtcta 1380 cctcccgcca taaaaaactc atgttcaaga cagaagggcc tgactcagac tgacattctc 1440 cacttcttgt tccccactga aggcctccc acccct gccattttgg 1500
cattettgt tececatga cagettecca eccecatete teceteecet gecattetgg 1500 gttttgggte tttgaaceet tgettgeaat aggtgtgegt cagaageace caggaettee 1560 atttgettg teceggget ecaetgaaca agttggeetg caetggtgt ttgttgtggg 1620 gaggaggatg ggagtagga cataceaget tagatttaa ggttttaet gtgagggatg 1680 tttgggagat gtaagaaatg ttettgeagt taagggtag tttacaatea gecacattet 1740 aggtaggtag gggeecaett eaecgtaeta accagggaag etgteectea tgttgaatt 1800 tetetaactt eaaggeecat atetggaaa tgetggeatt tgeacetaee teaeagagtg 1860 cattgtgaag gttaatgaaa taatgtaeat etggeectta aaecaecttt taatgaatg 1920
cattgtgagg gttaatgaaa taatgtacat ctggccttga aaccaccttt tattacatgg 1920 ggtctaaaac ttgacccct tgagggtgcc tgttcctct ccctctcct gttggctggt 1980 gggttggtag ttctacagt tgggcagctg gttaggtaga gggagttgt aagtcttgct 2040 ggcccagcca aaccctgtct gacaacctct tggtcgacct tagtacctaa aaggaaatct 2100
ggcccagcca aaccctgtct gacaacctct tggtcgacct tagtacctaa aaggaaatct 2100 caccccatcc cacaccctgg aggattcat ctcttgtata tgatgatctg gatccaccaa 2160 gacttgttt atgctcaggg tcaatttctt tttttttt tttttttt tttcttttt 2220 tttgagactg ggtctcgctt tgttgcccag gctggagtgg agtggcgtga tcttggctta 2280 ctgcagcctt tgcctcccg gctcgagcag tcctgcctca gcctccggag tagctgggac 2340 cacaggttca tgccaccatg gccagccaac ttttgcatgt tttgtagaga tggggtctca 2400 cagtgttgcc caggctggtc tcaaactcct gggctcaggc gatccacctg tctcagcctc 2460 ccagagtgct gggattacaa ttgtgagcca ccacgtggag ctggaagggt caacatcttt 2520 tacattctgc aagcacatct gcatttcac cccacccttc ccctcttct ccctttttat 2580 atcccattt tatatcgatc tcttattta caataaaact ttgctgcca
  <210> 347
   <211> 3442
   <212> DNA
   <213> Homo sapiens
   <400> 347
  agccggtgcg ccgcagacta gggcgcctcg ggccagggag cgcggaggag ccatggccac 60 cgctaacggg gccgtggaaa acgggcagcc ggacgggaag ccgccggccc tgccgcgcc 120 catccgcaac ctggaggtca agttcaccaa gatatttatc aacaatgaat ggcacgaatc 180
   caagagtggg aaaaagtttg ctacatgtaa cccttcaact cgggagcaaa tatgtgaagt 240
 gaagagtggg addadgtitg clacifyldd citticadit cygydycadd targryddy 240 ggaagaagga gataagcccg acgtggacaa ggctgtggag gctgcacagg ttgccttcca 300 gaggggctcg ccatggcgc ggctggatgc cctgagtcgt gggcggctgc tgcaccagct 360 ggctgacctg gtggagaggg accgcgccac cttggccgcc ctggagacga tggatacagg 420 gaagccatt cttcatgctt ttttcatcga cctggagggc tgtattagaa ccctcagata 480 cttgcaggg tgggcagaca aaatccaggg caagaccacc cccacagatg acaacgtcgt 540 atgctcacc aggcatgaga caatgggc cattggggcc atcactccat ggaacttccc 600 acctgctatag ctggtggaga acctagaga acctggacc cgccctctag tggggaaca ccatggtct 660
  cctgctgatg ctggtgtgga agctggcacc cgccctctgc tgtggggaca ccatggtcct 660 gaagcctgcg gagcagacac ctctcaccgc cctttatctc ggctctctga tcaaagaggc 720 cgggttccct ccaggagtgg tgaacattgt gccaggattc gggcccacag tgggagcagc 780 aatttcttct caccctcaga tcaacaagat cgccttcacc ggctccacag aggttggaaa 840
  actggttaaa gaagctgcgt cccggagcaa tctgaagcgg gtgacgctgg agctgggggg 900 gaagaacccc tgcatcgtgt gtgcggacgc tgacttggac ttggcagtgg agtgtgccca 960 tcagggagtg ttcttcaacc aaggccagtg ttgcacggca gcctccaggg tgttcgtgga 1020 ggagcaggtc tactctgagt ttgcaagga gagcgtggag tatgccaaga aacggcccgt 1080
   gggagacccc ttcgatgtca aaacagaaca ggggcctcag attgatcaaa agcagttcga 1140
  caaaatctta gagctgatcg agagtgggaa gaaggaaggg gccaagctgg aatgcggggg 1200 ctcagccatg gaagacaagg ggctcttcat caaacccact gtcttctag aagtcacaga 1260 caacatgcgg attgccaaag aggagattt cgggccagtg caaccaatac tgaagttcaa 1320 aagtatcgaa gaagtgataa aaagagcgaa tagcaccgac tatggactca cagcagccgt 1380
   gticacaaaa aatctcgaca aagccctgaa gttggcttct gccttagagt ctggaacggt 1440 ctggatcaac tgctacaacg ccctctatgc acaggctcca tttggtggct ttaaaatgtc 1500
                                                                                                                                                   Page 90
```

```
<210> 348 <211> 737
     <212> DNA
     <213> Homo sapiens
     ggagtttcgc cgccgcagtc ttcgccacca tgccgcccta caccgtggtc tatttcccag 60 ttcgaggccg ctgcgcggcc ctgcgcatgc tgctggcaga tcagggccag agctggaagg 120
    <210> 349
<211> 5189
      <212> DNA
       <213> Homo sapiens
      atggccaagt cgggtggctg cggcgcggga gccggcgtgg gcggcggcaa cggggcactg 60 acctgggtga acaatgctgc aaaaaaagaa gagtcagaaa ctgccaacaa aaatgattct 120
      acctgggtga acaatgctgc adadadagad yayttayada tiyttadaa acacatttt 180 tcaaagaagt tgtctgttga gagagtgtat cagaagaaga cacaacttga acacattctt 180 tctcgtctg atacatatat tgggtcagtg gagccattga cgcagttcat gtgggtgtat 240 gagaagaagatg taggaatgaa tttgcagggag gttacctttg tgccaggttt atacaagatc 300 ttgatgaagaa ttttggttaa tgctgctgac aataaacaga gggataagaa catgacttgt 360 tgaatctaac attataagca tttggaataa tgggaaaggc 420 attccagtag tagaacacaa ggtagagaaa gtttatgttc ctgctttaat ttttggacag 480
                                                                                Page 91
```

```
39740-0001PCT.txt
cttttaacat ccagtaacta tgatgatgat gagaaaaaag ttacaggtgg tcgtaatggt 540 tatggtgcaa aactttgtaa tattttcagt acaaagttta cagtagaaac agcttgcaaa 600 gaatacaaac acagtttaa gcagacatgg atgaataata tgatgaagac ttctgaagcc 660 aaaattaaga atttgatgg tgaagatta acatgcataa cattccaacc agatctgtcc 720 aaatttaaga tgaaaaaact tgacaaggat attgtggccc tcatgactag aagggcatat 780
ctcttctaa actcagacaa tgaaagatct ataccatctc ttgttgatgg ctttaaacct 2220 ggccagcgga aagtttatt tacctgtttc aagaggaatg ataaacgtga agtaaaagtt 2280 gcccagttgg ctggctctgt tgctgagatg tcggcttatc atcatggaga acaagcattg 2340 atgatgacta ttgtgaattt ggctcagaac tttgtgggaa gtaacaacat taacttgctt 2460 cagcctattg gtcagtttgg aactcggctt catggtggca aagatgctgc aagcctcgt 2460 ctcttaagt tcctttatga cactttagca cgtgtagagc ctgagtggta tattcctata 2580 attcccatgg ttttaataaa tggtgctgag ggcattggta ctggatggcc ttgtaaacta 2640 cccaactatg atgctaggag aattgtggaac aattgtcagac gaatgctaga tggcctggat 2700 cctcatcca tgcttccaaa ctacaaaaac tttaaaaggca cgattcaaga acttggtcaa 2760
 cctcatccca tgcttccaaa ctacaaaaac tttaaaggca cgattcaaga acttggtcaa 2760
                                                                                                              Page 92
```

```
tcagaatttg gcattccaaa gaagactaca acaccaaaag gtaaaggccg aggggcaaag 4620 aaaaggaaag catctggctc tgaaaatgaa ggcgattata accctggcag gaaaacatcc 4680 aaaacaacaa gcaagaaacc gaagaagaca tcttttgatc aggattcaga tgtggacatc 4740 gaagaagaaaa attttgcaga gtctgatgaa gaagaagatg atgttgattt tgcaatgttt 4860 gaagtaaaat attttgcaga gtctgatgaa gaagaagatg atgttgattt tgcaatgttt 4860 aattaagtgc ccaaagagca caaacattt tcaacaaata tcttgtgttg tccttttgtc 4920 tcttttattat tgtggtaggc ttttaacat tttgttctta cacatacagt tttatgcctc 5040 tttttactca tgaaaatgt acgtactgtc tgattggctt gtagaattgt tatagactgc 5100 cgtgcattag cacagatttt acatcagg gtaaaacat acaccaaaag acccggtcg gaaccaggtag 4980 tttttactca tgaaaatgt acgtactgtc tgattggctt gtagaattgt tatagactgc 5100 cgtgcattag cacagatttt acatcagg gtacaaaca acagacctgc tttttgaaca acagacctgc ttttttgaaca 5160 s189
                                                                                                                   39740-0001PCT.txt
   gaaatttaaa cattaaaaat ggaactgtg
   <210> 350
   <211> 1536
    <212> DNA
    <213> Homo sapiens
   <400> 350
ggggggggggg ggaccacttg gcctgcctcc gtcccgccgc gccacttggc ctgcctccgt 60
ggggggggggg ggaccacttg gcctccgtc cccgccgcc gcgccatgcc tgtggccgc 120
ccgccgcgc cacttcgcct gcctcccc gccgcacagg agcgggacgc cgagccgcgt 180
ccgccgcacg gggagctgca gtacctgggg cagatccaac acatcctccg ctgcggcgtc 240
aggaaggacg accgcacggg caccggacc ctgtcggtat tcggcatgca ggcgcgctac 300
agcctgagag atgaattcc tctgctgaca accaaacgtg tgttctggaa gggtgttttg 360
gaggagttgc tgtggttat caagggatcc acaaatgcta aagagctgtc ttccaaggga 420
graaaaatct gggatgcaa tggatcccaa tggatcccaa gactttttga acaacctaga attctccacc 480
   <210> 351
<211> 2386
         <212> DNA
          <213> Homo sapiens
       gcatatcaga gctttgaaca ggatactttt gtggaactct atgggaacaa tgcagcagcc 780 gagagccgaa agggccagga acgcttcaac cgctggttcc tgacgggcat gactgtggcc 840 ggcgtggttc tgctgggctc actcttcagt cggaaatgac cagacactga ccatccactc 900
                                                                                                                                              Page 93
```

```
39740-0001PCT.txt
taccetecca ecceptete tgetecacca catectecgt ecageegeca ttgecaccag 960
<211> 1270
 <212> DNA
 <213> Homo sapiens
aaaaaaaaaa
  <210> 353
  <211> 1600
  <212> DNA
  <213> Homo sapiens
  gccccgccgc cggcagtgga ccgctgtgcg cgaaccctga accctacggt cccgacccgc 60 gggcgaggcc gggtacctgg gctgggatcc ggagcaagcg ggcgagggca gcgcctaag 120 caggcccgga gcgatggcag ccttgatgac cccgggaacc ggggccccac ccgcgcctgg 180 tgactctcc ggggaaggga gccagggact tcccgaccct tcgccagagc ccaagcagct 240 tgactctcc ggggaaggga gccagggact aggcgaccta aggcagagc acatcaggga 300
  cccggagctg atccgcatga agcgagacgg aggccgcctg agcgaagcgg acatcagggg cttcgtggcc gctgtggtga atgggagcgc gcagggcgca cagatcgggg ccatgctgat
  ggccatccga cttcggggca tggatctgga ggagacctcg gtgctgaccc aggccctggc 420
                                               Page 94
```

```
tcagtcggaa cagcagctgg agtggccaga ggcctggcgc cagcagcttg tggacaagca 480 tccacaggg gtgtgggtg acaaggtcag cctggtcctc ggacctgcc tggcggcaag gtgccaatga tcagcggacg tggtctgggg cacacaggag gcaccttggacgc cagcagcagag tcgggccagag tcagcaggacg tggtctgggg cacacaggag gcaccttggacgagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagagacacagaacacagagagacacagaacacagagagacacagaacacagagagacacagagacacagaacacagagagacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagaacacagacacagaacacagacacagaacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacacagacacagacacagacacagacacagacacagacacagacacagacacagacacagacacacagacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacagagacacacacagacacacagacacacagacacacagacacagacacacagacacagacacacagacacagacacacagacacagacacacagacacagacacagacacagacacacagacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacacagacacagacacacagacacagacacagacacagacacacagacacagacacagacagacacacagacacagacacacagac
                  <210> 354
                   <211> 1842
                    <212> DNA
            <400> 354
cgatcagatc
cggatacagat
ataacatc
aagaggagaaa
aacggaatct
aagaggagaa
aacggaatct
aacaggagga
attagacatc
cccttacagaa
cacttggcaag
ccttacagaa
ccttgacaacc
aagatggta
aatacactga
aagaggagaa
attacacttga
aagaggagat
attagactggta
tigagcctat
attacattga
acaacagca
gagacgaagt
ctgtgcctta
aattacattga
acaacagca
gagacgaagt
ctgtgtgcta
aattacattga
acaacagca
gagacgaagt
ctgtgtgcta
attacattga
acaacagca
gagacgaagt
ctgtgtgcta
attacattga
acaacagca
gagacgaagt
ctgtgtgcta
attacattga
acaacagca
gagacgaagt
ctttgatgat
aattacattga
gctgttacac
attagggag
gctgttacac
attgttgttt
aagaagacac
gatttgggagaa
ttccacgc
tttgttgttt
aagaagacac
gatttggtga
attagagga
gctgttacac
attgttgttt
agagaccacaa
ttccatctta
aggttcattt
tttttttt
aggtacacatc
cccagaacca
attgttcatt
attacattta
aggtttgaaa
tggtttgaaa
tggtttgaaa
tggttgaaa
tggtagaagaa
aaagaggagaa
ttaaaaggga
gagaaaaaca
aaggggagaa
ttaaagggagaa
taacatgga
gagaaaaaca
aacagggagaa
gacaccgac
gactcgatc
gactcgatc
gactcgatc
gactcgatc
gacttggac
ctgatatgga
aacaggagaa
acaagggagaa
acaaggagaa
gacaaaaca
gagagaaaa
aatgggaaaa
aacaggagaa
gacacagac
gactcgatc
gactcgatc
gactcgatc
gactcgatc
gactcgatc
gactcgatc
gactggat
tggaaaggta
acaagggagaa
gacaaggta
gacaaggag
gacaaggta
ataggagaa
gacaggta
gactcgac
gactcgatc
gactcgatc
gactcgatc
gactaggag
gactgctc
cccagaacac
gactaagggag
gactacagag
gactaggta
ataggagag
gacacagt
gacaaggag
gacactgat
tccactgat
atagggagag
gactacagag
gactaggaa
gactaggaa
gactaggaa
gactaggaa
gactaggaa
gactaggaa
gactaggaa
gacaggaga
gacaggta
cctaaaagggag
gactccacaa
aagctggaag
gactacaaa
tggttgata
tgggaaaaca
gacagtagaa
tcctaaaa
tggttgaaca
cctaggaagat

                    <213> Homo sapiens
                                ataaaatyiy tatayiyaat tyittiay ataatiayat tigittii attittiat 1000 ctttatagaa ggaattigta cttcttattg caggcaagtc tctatattat gtcctctttt 1740 gtggtgtctt ccatgtgaac agcataagtt tggagcacta gtttgattat tatgtttatt 1800 acaatttta ataaattgaa taggtagtat catatatatg ga
                                     <210> 355
                                     <211> 4975
                                      <212> DNA
                                       <213> Homo sapiens
                                      ctctcacaca cacacaccc tccctgcca tccctcccg gactccggct ccggctccga 60 ttgcaatttg caacctccgc tgccgtcgcc gcagcagcca ccaattcgcc agcggttcag 120
                                       gtggctcttg cctcgatgtc ctagcctagg ggcccccggg ccggacttgg ctgggctccc 180
Page 95
```

```
39740-0001PCT.txt
ttcaccctct gcggagtcat gagggcgaac gacgctctgc aggtgctggg cttgcttttc 240
gattatgcag ccatgggggc ctgcccagca tctgagcaag ggtatgaaga gatgagagct 4080 tttcaggggc ctggacatca ggcccccat gtccattatg cccgcctaaa aactctacgt 4140 agcttagagg ctacagactc tgcctttgat aaccctgatt actggcatag caggcttttc 4200 cccaaggcta atgcccagag aacgtaactc ctgctccctg tggcactcag ggagcattta 4260
                                                Page 96
```

```
39740-0001PCT.txt
  <210> 356
<211> 4627
  <212> DNA
  <213> Homo sapiens
 tcacttgct gatatttcca gtgtcagagg gacacagcca acgtggggtc ccttctaggc 60 tgacagccgc tctccagcca ctgccgcgag cccgtctgct cccgccctgc ccgtgcactc 120
     gtcatttggt gctctgctaa ccatttatat aaaacttaaa aacaagagaa aagaaaaatc 2460
     gtcatttggt gctctgctaa ccatttatat aaaacttaaa aacaagagaa aagaaaaatc 2460 aattagatct aaacagttat ttctgttcc tatttaatat agctgaagtc aaaatatgta 2520 agaacacatt taaatactc tacttacagt tggccctctg tggttagtc cacatctgtg 2580 gattataacaa ccaaggacg gaaaatgctt aaaaaaataat acaacaacaa caaaaaatac 2640 attataacaa ctatttactt tttttttt ctttttgaga tggagtctcg ctctgttgcc 2700 aggttggag tgcagtggca cgatctcggc tcactgcaac ctcacctccc gggttcaaga 2760 aggactccctg cctcagcctc ctgagcagct gggactacag gcgcatgcca ccatgcccag 2820 agagcttttggccagga tggtctcaat 2880 ctcctaacct tgagatccac cctccacagc ccccaaact gctgggatta caggcgtgag 2940 Page 97
```

<210> 357 <211> 2634 <212> DNA <213> Homo sapiens

```
39740-0001PCT.txt
atgaattatg tgaatgccca gagttacttg gatcagcatt taggaaagta aaatatagtg 1980 gaagtaaaac tgactcatcc aactagacat tctacagaaa gaaaaatgca ttattgacga 2040 actggctaca gtaccatgcc tctcagcccg tgtgtataat atgaagacca aatgatagaa 2100 ctgtactgtt ttctggccca atgaccaga aattgattaa aggattacttt tctggccca atgaccaga aattgattaa aggattacttt tctggccca atgaccaga aattgattaa aggattacttt
 actygical glaciatyce celeagecy tytgialaat algaayacta aatyalayaa 2100 ctgtactgtt teetgggcca gtgagccaga aattgattaa ggetteettt ggtaggtaaa 2160 teragagttt atacagtgta catgtacata gtaaagtatt tegattaac aatgtattt 2220 aataacatat etaaagtcat catgaactgg cetgtacatt tetaaattee tacteeggag 2280 caacetactg tetaagcagt tegataaatg teetgaaat tgtacaatac tegateca 2340 gagttaaaat gettacegta aatteegt eestaattee tegetaatte teetetgea teetgeagaattee eestaaleeggaattee eestaaleeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteeggaatteegga
  tgtctacatt aaatcacttg aatccattga aagtgcttca agggtaatct tgggtttcta 2520 gcaccttatc tatgatgtt cttttgcaat tggaataatc acttggtcac cttgccccaa 2580 gctttcccct ctgaataaat acccattgaa ctctgaaaaa aaaaaaaaa 2634
    <210> 358
     <211> 1246
     <212> DNA
      <213> Homo sapiens
  1080
                                                                                                                                                                                                                                                                                                                    1140
                                                                                                                                                                                                                                                                                                                   1200
                                                                                                                                                                                                                                                                                                                     1246
         ttgatacata ataaaaaatt atgacaatgt caaaaaaaaa aaaaaa
         <210> 359
<211> 2360
          <212> DNA
           <213> Homo sapiens
        tccgatggta tctgggtaag aagaaagcaa aagcaaggga ccttcatgcc cttctgattc 1140 ccctccacca aaccccactt cccctcataa gtttgttaa acacttatct tctggattag 1200 aatgccggtt aaattccata tcctccaca tcttcaga tctttaacta
              aatgccggtt aaattccata tgctccagga tctttgactg aaaaaaaaa agaagaagaa 1260
                                                                                                                                                                                      Page 99
```

```
39740-0001PCT.txt
 gaaggagagc aagaaggaaa gatttgtgaa ctggaagaaa gcaacaaaga ttgagaagcc 1320 atgtactcaa gtaccacaa gggatctgcc attgggaccc tccagtgctg gatttgatga 1380 gttaactgtg aaataccaca agcctgagaa ctgaattttg ggacttctac ccagatggaa 1440 aaataacaac tattttgtt gttgttgttt gtaaatgcct cttaaattat atatttattt 1500
ataaaaaaaa aaaaaaaaaa
     <210> 360
<211> 1433
       <212> DNA
       <213> Homo sapiens
  <210> 361
          <211> 1632
          <212> DNA
          <213> Homo sapiens
          <400> 361
          gccggccgaa cccagacccg aggttttaga agcagagtca ggcgaagctg ggccagaacc 60 gcgacctccg caaccttgag cggcatccgt ggagtgcgcc tgcgcagcta cgaccgcagc 12
          aggaaagcgc cgccggccag gcccagctgt ggccggacag ggactggaag agaggacgcg 180 gtcgagtagg tgtgcaccag ccctggcaac gagagcgtct accccgaac ctgctggcct 240 tgaggtggg aagccgggag gggcggtga acaggttta acactgaat ctacatca 360 cgggcaggc agcctcgag ccgggtggac acaggttta aaacatgaat cctacactca 360 cgggcaggcc cttttacac cttttacac cacactac cacactac
          tccttgctgc cttttgcctg ggaattgcct cagctactct acatttgat cacagtttag 420 aggcacagtg gaccaagtgg aaggcgatgc acaacagatt atacggcatg aatgaagaag 480 gatggaggag agcagtgtgg gagaagaaca tgaagatgat tgaactgcac aatcaggaat 540 acagggaagg gaaacacagc ttcacaatgg ccatgaagacg ctttggagac atgaccagtg 600 aagaattcag gcaggtgatg aatggctttc aacatttgat cacagtttag 420 cacagggaaggatg acaacagatt atacggcatg aatcaggaat 540 acaacaggaat ccatgaagacg ctttggagac atgaccagtg 660
                                                                                                                                                                                                                    Page 100
```

```
39740-0001PCT.txt
tccaggaacc tctgttttat gaggccccca gatctgtgga ttggagagag aaaggctacg
atttcaaatg ta
<210> 362
<211> 2756
<212> DNA
<213> Homo sapiens
1020
                               1080
 tcatattgag gggcaactcc agaagtggag ttttctgtga gaataaagca tttcaccttt 2640
```

Page 101

```
39740-0001PCT.txt
<210> 363
<211> 2768
<212> DNA
<213> Homo sapiens
gattggtc
 <210> 364
<211> 2984
 <212> DNA
 <213> Homo sapiens
 <400> 364
 gaggaggaac agaaaagaaa agaaaagaaa aagtgggaaa caaataatct aagaatgagg 60
 gaygaygaac ayaaaayaaa ayaaaayaaa aagtyyggaa caattattt aagaatgagy 00 agaaagcaag aagagtgacc cccttgtggg cactccattg gttttatggc gccttactt 120 tctggagttt gtgtaaaaca aaaatattat ggtctttgtg cacattaca tcaagctcag 180 cctgggcggc acagccagat gcgagatgcg tctctgctga tctgagtctg cctgcagcat 240
 ggacctgggt cttccctgaa gcatctccag ggctggaggg acgactgcca tgcaccgagg 300
                                  Page 102
```

```
39740-0001PCT.txt
 gctcatccat ccacagagca gggcagtggg aggagacgcc atgaccccca tcctcacggt 360
   <210> 365
<211> 3061
   <212> DNA
   <213> Homo sapiens
   cggcacgagg cgactttggt ggaggtagtt ctttggcagc gggcatggcg ggtaccgtgg 60 tgctggacga tgtggagctg cgggaggctc agaggagatta cctggacttc ctggacgacg 120 aggaagacca gggaatttat cagagcaaag ttcgggagct gatcagtgac aaccaatacc 180 ggctgattgt caatgtgaat gacctgcgca ggaaaaacga gaagagggct aaccggcttc 240 tgaacaatgc ctttgaggag ctggttgct tccagcgggc cttaaaggat tttgtggcct 300 ccattgatgc tacctatgcc aaccactata aggacttcta cotaggacta gaagaggct aaccggct 360
   Page 103
```

```
39740-0001PCT.txt
<210> 366
<211> 1360
<212> DNA
 1360
<213> Homo sapiens
```

<210> 367

Page 104

#### 39740-0001PCT.txt

```
<211> 1412
    <212> DNA
     <213> Homo sapiens
<210> 368
                 <211> 1075
                 <212> DNA
                   <213> Homo sapiens
                acatttatgg caaccctatc aagaggatcc agtatgagat caagcagata aagatgttca 540 aagggcctga gaaggatata gagtttatct acacggcccc ctctcggca gaggggaga aagaaggaat atctcattgc aggaaaggcc gagggggacg 660 aggaagagagac ctgaaccac tgtgacttca tgtgacttca tgtggccctg ggacaccctg aggacaccctg aggaagagagac cctgaaccac aggtaccaga tgggctgcga gtgcaagatc acgggtgccc catcaagaga cctgaacaac caacgggcaagt tcttcgcctg ccaagagagac acgagtgcc ccaagagaacat caacgggcac caggccaagt tcttcgcctg gtaccgcgc gcggcgccc caagcagga acagcagata aagatgtca 540 ctcctcggca gtgtgtgggg 600 aggagaaggcc gagggggacg 660 aggacaccctg agcaccacc 720 agcaccaccc 780 ctggaagaacat caacgggcaagat tcttcgcctg caagaagac acgagtgcc caagaagac acgagtgcc ccaagaagaacat caacgggcac ccaagcagaa acgagtgcc aggacaccctc aggacacaccc 780 ctggaagaacat caacgggcac caagcagga acgagtgcc ccaagcagga gttctcgacac agggacaccct aaggagacc acgagtaccacc 1075 acgagaccaccc 720 agcaccaccc 720 acgagagacc acgagagacc acgagtgcc ccaagcagac acgagtgcc ccaagcagac acgagtgcc aggagagacc acgagaccaccct aggaccaccct aggaccaccct aggaccaccct acgaccaccc 720 agcaccaccc 720 agcaccctg acgagagacc acgagagacc acgagagacc acgagagacc acgagagacc acgagacccctg agcaccctg agcaccaccc 720 agcaccccc 720 agcaccaccc 720 agcaccccacc 720 agcaccccacc 720 agcaccaccc 720 agcaccaccc 720 agcaccaccc 720 agcaccccaccc 720 agcaccaccc 720 agcaccaccaccc 720 agca
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1020
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1075
                           <210> 369
                            <211> 1127
                             <212> DNA
                              <213> Homo sapiens
                            cacgggcggg gcggggcctg ggtccaccgg ggttctgagg ggagactgag gtcctgagcc 60 gacagcctca gctccctgcc aggccagacc cggcagacag atgagggccc aggaggcctg 120
                            gacagetta gerectige aggerage eagecage acgerage a
```

```
39740-0001PCT.txt
tcatggaggc gctggggctg tggagatccg gagtcgccac agctcctacc ccgcggggac 480 ggaggacgac gaagggatgg gggaggagcc cagcccttt cggggccgct cgcgctcggc 540
gcccccaac ctctgggcag cacagcgcta tggccgcgag ctccggagga tgagtgacga 600 gtttgtggac tcctttaaga agggacttcc tcgcccgaag agcgcgggca cagcaacgca 660 gatgcggcaa agctccagct ggacgcgagt cttccagtcc tggtgggatc ggaacttggg 720 caggggaagc tccgcccct cccagtgacc ttcgctccac atccccgaac tccacccgt 780
caggggaage telycelet telagrate tregetera actregatal telaceget 7.80 cocactgood tegggcagood tettgaatat gggcggaagt acttcood ggcctatgoa 840 aaaagaggat ccgtgctgtc teetttggag ggagggctga cccagattcc etteeggtgc 900 gtgtgaagec acggaagget teggtcood eggaagttttg ggtttteeggget tecettegge eggecteagget tecettegg etceggget tecettegg etceggget tecettegg 1020 agtegegge caggtttaac egttgegta ecgggaceeg agecceegeg atgecettegg 1080 ggccgtgete actaccaaat gttaataaag eccgegtetg tgeegee 1127
<210> 370
<211> 1890
  <212> DNA
  <213> Homo sapiens
 <400> 370
 cttaataaga agagaaggct tcaatggaac cttttgtggt cctggtgctg tgtctctctt 60 ttatgcttct cttttcactc tggagacaga gctgtaggag aaggaagctc cctcctggcc 120 ccactcctct tcctattatt ggaaatatgc tacagataga tgttaaggac atctgcaaat 180
 ctttcaccaa tttctcaaaa gtctatggtc ctgtgttcac cgtgtatttt ggcatgaatc 240 ccatagtggt gtttcatgga tatgaggcag tgaaggaagc cctgattgat aatggagagg 300 agtttctgg aagaggaaat tccccaatat ctcaaagaat tactaaagga cttggaatca 360 tttccagcaa tggaaggaga tccggcgttt ctcctcaca aacttgcgga 420
 tttccagcaa tggaaagaga tggaaggaga tccggcgttt ctccctcaca aacttgcgga 420 attttgggat ggggaagagg agcattgagg accgtgttca agaggaagct cactgccttg 480 tggaggagtt gagaaaaacc aaggcttcac cctgtgatcc cactttcatc ctgggctgtg 540 ctccctgcaa tgtgatctgc tccgttgtt tccagaaacg atttgatat aaagatcaga 660 attttctcac cctgatgaaa agattcaatg aaaacttcag gattctgaac tcccatgga 660 tccaggtctg caataatttc cctctactca ttgattgtt cccaggaact cacaacaaag 720 tgcttaaaaa tgttgctctt acacgaagtt acattaggag gaaagtaaaa gaacaccaag 780 catcactgga tgttaacaat cctcgggact ttatggattg cttcctgatc aaaatggagc 840 aggaaaagga caaccaaaag tcagaattca atattgaaaa cttggttggc actgtagctg 900 attattgg toctggaaca gagacaacaa gcaccactct gagaatatoaa ctcctoctcc 960
  ctgttgatga tttaaagaac ctcaatacta ctgcagttac caaagggatt gtttctctgc 1500 caccctcata ccagatctgc ttcatccctg tctgaagaat gctagcccat ctggctgctg 1560 atctgctatc acctgcaact cttttttat caaggacatt cccactatta tgtcttctct 1620
   gacctctcat caaatcttcc cattcactca atatcccata agcatccaaa ctccattaag 1680 gagagttgtt caggtcactg cacaaatata tctgcaatta ttcatactct gtaacacttg 1740 tattaattgc tgcatatgct aatactttc taatgctgac tttttaatat gttatcactg 1800
                                                                                                                                                                                                                                    1860
    taaaacacag aaaagtgatt aatgaatgat aatttagtcc atttcttttg tgaatgtgct
                                                                                                                                                                                                                                     1890
    aaataaaaag tgttattaat tgctggttca
    <210> 371
    <211> 4946
     <212> DNA
     <213> Homo sapiens
    agtcagcct gctgccagcc agtgccggt gctggggact caggggaggcc cgccgggacc 60 actgcgggac agtgagccga gcagaagctg gaacgcagga gaggaaggag aggggggggt 120 cagggctctc aggaggccggg tcctgggcaa ggcgcagccg ttttcaaatt ttcaggaaag 180 cggtcggctc acactcgagc agtaaaaaga tgcctctggg gaggaggcc gtgcagctc 240 ccgggcaatg gtggtggct ggcctagaga gcgggtagtg gaacgcagac cctggtgggg 300 gaatgacatc aagggaggaa acggggggaa ccccagattt ctgcctgtgg gcgatggaag 360 tgagggtcac tggccagcgg agccggaca agaacgcgca aaacgccgtg taggcctgga 420
     <400> 371
     ggagccgaag agcagggga cccctccgc gggggaacag tttccgccgg gagcacaaag 480 caacggaccg gaagtgggg gcggaagtgc agtgggctca gcgccgactg cgcgcctctg 540 cccgcgaaaa ctctgagctg gctgacagct ggggacgggt ggcggccctc gactggagtc 600
                                                                                                                                  Page 106
```

```
39740-0001PCT.txt
```

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/07713

A. CLASSIFICATION OF SUBJECT MATTER  IPC(7) : C12Q 1/68; G01N 33/53  US CL : 435/6, 7.1					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/6, 7.1					
ļ <u> </u>	<u> </u>				
Documentati	on searched other than minimum documentation to the	extent that such documents are included in the fields searched			
`					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet					
C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
	· · · · · · · · · · · · · · · · · · ·				
Category *	Citation of document, with indication, where a				
Y	US 6,316,208 B1 (ROBERTS et al.) 13 November 3 43-47.	2001 (13.11.2001), columns 18-20 and 18-24,32,37,38			
A		1-17,25-31,33-36,39-			
A	US 6,180,333 B1 (GIORDANO) 30 January 2001 (	30.01.2001). 45 1-45			
Α .	US 5,563,035 A (WEIGEL) 08 October 1996 (08.1)	0.1996). 1-45			
] .					
	·				
	<u> </u>				
Further documents are listed in the continuation of Box C.  See patent family annex.					
• S <sub>I</sub>	pecial categories of cited documents:	"T" tater document published after the international filing date or priority			
date and not in conflict with the application but cited to understand the "A" document defining the general state of the art which is not considered to be principle or theory underlying the invention					
of particular relevance  "X"  document of particular relevance; the claimed invention ca  "E"  earlier application or patent published on or after the international filing date  considered novel or cannot be considered to involve an inv					
	which may throw doubts on priority claim(s) or which is cited to	when the document is taken alone			
establish t specified)	the publication date of another citation or other special reason (as	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination			
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the art			
	published prior to the international filing date but later than the ate claimed	"&" document member of the same patent family			
Date of the actual completion of the international search  Date of mailing of the international search report					
10 June 2003	(10.06.2003)	03 JUL 2003			
Name and mailing address of the ISA/US  Authorized officer					
	I Stop PCT, Attn: ISA/US	Authorized officer D. Roberto Goo			
	nmissioner for Patents . Box 1450				
Alex	xandria, Virginia 22313-1450	Telephone No. 703-308-0196			
Facsimile No. (703)305-3230					

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/07713

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)				
This in	nternatio	onal report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1. [		Claim Nos		
		because they relate to subject matter not required to be searched by this Authority, namely:		
. •				
ź. T	$\Box$	Claim Nos.:		
	<u>.</u>	because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:		
	•			
⋅3.		Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
		because they are dependent claims and are not didness in deep claims.		
Box 1	II Ob	servations where unity of invention is lacking (Continuation of Item 2 of first sheet)		
		the investigation of follows:		
This I Please	Internat e See C	ional Searching Authority found multiple inventions in this international application, as follows: ontinuation Sheet		
1				
1.				
	K-2	the sky continues this international search report covers all		
1.	$\boxtimes$	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.		
2.		As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.		
3.		As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:		
		covers only mose claims for which tees were paid, specifically claims		
1				
4.		No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:		
1				
Rem	nark on	Protest		
		No protest accompanied the payment of additional search fees.		

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

### INTERNATIONAL SEARCH REPORT

#### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-17, drawn to a method for predicting clinical outcome for a patient diagnosed with cancer.

Group II, claim(s) 18-24, drawn to a method of predicting the likelihood of the recurrence of cancer following treatment in a cancer patient.

Group III, claim(s) 25-31, drawn to a method for classifying cancer.

Group IV, claim(s) 32-40, drawn to a method for predicting the likelihood of long-term survival of a breast cancer patient, and an array for use therein.

Group V, claim(s) 41 and 44, drawn to a method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, and an array for use therein.

Group VI, claim(s) 42, 43, and 45, drawn to a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor-positive invasive breast cancer, and an array for use therein.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each of the groups corresponds to a specific relationship between a specific type of cancer and a specific set of genes; thus, there is clearly no special technical feature in common

Continuation of B. FIELDS SEARCHED Item 3: USPAT, PGPUB, DERWENT, MEDLINE, BIOSIS search terms: cancer, tumor, prognosis, expression, p27, p53BP2, etc.

Form PCT/ISA/210 (second sheet) (July 1998)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

M BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.